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Abstract 
 
Centrosome amplification has been observed in most cancer cells, and is considered to be a 
“hallmark” of cancer cells. This process is commonly associated with chromosome segregation 
process in the mitosis phase in the cell cycle, which is tightly controlled by mitotic kinases. 
Among these kinases, the Aurora kinase family, Aurora A (AURKA), Aurora B (AURKB) and 
Aurora C (AURKC), ensures the accurate progression of mitosis, including the formation of a 
bipolar mitotic spindle, accurate segregation of chromosomes and the completion of 
cytokinesis. AURKA has been seen to have the largest role in mitotic progression and 
checkpoint control pathways and overexpression of AURKA is most associated with cancer. 
Hence, interfering with AURKA activity has been considered to be a promising approach to 
anticancer agents. Professor Gout’s group has recently shown that Coenzyme A (CoA) 
selectively inhibits AURKA activity (IC50 of 4.4 µM). However, its large molecular weight 
(>500) and negatively charged phosphate group make it unsuitable as a drug candidate. This 
project was set to investigate the possible binding modes of CoA in the catalytic domain of 
AURKA. The corresponding interactions between CoA and protein residues would provide 
some insights in the selectivity of CoA towards AURKA. Furthermore, based on the 
understanding of the interactions between CoA and the catalytic domain of AURKA and the 
possible reasons behind the selectivity of CoA towards AURKA, in silico design and synthesis 
of a new highly selective and potent AURKA inhibitor based on the structure of CoA and 
current lead compounds which are in clinical trials for Aurora kinase inhibitors could be carried 
out.  
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ADP Adenosine diphosphate 
ATP Adenosine triphosphate 
HOAt 1-Hydroxy-7-azabenzotriazole 
Boc2O Di-tert-butyl dicarbonate (Boc anhydride) 
BzCl Benzoyl chloride 
CoA Coenzyme A 
DavePhos Dicyclohexylphosphino-2'-(N,N-dimethylamino)biphenyl 
DCC N,N’-dicyclohexylcarbodiimide 
DIPEA Diisopropylethylamine 
DMAP 4-Dimethylaminopyridine 
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DPPA Diphenylphosphoryl azide 
EtOAc Ethyl acetate  
FMOC Fluorenylmethyloxycarbonyl chloride 
FmocOSu N-(9-Fluorenylmethoxycarbonyloxy)succinimide 
Glu Glutamic acid 
HBTU O-Benzotriazole-N,N,N’,N’-tetramethyl-uronium-hexafluoro-phosphate 
HATU (1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 
3-oxid hexafluorophosphate) 
HRMS High resolution mass spectroscopy 
HPLC High performance liquid chromatography 
Hex Hexane  
IC50 Half maximal inhibitory concentration 
LCMS Liquid chromatography mass spectrometry 
micrw Microwave 
MHz Megahertz 
MW Molecular weight 
NHEt2 Diethylamine   
NH4OAc Ammonium acetate 
NMM N-methylmorpholine 
PMBCl para-methoxybenzyl chloride 
PyAOP ((7-Azabenzotriazol-1-yloxy)tripyrrolidinophosphonium 
hexafluorophosphate) 
QPhos 1,2,3,4,5-Pentaphenyl-1′-(di-tert-butylphosphino)ferrocene 
TBAI Tetrabutylammonium iodide 
(R)-BINAP (R)-(+)-(1,1′-Binaphthalene-2,2′-diyl)bis(diphenylphosphine) 
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t-Bu tert-Butyl 
t-BuXPhos 2-Di-tert-butylphosphino-2′,4′,6′-triisopropylbiphenyl 
TBTA Tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine 
TCEP Tris-(carboxyethyl) phosphine hydrochloride 
TEA or NEt3 Triethylamine 
THF Tetrahydrofuran 
THPTA Tris(3-hydroxypropyltriazolylmethyl)amine 
TFA Trifluoroacetic acid 
TLC Thin layer chromatography 
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1. Introduction of biochemistry background and thesis proposal 
1.1. An introduction on cancer 1 
Cancer, known otherwise as malignant tumours and neoplasms, is a group of diseases that can 
affect any part of the body, causing 15% of deaths worldwide (8.2 million) in 2012. 2 In the 
UK, approximately 1 in 4 of all deaths in 2011 were due to cancer. In 2014, there were 163,444 
death counts in the UK with cancer being listed as the cause. Almost half of all the deaths due 
to cancer were lung, bowel, breast or prostate (UK, 2014). 2 The risk of developing cancer in 
humans depends on many factors, including age, genetics and environmental factors such as 
lifestyle (e.g. diet, smoking) and exposure to chemicals, radiation and pollution. According to 
Cancer Research UK, 42% of cancer cases in the UK each year are linked to lifestyle factors. In 
particular, smoking is the largest single cause of cancer in the UK. It accounts for 
approximately 19% of cancer cases each year in the UK, with lung cancer having the highest 
proportion of smoking-linked cases. Worldwide, tobacco is also considered the single most 
important risk factor for cancer, linked to 71% of lung cancer deaths in 2008 (approximately 1 
million).  
 
The main features of cancer include uncontrolled growth and proliferation of cells followed by 
loss of function and de-differentiation of cells forming localised tumours. The localised tumours 
can then invade the surroundings and metastasise to other parts of the body through the 
bloodstream or lymphatic system, forming a secondary (metastatic) deposit. 1c In order to ensure 
the nourishment for the malignant cells to survive and grow, formation of new blood vessels 
occurs (angiogenesis). 
 
At the molecular level, the causes of cancer lie in the breakdown of the mechanisms regulating 
cell division and cell proliferation (mitosis). A cell is the fundamental unit of all living matter. 
There are two types of cells: prokaryotes (cells that lack a nuclear membrane) and eukaryotes 
(cells that contain membrane-bound cell organelles). A human cell is eukaryotic, which means 
it contains a true nucleus. A nucleus has three main components: a nucleolus, which produces 
ribosomes, a nuclear envelope, which is a double-layered membrane separating the nucleus 
from the cytoplasm and chromatin, and a DNA/protein complex containing our genes. All the 
cells in a human body are classified as belonging to either the germ-line or somatic tissue. 
Germ-line tissue is responsible for the formation of the gonads. All other cells of the body 
belong to somatic tissues. Most cancers arise in somatic rather than germ cells. 1a, b An active 
dividing eukaryotic cell (somatic cell) passes through a series of stages known as the cell cycle. 
The cell cycle consists of four phases, G1, S, G2 and M phase. The G1 phase is where the cell 
grows in size and metabolic changes occur to prepare for cell division. At the G1 stage, cells 
may leave the cell cycle for a resting period (G0). Otherwise, after the G1 phase, cells may 
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enter S phase where DNA synthesis occurs, leading to the replication of genetic materials. The 
centrosome, an organelle near the nucleus that is responsible for organising microtubules 
throughout the cell cycle, begins its duplication process. The G2 phase is where metabolic 
changes prepare the cytoplasmic materials for mitosis and cytokinesis. The M phase is where 
nuclear division (mitosis) occurs followed by cell division (cytokinesis). Mitosis is further 
divided into 5 phases. The prophase is the first phase of mitosis where the genetic material, 
duplicated chromatin, condenses into visible chromosomes. Each chromosome contains two 
genetically identical sister chromatids, joined together at the centromere. Microtubules, which 
construct the cell shape, are disassembled and their components are used to form the mitotic 
spindle, which assists the correct division of chromosomes. Prometaphase is the second mitotic 
phase where the nuclear envelope completely breaks down. The mitotic spindle fibres elongate 
to specific areas on the chromosomes and the formation of a protein, kinetochore around the 
centromere occurs. Metaphase is the third phase where the chromosomes are aligned at the 
equator of the cell, attached to the mitotic spindle through kinetochores. The spindle is 
organised by two centrosomes at the two opposite poles of the cell. Anaphase is the fourth 
phase where the sister chromatids are separated into two identical ones at the centromere by the 
mitotic spindle. The separated chromatids are pulled towards the centrosomes at the two 
opposite poles by the spindle. The final phase of mitosis is called telophase where the separated 
chromosomes arrive at the two cell poles, and then uncoil. The nuclear membrane starts 
forming around each set of chromosomes. Telophase is followed by cytokinesis, a process 
where the cytoplasm of the parent cell divides to complete the formation of two identical 
daughter cells. (Figure 1.1 3 )  Each phase of the cell cycle contains checkpoints, where 
progression is halted until certain conditions are met. For instance, the checkpoints at the end of 
G1, S and late G2 phases allow the cell to assess DNA damage for repair or apoptosis 
(programmed cell death) if the damage is too extensive to repair. Understanding the cell cycle 
and its control may assist the development of effective therapies to treat the disease. 1c 
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Centrosome cycle. 4 The description of the cell cycle shows that centrosomes (the microtubule-
organising centres of cells) play a fundamental role in regulating accurate cell division in 
mitosis. In mitosis, the segregation of centrosomes is linked to the segregation of chromosomes. 
It was noticed that there is a strong correlation between aberrant centrosome number and 
aberrant chromosome number in cancer cells. 4b 
 
Figure 1.2. Centriole biogenesis. This schematic representation of the centriole duplication cycle 
shows centrioles (green) and pericentriolar material (PCM) (grey), with emphasis on two distinct 
linker structures. The G1–G2 tether (GGT; blue) connects the proximal ends of the two parental 
centrioles from G1 to late G2; it is important to ensure microtubule nucleation from a single 
microtubule organizing centre. The S–M Linker (SML; red) forms during S phase and connects the 
proximal end of the nascent procentriole to the lateral surface of the mother centriole. The removal 
of this tight connection in late M phase (disengagement) is an important element of cell cycle 
control of centriole duplication. Both the molecular components of the GGT and SML as well as the 
regulation of the formation and dissolution of these structures are expected to be distinct, although 
some PCM components are likely to be important for both GGT and SML. Also depicted are 
subdistal and distal appendages (triangles); although readily visible in electron micrographs during 
interphase, these appendages are difficult to visualize during M phase. In quiescent cells, the 
appendage-bearing centriole associates with the plasma membrane (PM) and acts as a basal body to 
form a primary cilium. Finally, in multi-ciliated epithelial cells, multiple centrioles form 
simultaneously from an amorphous structure termed the deuterosome (D). 4a (Reproduced from 
Figure 1 Reference 4a. Used by Permission of the publisher.) 
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A centrosome consists of two cylindrical microtubule-based centrioles, which recruit a matrix 
of associated pericentriolar material (PCM). During each cell cycle, the duplication of 
centrioles occurs once only, beginning around the end of the G1 to S phase. The newly formed 
structures are called procentrioles, which elongate throughout the S and G2 phases. There are 
two essential types of connection between the centrioles. The progression through the 
centrosome cycle involves the formation and dissolution of these two connections. The first 
type of connection is called ‘S-M linker’, formed during the S phase and connecting a 
procentriole to its adjacent ‘mother’. This linker is tight and persists until the separation of the 
mother-daughter centriole at metaphase. The disengagement of centriole pairs is coordinated 
with chromatid separation. The second type of connection is called the ‘G1-G2 tether’, which 
provides a loose connection between the proximal ends of the two parent centrioles. This spatial 
arrangement helps to focus the microtubule-organising activity of the centrosome. The 
centrosome cycle is presented in Figure 1.2 4a.  
 
Control of the cell cycle and carcinogenesis 5  
The cell cycle is controlled by many different proteins located within the cytoplasm. These 
regulatory proteins are products of two types of genes: proto-oncogenes and tumour suppressor 
genes. Genomic instability and mutation is an enabling characteristic of cancer cells. Proto-
oncogenes code for various proteins, whose functions are important in the regulation of the cell 
cycle, signal transduction and promoting cell progression through the cycle. Proto-oncogenes 
can be converted into oncogenes by mutations. 1a Oncogenes code for proteins that drive the 
cell cycle and promote continuous cell division that may lead to carcinogenesis. For example, 
the genetic alterations that lead to the enhanced function of the protein product or an increase in 
the synthesis of the protein products, which may control cell division, eventually activate the 
malignant transformation of cells. An important group of proteins coded by proto-oncogenes 
are cyclins, which are involved in the promotion of progression through the cell cycle. Cyclin-
dependent kinases (CDKs) are another group of proto-oncogenic proteins. A cyclin binds with a 
CDK to form a complex, which phosphorylates (transfers a phosphate group to) transcription 
factors, proteins that bind to genes to regulate gene expression. These transcription factors 
activate transcription of genes required for the next stage of the cell cycle. 1c Several other 
kinases and phosphatases have been identified as regulators of centrosomal and mitotic cycles 
such as Aurora A and Aurora B kinases. De Castro et al. in 2007 summarised mitotic alterations 
in cancer categorised by molecular or cellular function. (Figure 1.3 3)  
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Figure 1.3. Summary of mitotic alterations in cancer categorised by molecular or cellular 
function. Protein kinases (mostly centrosomal and checkpoint kinases) are significantly 
represented, suggesting diverse therapeutic uses in cancer. 3 (Reproduced from Figure 3 
Reference 3. Used by Permission of the publisher.) 
 
Tumour suppressor genes code for proteins that prevent excessive growth of a cell. In other 
words, these regulatory proteins inhibit cell progression through the cell cycle. There are two 
types of tumour suppressor genes: caretaker and gatekeeper genes. Protein products of caretaker 
genes e.g. BRC1 repair structurally damaged chromosomes and correct DNA mutations. Protein 
products of gatekeeper genes exhibit inhibitory effects on cell growth (cell cycle arrest and/or 
apoptosis), their function is lost in cancers. Together with oncogenes, they play major roles in 
carcinogenesis. The most well-known ones are p53 and the retinoblastoma (Rb) gene. In normal 
cells, Rb protein blocks cell proliferation through binding and inactivating a transcription 
factor. Ser/Thr phosphorylation of Rb protein prevents this interaction, stopping the blockage. 
Its inhibitory activity usually synergises with p53 protein. 1b The other enabling characteristic of 
cancer is tumour-promoting inflammation. This may involve necrosis, a process of cell death as 
a result of acute injury. The necrotic cells swell and burst, releasing their contents into the local 
tissue microenvironment. This may signal an inflammatory response from the immune system, 
sending signals e.g. growth factors promoting adjacent healthy cells to divide to compensate for 
the loss. 5, 6  
14 
 
Hanahan and Weinberg in 2000 7 and in 2011 5 reviewed that there are six major cell alterations 
dictating malignant growth. One hallmark is self-sufficiency in growth signals, which means 
that cancer cells are capable of synthesising growth factors, producing their own growth signals 
to which they respond. Alternatively, they may signal healthy cells within the same 
environment to supply various growth factors. Cancer cells may also increase the number of 
growth receptor proteins displayed on the surface, making them hyper-responsive to growth 
factor ligands. Another hallmark is insensitivity to inhibitory signals. For example, in 
retinoblasma cancer, deletion or mutation of the RB1 gene inactivates the tumour suppressor 
protein, Rb protein. Rb protein integrates signals from extracellular and intracellular sources to 
decide a cell progression or suspension in the cell cycle. 8  A third feature is evasion of 
apoptosis, e.g. the deletion or mutation of tumour suppressor gene p53. Another hallmark is 
limitless replicative potential. The number of divisions that a normal cell can carry out is 
controlled by telomeres, the two ends of each chromosome. Telomeres, containing several 
repetitions of the short nucleotide sequence TTAGGG, do not code for genetic information but 
are to protect the ends of chromosomal DNA from end-to-end fusions. They are shortened 
progressively over each cell cycle, ultimately determining the number of cycles a normal cell 
can go through. Telomerase is an enzyme that binds to telomeres, preventing the shortening 
process from occurring, resulting in limitless replicative potential. In cancer cells, this enzyme 
is reportedly expressed in significant levels. The fifth and sixth features of cancer are sustained 
angiogenesis, which supplies nutrients and oxygen to the tumour and removes metabolic waste 
and carbon dioxide from it, and tissue invasion and metastasis, which involve the physical 
spreading of cancer cells from the primary location to distant tissues followed by the adaptation 
of these cells to foreign microenvironments, resulting in colonisation and formation of 
secondary macroscopic tumours.  
 
Principles of cancer treatment 1a, b 
The development of a malignant tumour is characterised by stages of disease (tumour size and 
degree of spread) and by grades of disease (cellular characteristics of the cancer). Cancers are 
commonly categorised into stages using the TNM system, which is based on three factors:  
tumour size, spread to the lymph nodes and metastasis to distant sites. In terms of grading, a 
low-grade tumour histologically resembles the original tissue much more than a high-grade 
cancer, which has gone through many changes (cellular heterogeneity). 1b These two factors 
(stages and grades) are essential to outline an effective course of treatment for cancer. 
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Three traditional forms of cancer treatment are surgery, radiation and chemotherapy. Surgery 
and radiation are generally used in treatments of localised tumours that are confined to specific 
locations whereas chemotherapy is a systemic treatment. 1a Surgery is primarily used to reduce 
or possibly remove the entire tumour. It can also be used for the purpose of preventing the risk 
of cancer development. Radiation therapy mostly uses high-energy X-rays to destroy tumours 
by causing DNA damage. Minimal damage to adjacent healthy cells is obtained by selective 
shielding and varying the direction of the radiation beams. Radiation therapy is based on the 
theory that cancer cells have reduced ability to provide protection against or repair DNA 
damage compared to healthy cells due to the lack of functional protein products of tumour 
suppressor genes. Chemotherapy is, as mentioned, a systemic treatment. It refers to the use of 
cytotoxic drugs to inhibit the growth of cells and kill them. Chemotherapeutic drugs can enter 
the bloodstream and be delivered to various sites, so chemotherapy is systemic. 
 
Chemotherapeutic drugs often bind to molecules and interfere with their ability to carry out 
certain functions in particular stages of the cell cycle. Actively proliferating cells are most 
susceptible to chemotherapeutic drugs. Alkylating agents (e.g. cyclophosphamide) form adducts 
with DNA bases, disrupting DNA synthesis. Antimetabolites (e.g. methotrexate) inhibit nucleic 
acid synthesis. Other targets include topoisomerase, the enzyme that unwinds the DNA helix 
during and after replication and microtubules in mitosis. One famous example is Imatinib, a 
tyrosine kinase inhibitor, used in the treatment of chronic myeloid leukaemia and 
gastrointestinal stromal tumours. In this project, I focused on protein kinases, which are 
dominant in regulating cell proliferation and have been considered as a possible therapeutic 
target in cytotoxic chemotherapy. A background on kinases and their role in chemotherapy is 
presented in Section 1.2. 
1.2. Protein kinases for cancer therapy 9, 10 
Protein phosphorylation is a common post-translational modification of proteins in signal 
transduction, playing an important role in cellular and extracellular processes including 
differentiation, membrane transport, metabolism and growth. A protein kinase is an enzyme that 
catalyses the transfer of the gamma phosphate group from ATP onto hydroxyl groups of various 
substrates such as lipids, sugars and amino acids. The reverse process is catalysed by 
phosphatases. In eukaryotes, the three common amino acids of proteins that are sites of 
phosphorylation are tyrosine, serine and threonine. Eukaryotic protein kinases are classified into 
three groups: tyrosine-specific protein kinases, serine/threonine-specific protein kinases and 
dual-specific (both tyrosine- and serine/threonine-specific) protein kinases. The majority of 
eukaryotic protein kinases are serine/threonine-specific protein kinases, reflecting in the ratio of 
cellular phosphorylation (pSer : pThr : pTyr = 1000 : 100 : 1). 9, 11 
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Protein kinases are one of the largest families of genes in eukaryotes, making up about 2% of 
the human genome. The classification of kinases was primarily perfomed by sequence 
comparison of their catalytic domain, supported by the information of sequence similarity and 
domain structure outside of the catalytic domains. The protein kinase complement of the human 
genome, the human kinome, contains 518 eukaryotic protein kinase genes according to the 
latest count. 12 These are subdivided into seven families of typical and seven families of atypical 
kinases. The typical kinases are those that contain a conserved catalytic domain belonging to 
the eukaryotic protein kinase superfamily. Atypical kinases lack sequence similarity to the 
typical kinase catalytic domain but have been shown experimentally to exhibit protein kinase 
activity. In general, members of the same kinase family have the same domain structure. The 
seven families of the typical kinases are AGC (PKA, PKG and PKC) kinases, CAMK 
(CAlcium/CalModulin-dependent) kinases, CMGC (the Cyclin-dependent kinases, MAP 
kinases, Glycogen synthase kinases, Casein kinases 2) kinases, CK1 (Casein Kinase 1) kinases, 
STE kinases, TKL (the Tyrosine Kinase Like) kinases and TK (Tyrosine Kinase) kinases. Apart 
from the TK family, the other 6 families are serine/threonine-specific protein kinases. About 
10% of all eukaryotic kinase domains (50 domains) lack catalytic activity due to sequence 
change in essential motifs and are called pseudo-kinases. However, it was postulated that they 
retained other non-catalytic functions. 13  Some may act as modulators of other catalytic 
domains. For example, GCN2 (General Control Non-derepressible 2), a serine/threonine-
specific protein kinase that senses amino acid deﬁciency through binding to uncharged transfer 
RNA and plays a key role in modulating amino acid metabolism as a response to nutrient 
deprivation, has dual domains; one of which is inactive and may regulate the active domain. 14 
 
Studies in cancer genomics have demonstrated the importance of protein kinases in cancer 
development. Early work by Futreal et al. in 2004 15 on the Cancer Gene Census, a literature 
based census of genes that were mutated and causally implicated in cancer development showed 
27 of 291 “cancer genes” encoded protein kinases. In 2010, Kan et al. 16 studied 441 specimens 
derived from various human cancers and revealed that mutations were found in 157 of the 230 
investigated protein kinases. Recent studies of large-scale cancer genome sequencing, including 
The Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium (ICGC), 
to address somatic genetic alterations characteristic of common human cancer types revealed 
that certain protein kinases were mutated at relatively high frequency (>10%) in one or more 
human cancers. 17 Some notable examples include BRAF in thyroid cancer, skin cutaneous 
melanoma (60% and 51% respectively) and Fms-related tyrosine kinase 3 in acute myeloid 
leukemia (27%). These studies were also able to detect cancer drivers (a term which refers to 
both oncogenes and tumour suppressors) that mutated at intermediate (1-10%) or low (<1%) 
frequency. Fleuren and Zhang et al. 10 in 2016 summarised the functional annotation of the 
identified 91 kinase drivers in cancer, including signalling pathways via transmembrane 
17 
 
receptors, signalling pathways via cytoplasmic proteins, signalling to the nucleus, cell-cycle 
progression, DNA repair and regulation of apoptosis. (Figure 1.4) Receptor tyrosine kinases are 
major kinase drivers with about half of the 58 known tyrosine kinases being among the 
identified kinase drivers. (Figure 1.4a) These transmembrane proteins are single subunit 
receptors, composed of an extracellular N-terminal region and an intracellular C-terminal 
region. The intracellular region contains a highly conserved catalytic site, responsible for the 
activation of the kinase through the phosphorylation process. The extracellular region contains a 
ligand-binding site to bind extracellular ligands such as hormones and growth factors (e.g. 
epidermal growth factors - EGF, vascular endothelial growth factors - VEGFR and platelet-
derived growth factor - PDGF). EGF takes part in the regulation of cell growth and 
differentiation. PDGF regulates cell growth and development. VEGFR is involved in the 
creation of blood vessels. As a result, these receptor tyrosine kinases regulate various cellular 
responses such as cell proliferation and migration. Another type of kinase drivers reported was 
the serine/threonine-specific kinases that were parts of the receptor complexes for transforming 
growth factor-β (TGFβR) listed in Figure 1.4b. The non-receptor tyrosine kinases, which 
transduce and/or regulate signals downstream of specific cell surface receptors, were also listed 
as cancer drivers. (Figure 1.4c) These include members of the ABL, Src, and JAK kinases.  
ABL1 was also involved in DNA repair process and in the regulation of the organisation of the 
cytoskeleton. (Figure 1.4h and 1.4f) Six kinase drivers involved in the PI3K/AKT/mTOR 
signalling pathway in the cytoplasm, which promotes cell proliferation, survival and protein 
synthesis are listed in Figure 1.4d. Other key signalling pathways include MAPK cascades, 
which transduce signals from the cell surface such as growth signals, stress and inflammatory 
signals to the DNA and are essential in the regulation of normal cell proliferation, survival and 
differentiation. As a result, it is understandable that many members of the MAPK kinase family 
were also listed as cancer drivers (Figure 1.4e) Other kinase drivers include the regulators of the 
cell cycle such as cyclin-dependent kinases CDK4 and CDK6, which promote cell-cycle 
progression and AURKA and NEK9, which are known to regulate spindle assembly and 
chromosome separation and segregation.  
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The structure and catalytic mechanism of eukaryotic protein kinases 11 
All the protein kinases share a common protein folding and catalytic mechanism. The catalytic 
domains of protein kinases are usually about 250 amino acids long and highly conserved, 
containing a β-stranded N lobe and an α-helical C lobe connected together by a short hinge 
region. The hinge region is where the protein kinases bind ATP. In other words, the ATP 
binding site of a protein kinase is positioned in a cleft between the N- and C-terminal of the 
protein. The catalytic domain is defined mainly by the hinge region, where ADP/ATP binds and 
the activation loop, which is highly disordered. The hinge region is conserved among kinases. 
The adenine group of ATP binds to the hinge region through hydrogen bonding (H-bond) with 
the backbone –C=O and –NH groups of the hinge region’s residues pointing into the cleft. The 
ribose and triphosphate group of ATP bind to a hydrophilic channel, extending to the activation 
loop. 18 The protein substrate binds along the cleft and a set of conserved residues within the 
kinase catalytic domain catalyse the transfer of the terminal γ-phosphate of ATP to the hydroxyl 
of the Ser, Thr or Tyr residue of the substrate. The summary of this process was illustrated in a 
review of the mechanisms of specificity in protein phosphorylation by Ubersax and Ferrell. 
(Figure 1.5 11)  
 
Figure 1.5. The basic catalytic cycle for substrate phosphorylation by a protein kinase. 11 
(Reproduced from Figure 1a Reference 11. Used by Permission of the publisher.) 
 
The activation loop plays an essential role in the regulation of enzyme activity by providing the 
platform for binding and positioning of the hydroxyl group residue of the peptide substrate. It 
generally starts with a conserved three amino acid DFG motif. This region is extremely flexible 
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and can assume many different conformations as it regulates the on and off state of the kinase. 
As such it is very difficult to capture one single conformation of the activation loop in the 
crystal structures and these therefore appear as a disordered region. In the inactive state, the 
activation loop usually points upwards and towards the cleft, partly blocking the catalytic 
domain. Phosphorylation of one or more residues in this region generally pulls the activation 
loop downward, and the Phe residue of the DFG motif moves from the DFG-out into the DFG-
in position (i.e. being buried in a hydrophobic pocket in the groove between the two lobes of the 
kinase). This starts the activation of the enzyme. Figure 1.6 illustrates an example of the ATP 
binding site of Aurora A kinase (AURKA) where a nearly complete conformation of the 
activation loop is captured (PDB: 1OL7). 19 In this structure, ATP molecule is bound to the 
hinge region of AURKA by hydrogen bonding between the adenosine moiety and the backbone 
–C=O and –N-H of A211 and E213. Two residues located in the activation loop, T287 and 
T288 were phosphorylated. This is the most complete crystal structure found among the 
reported crystal structures of AURKA kinase in RCSB PDB. However, even in this structure, a 
few side-chains of the residues composing the activation loop were missing due to its 
flexibility.  
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Figure 1.6. ATP binding site of a protein kinase. Example: human AURKA kinase, PDB: 
1OL7. Molecule: ADP (C atoms in green), DFG in. Hinge region (yellow), glycine-rich loop 
(green), DFG motif (cyan), activation loop* (purple): phosphorylated threonine residues. 
 
The depth and hydrophobicity characteristics of kinases often increase the binding preference 
for substrates. These features help maintain the specificity of kinases in signalling pathways. 
For example, tyrosine kinases generally have a deeper catalytic cleft than serine/threonine 
kinases to accommodate the sidechain of the tyrosine residue pointing into the catalytic cleft. 
The same feature was found in tyrosine phosphatases and serine/threonine phosphatases. 20 
Outside of the catalytic domain, some protein kinases contain allosteric sites which may 
positively or negatively contribute to the regulation of kinase activity. An example of this is the 
Hydrophobic pocket I 
Hydrophobic pocket II 
(back) 
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PDK1-interacting fragment (PIF) pocket of PDK1 kinase of AGC family, which recruits 
downstream substrate kinases to allosterically regulate PDK1 activity. 21 
 
Kinase inhibitors in chemotherapy 9, 18, 22 
As many kinases have been found to take part in the process leading to tumour cell proliferation 
and survival, oncology drug discovery has been exploiting them as therapeutic targets for 
cancer therapy. The current kinase inhibitors can bind either covalently or reversibly (non-
covalent) to kinases. They are generally categorised into 4 types according to different modes of 
action elucidated by X-ray crystallography. 9, 18 
Type 1 inhibitors, ATP-competitive inhibitors bind to the active conformation of the kinase 
(DFG-in conformation). They typically consist of a heterocyclic system that occupies the hinge 
region and the extended sidechains that occupy hydrophobic pockets nearby. An example of 
this is inhibitor PD166326 of ABL1. (Figure 1.7a) Type 2 inhibitors, such as Imatinib and 
Sorafenib, still have contact with the hinge region but stabilise the inactive conformation of the 
kinase (DFG-out conformation). (Figure 1.7b) Type 3 inhibitors, allosteric inhibitors, as the 
name suggests, bind to an allosteric site, distant from the hinge region but adjacent to the ATP 
binding site, and they may differ from kinase to kinase. 23 As a result, these may exhibit a 
higher degree of selectivity by exploiting binding sites and regulatory mechanisms that are 
unique to a particular kinase. An example of this is CI-1040, inhibiting MEK1 and MEK2. 
(Figure 1.7c) Type 4 inhibitors, covalent or irreversible inhibitors, may form a covalent bond 
with a residue in the active site. The common target kinase is one with a reactive cysteine 
residue within the ATP binding site. Due to the nature of strong covalent bonding, these 
inhibitors may exhibit higher potency and improved inhibition kinetics than those of other 
types. There are a number of marketed drugs which covalently bound to their targets. 24 
However, there is also a concern of their potential for off-target reactivity which may lead to 
potential toxicity. This explains the reluctance to apply a covalent mode of action in drug 
discovery programmes. For covalent inhibitors, the target sites are usually the Lys or Cys 
residues located in or around the ATP binding site. An example of this type is inhibitor 34-JAB 
against EGFR kinase (PDB: 2J5F). (Figure 1.7d) 
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Figure 1.7. Types of kinase inhibitors. Kinase inhibitor-Protein interaction is depicted by 
ribbon structure and chemical structure. a) ABL1 in complex with the type 1 ATP-competitive 
inhibitor PD166326 (PDB: 1OPK); b) The DFG-out conformation of the activation loop of 
1.7a 
1.7b 
1.7c 
1.7d 
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ABL1 (dark blue) with the type 2 inhibitor Imatinib (PDB: 1IEP). The allosteric site exposed in 
the DFG-out conformation is indicated in blue shaded area; c) Allosteric kinase inhibitors. CI-
1040, PD334581 and AZD-6244 of MEK1 kinase. CI-1040 binds to MEK1 (PDB: 1S9I); d) 
The DFG-in conformation of EGFR with covalent inhibitor 34-JAB (PDB: 2J5F). The covalent 
bond is indicated between C773 and the inhibitor.  18 (Modified version of Figure 1, Figure 3 
and Supplementary information S2 in Reference 18. Used by Permission of the publisher.) 
 
Of the 91 identified kinase drivers, 20 kinases (22%) are approved by the FDA (US Food and 
Drug Administration) as drugs. Almost all of them are tyrosine kinases. Twenty-three of the 
kinases (25%), which are in clinical trials, are dominated by tyrosine kinases but also consist of 
serine/threonine-specific kinases. The most well-known example of a tyrosine kinase inhibitor 
as a successful anticancer agent, and also the first marketed kinase inhibitor (in 2001), is 
Imatinib/Gleevec. It is a potent inhibitor of ABL kinases, including the BCR-ABL fusion 
protein uniquely expressed in leukemia cells. It also inhibits two other receptor tyrosine kinases, 
c-Kit and PDGFR via binding to the inactive conformations of these kinases. Sunitinib, an 
FDA-approved marketed drug by Pfizer is another receptor tyrosine kinase inhibitor. It is used 
for for the treatment of renal cell carcinoma and imatinib-resistant gastrointestinal stromal 
tumors. Another example of the marketed tyrosine kinase inhibitors as anticancer agents is 
Lapatinib, which dually inhibits EGFR and HER2/neu (Human EGFR type 2). 25 One common 
biochemical characteristic of the three drugs is that these inhibitors all compete with ATP for 
the binding to the catalytic site of the receptor tyrosine kinases. In fact, there are still few 
inhibitors that interact with the region, above which the ribose of ATP resides, and/or interact 
with the activation loop. It is open for investigation as to whether there is any benefit in terms 
of inhibitory effect and selectivity from interactions with these regions. For the development of 
the next generation of kinase inhibitors, it is desirable to achieve a more selective kinase 
inhibitor and to have a better understanding of the structure of the extended ATP binding site 
(activation loop), apart from the hinge region. 
 
Besides the dominance of the tyrosine kinase inhibitors in clinical trials, inhibitors of the 
serine/threonine-specific kinases that are members of the AGC family have also presented a 
significant portion in clinical trials. One example are the Aurora kinases, which have been 
mentioned to play significant roles in regulating cell-cycle progression. The first strong 
supporting evidence for this was the reported preclinical results for VX680 compound in 2004, 
which demonstrated that Aurora kinase inhibitors could prevent tumour progression in human 
models of solid tumour cancers. 26 This project focuses on Aurora A kinase as a therapeutic 
target for cancer. 
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1.3. Aurora A kinase (AURKA) for cancer therapy 27 
The Aurora kinase family consists of three members: Aurora A (AURKA), Aurora B (AURKB) 
and Aurora C (AURKC). The three are serine/threonine-specific kinases and share a highly 
conserved catalytic domain containing auto-phosphorylating sites. AURKA and AURKB are 
commonly expressed in most cell types whereas AURKC is found in the testes. Functionally, 
AURKC plays a role in spermatogenesis. The three Aurora kinases also function as mitotic 
kinases. AURKA and AURKB take part in the regulation of the cell-cycle progression from G2 
to cytokinesis. Consequently, overexpression or amplification of AURKA and AURKB has 
been detected in many types of cancer such as breast, colorectal, pancreatic, ovarian, 
oesophageal, gastric and bladder cancers. 28 AURKC is also found as a chromosomal passenger 
protein (like AURKB) during mitosis. However, there is little information regarding its precise 
function and its role in carcinogenesis. Structurally, AURKA kinase has been extensively 
studied compared to AURKB and AURKC. There have been a number of crystal structures 
reported for human AURKA. However, there is currently no human AURKB crystal structure 
reported. 29 Hence, this project will focus on interfering with AURKA activity as a therapeutic 
target for cancer treatment. 
 
Localisation and Functions of AURKA 30, 31 
In the cell cycle, AURKA is first detected at the centrosomes during the S phase. The amount of 
AURKA rises at the centrosomes during late G2 phase and the kinase becomes activated. The 
amount of active AURKA reaches its peak and is detected on the bipolar spindles and spindle 
poles during the prometaphase and metaphase. After that, the majority of AURKA becomes 
inactivated and degraded in anaphase and only a small amount is found on the centrosomes and 
the spindles particularly the spindle midzone and remains there through telophase and 
cytokinesis. A brief illustration of the expression patterns and localisation of AURKA and 
AURKB was presented in Yan et al. review in 2016. (Figure 1.8) 27 
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Figure 1.8. The expression levels and localisation of AURKA and AURKB in the cell cycle. In 
the G1 phase, AURKA is rarely detectable. During S phase, a small proportion of AURKA is 
first detected at centrosomes. During late G2 phase, AURKA accumulates evidently at the 
centrosomes and becomes activated. During prometaphase and metaphase, active AURKA 
localizes to bipolar spindles and spindle poles following nuclear-envelope breakdown (NEBD). 
At the metaphase-anaphase transition, the majority of AURKA is inactivated and degraded. A 
small fraction of AURKA remains on the centrosomes and the spindles at the onset of 
anaphase, and localises to the spindle midzone and centrosomes during late anaphase and 
telophase/cytokinesis. In mammalian cells, AURKB is first found on pericentromeric 
heterochromatin during late S phase, and maintains its activity throughout mitosis with its 
protein level peaking in the G2/M phase. During prophase, AURKB is targeted to the 
heterochromatin and is further enriched at the inner centromeres during prometaphase before 
the metaphase-to-anaphase transition. At the onset of anaphase, AURKB relocates to spindle 
microtubules and then to the equatorial cell cortex during cytokinesis. 27 (Modified version of 
Figure 1c in Reference 27. Used by Permission of the publisher.) 
 
The review of AURKA by Yan et al. in 2016 27 also summarised three key functions of 
AURKA in mitosis, asymmetric division and cilia dynamics. In mitosis, AURKA has been 
known to play a role in the regulation of mitosis entry, chromosome alignment, centrosome 
separation and maturation and of spindle assembly. 27, 30 AURKA participates in the G2-M 
checkpoint and the regulation of mitosis entry. Prior to the M phase, AURKA, coupled with 
hBora protein, is involved in the phosphorylation and activation of polo-like kinase 1 (PLK1), 
which specifically participates in mitotic entry and mitotic progression by triggering the 
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activation of CDK1/Cyclin B complex, a mitosis-promoting factor. PLK1 is also indicated in 
centrosome maturation. It helps targeting AURKA to the centrosomes. 32 AURKA promotes 
centrosomal microtubule stabilisation by inducing the phosphorylation of transforming acidic 
coiled-coil-containing protein (TACC), which leads to its complex formation with XMAP215. 
33 AURKA also phosphorylates Ajuba, which in turn further activates AURKA at late G2, 
forming a positive feedback loop to promote mitosis entry. In prophase, AURKA induces the 
phosphorylation of Eg5, a kinesin-like motor, to enhance centrosome separation and spindle 
assembly. Another substrate of AURKA is TPX2, upon binding to which AURKA adopts an 
active conformation. This activation is required in localisation of the kinase to spindle 
microtubules but not to spindle poles. 34  In metaphase, AURKA is involved in regulating 
chromosome alignment and kinetochore function by phosphorylating centrosome protein A, 
CENP-A, which triggers the AURKB-dependent phosphorylation of CENP-A and kinetochore 
function and CENP-E, which leads to the delivery of protein phosphatase 1 (PP1) to the 
kinetochore to stabilise the biorientation of chromosomes. 35  At the spindle checkpoint, 
AURKA is involved in promoting the activation of APC/Cdc20 complex, which assists cell-
cycle progression. At the end of mitosis, degradation of AURKA by the APC/Cdh1 complex 
ensures proper cytokinesis and mitotic exit. 36 
Besides its important roles as a mitotic kinase, AURKA is also indicated in the regulation of 
primary cilia. The cilia are microtubule-based structures that protrude from the cell surface, and 
function as sensors for mechanical and chemical environmental cues that regulate cellular 
differentiation or division. AURKA negatively regulates ciliary dynamics in proliferating cells, 
promoting the disassembly of the cilia at the re-entry of the cell cycle and continuously 
supresses the regeneration of the cilia during cell proliferation. These are achieved by the 
interaction of AURKA with the enhancer of filamentation 1 (HEF1/NEDD9). 37 
Studies on Drosophila neuroblasts suggested the involvement of AURKA in the regulation of 
cell polarity and asymmetric division. Asymmetric cell division is a process by which a cell 
divides to generate two daughter cells that are already different at birth. Such divisions are 
widely used by invertebrates to generate cellular diversity during development. The astonishing 
cellular diversity in the central nervous system arises from neural progenitors, which can 
undergo different modes of symmetric and asymmetric divisions to self-renew as well as 
produce differentiated neuronal and glial progeny. Drosophila CNS neural progenitor cells, 
neuroblasts, have been utilised as a model to stimulate the understanding of the processes of 
asymmetric division, generation of neuronal lineages and, more recently, stem cell biology in 
vertebrates. 38 Wirtz-Peitz et al. showed that AURKA negatively regulated Notch signalling, 
which was an important cell-cell communicating pathway and participated in neuronal function 
and differentiation. 39  Loss of AURKA might result in the suppression of self-renewal of 
neuroblasts and the promotion of neuronal differentiation. 40    
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AURKA in cancer cells 
The aberrant expression and localisation of AURKA was shown to strongly link to 
tumorigenesis. In cancer cells, AURKA was reported to be overexpressed and distributed in 
both the nucleus and cytoplasm, regardless of their cell-cycle phases. 41 One oncogenic role of 
AURKA is its participation in the uncontrolled proliferation of many cancer cells. The 
inhibition of AURKA in ovarian cancer cells was reported to promote the expression of the 
tumour suppressor pRb, attenuating the G1/S transition. 42 The interaction between AURKA 
and tumour suppressor p53 was found to relate to uncontrolled cell growth. AURKA inhibitors 
could activate p53, resulting in proliferation arrest and senescence in melanoma tumour cells. 
Besides, other oncogenes may stimulate uncontrolled proliferation by inducing AURKA. For 
example, BRC-ABL promotes chronic myeloid leukaemia cell proliferation by activating 
AURKA and AURKB. 43  Overexpression of AURKA may lead to aneuploidy and genomic 
instability by disrupting the cell-cycle checkpoints. Studies showed that overexpressed AURKA 
induced the activation of CDK1, negating the G2/M DNA damage checkpoint. 44  Another 
oncogenic role of AURKA is supporting cancer cell survival and chemoresistance through 
activating the PI3K/AKT/GSK3 signalling cascade. For example, in experimental colon 
carcinogenesis, inhibition of AURKA-induced PI3K/AKT/GSK3 signalling cascades led to 
apoptosis. 45 In addition, AURKA promotes tumour cell migration and metastasis by activating 
several oncogenic signalling pathways such as AKT 46  and mitotic centromere-associated 
kinesis (MCAK) pathways 47.    
 
Structure of AURKA 30 
 AURKA lies within a region of chromosome 20q13 and AURKB is located at chromosome 
17p13.1 48  The C-terminal region of AURKA contains a short amino acid motif called the 
destruction box, D-box. The D-box is recognised by the anaphase-promoting 
complex/cyclosome (APC/C) complex for degradation. It is only functional in the presence of 
the D-box-activating-domain, DAD/A-box. Phosphorylation of the DAD/A-box results in the 
resistance of AURKA to APC/C-induced degradation. (Figure 1.9) 
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Figure 1.9. Structure and domains of human AURKA. 30 
 
The catalytic domain of the Aurora kinases is highly conserved. In other words, the catalytic 
domain of AURKA shares several characteristics with those of AURKB and AURKC. 
Following the general folding of kinases, the catalytic domain of Aurora kinases consists of the 
conserved C-terminal domain and short N-terminal domain, linked together by a hinge region 
which forms a part of the active site. AURKA displays high flexibility during activation, 
particularly in the activation loop of the catalytic domain. Its structure was presented in Figure 
1.10. In addition, using ATP-competitive inhibitors such as VX680 (tozasertib) scaffold, the 
ATP binding site around the hinge region is explored. (Figure 1.10, PDB: 3E5A) 49 
 Human AURKA 
131 383 402 
DAD/A-box 
XXXXRXLXPSNX D-box 
LLXXXPXXRXXLXXXXXHPW 
Activation loop 
DFGWSVH-P----R-T-CGTLDYLPPE 
 
Catalytic 
domain 
Activation 
loop 
Destruction 
box 
DAD/A-box 
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1.10b. Surface 
interaction maps of 
VX680 in TPX2-bound 
AURKA generated by 
MOE. VX680 (C atoms in 
green). Hydrophobic area 
(grey), polar areas (red 
and cyan). Calculated van 
der Waals interactions 
(mesh). 
1.10a. VX680 in phosphorylated  
TPX2-bound AURKA (PDB: 
3E5A), superimposed with 
ADP/TPX2 AURKA (PDB: 
1OL5).  VX680 (C atoms in 
green), ADP (C atoms in grey) 
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Figure 1.10. Crystal structure of VX680 within the ATP binding pocket of AURKA. (PDB: 
3E5A)  
 
In detail, the catalytic domain consists of 5 regions: a kinase hinge region where the main 
heteroaromatic core (adenine) sits, a ribose-binding region, a buried region (back pocket) for 
nonpolar interactions, a solvent accessible region (where the piperazine group of VX680 points) 
and a phosphate binding region that extends to the activation loop. (Figure 1.6) E211 and A213 
of the hinge region form direct hydrogen bonds with the main scaffold of the inhibitors. The 
buried region usually forms hydrophobic interactions, whereas the solvent accessible region 
may form polar interactions and fixes the inhibitors in a particular conformation. In a biological 
environment, the phosphate group exists as a negatively charged species so the group designed 
to reach the phosphate binding region may form ionic interactions with the residues. The sizes 
of the chemical groups, which form the inhibitor scaffold are also important. For example, the 
buried region can only accommodate small groups, whilst an extended chain is probably 
required for better interactions with the phosphate binding region. The activation loop domains 
of AURKA, AURKB and AURKC are less conserved than the hinge region where ATP is 
bound. The conserved consensus sequence is DFGWSxxxxxxxxxRxT288xCGTxDYLPPE. 50 
Phosphorylation of this sequence at T288 usually results in activation of the kinases.   
 
 
1.10c. Ligand interaction 
maps of VX680 in TPX2-
bound AURKA generated 
by MOE.  
32 
 
 
The regulations of AURKA activities 
The activities of AURKA are regulated by phosphorylation and dephosphorylation. Studies on 
Xenopus oocyte maturation revealed there are three main phosphorylation sites of AURKA in 
metaphase S53, T295, and S349, equivalent to S51, T288 and S342 in human AURKA. 31,  51 
Mutation of S53 to Asp results in in vitro inhibition of AURKA destruction. 52 Activity of 
AURKA is also controlled by other proteins present at the centrosomes and spindles. In 
particular, AURKA is activated by TPX2, a target protein for Xenopus kinesin-like protein 2, 
which is a microtubule-associated protein required for spindle stability and AURKA 
localisation. 19 TPX2 was demonstrated to bind and stimulate auto-phosphorylation of AURKA 
T295. 53 , 54  Interactions of TPX2 with NuMA, nuclear mitotic apparatus protein, and Ran 
(GTPase) regulate mitotic spindle assembly. 19 The phosphorylated activation segment of 
AURKA is reported not to be in the fully active conformation in the absence of TPX2 (PDB: 
1OL7). 19 The structure of phosphorylated TPX2-bound AURKA (PDB: 1OL5) 19 is highly 
similar to that of phosphorylated TPX2-unbound AURKA. The only difference is in the 
divergence of conformation of the activation loop between H280 – L293. (Figure 1.11) The 
crystal structures showed that the phosphorylated activation segment of AURKA in TPX2-
bound state was pulled down compared to that in TPX2-unbound state. However, TPX2 is not 
always associated with AURKA. It is present for AURKA activity involved in mitotic spindle 
but not associated with control of the function of centrosome. This information is essentially 
related to the biochemical findings present in the next section. 
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Figure 1.11. Comparison of the conformations of the phosphorylated activation segment of 
AURKA (dotted purple) in two states: TPX2-bound (PDB: 1OL5) and TPX2-unbound (PDB: 
1OL7). 
Activity of AURKA is also further regulated by phosphatase PP1 and p53 tumour suppressor 
protein. AURKA has two PP1-binding sites. The AURKA mutants that are unable to bind PP1 
were hyper-phosphorylated. Studies suggested that PP1 inhibits AURKA activity by 
dephosphorylating some crucial residues. 48 The p53 protein also appears to bind to the N-
terminal non-catalytic domain of AURKA, suppressing the kinase activity. 55 
 
AURKA Inhibitors 27, 56 
Although there have been a number of Aurora kinase inhibitors entering phase I/II/III clinical 
trials, none have been approved as an anticancer drug. Most of them failed to pass through 
Phase I/II due to toxicity. In the review in 2016, 27 ten AURKA inhibitors were reported to yield 
some encouraging results in clinical trials. Among them, AURKA selective inhibitor MLN8237 
(alisertib) is the most actively pursued agent, undergoing phase III testing in clinical trials. 57 
TPX2-unbound 
TPX2-bound 
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Some potent AURKA and AURKB inhibitors that made it to clinical trials are VX680, 58    
AZD1152, 59 MLN8054, 60 MLN8237 60 and ENMD2076 61. (Figure 1.12) Their IC50 for Aurora 
kinases are summarised in Table 1.1.  
 
Table 1.1 – IC50 of some current lead compounds for Aurora kinase inhibitions 
 IC50 values in nM 
AURKA AURKB AURKC 
VX680 58 0.6 18 4.6 
AZD1152 59 1369 0.36 n/a 
MLN8054 60 4 172 n/a 
MLN8237 60 1.2 397 n/a 
ENMD2076 61 14 350 - 
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Figure 1.12. Chemical structures of some Aurora kinase inhibitors in clinical development. 
Compounds that have entered phase III (circled). 
 
 
ENMD 2076 (EntreMed) 
AURKA selective 
Phase II testing 
MLN8237 (Millenium) 
AURKA selective 
Phase III testing 
VX680/MK-0457 (Vertex) 
Pan-selective 
Withdrawn from Phase II testing 
MLN8054 (Millenium) 
AURKA selective 
Withdrawn from Phase I testing 
AZD1152 (AstraZeneca) 
AURKB selective 
Phase II/III testing 
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VX680 is a potent pan inhibitor of Aurora kinases. In in vivo leukaemia models VX680 was 
shown to reduce the tumour growth. 62 It also showed promising activity in patients with the 
T315I mutation who are resistant to BCR-ABL inhibitors such as Imatinib. 63 Unfortunately, 
VX680 was suspended in Phase I/II due to QTc prolongation (QT interval in the heart’s 
electrical cycle represents electrical depolarization and repolarization of the left and right 
ventricles). MLN8054, developed by Millennium, is an ATP-competitive and reversibible 
inhibitor, selective for AURKA. It exhibits a selectivity of >40-fold for AURKA over AURKB. 
Treatment of 1 µM MLN8054 in human HCT-116 colorectal and PC-3 prostate tumour cells 
showed delay in G2/M progression. 64 However, MLN8054 terminated in Phase I due to CNS 
effects. 65  Its successor, MLN8237 seems to be more potent than MLN8054 and has less 
benzodiazepine-like effects. MLN8237 also showed high selectivity for AURKA (IC50 of 1.2 
nM) over AURKB (IC50 of 397 nM), with over 200-fold selectivity in cell assay. Its anticancer 
activity was shown to be achieved by disrupting the assembly of the mitotic spindle apparatus 
and chromosomal segregation. It was also shown to inhibit tumour cell proliferation in vitro and 
tumour growth in solid tumour xenograft models. 66 A number of phase II clinical studies have 
been carried out on MLN8237 in patients with ovarian, fallopian tube and peritoneal carcinoma, 
acute myeloid leukaemia and high-grade myelodysplastic syndrome. Sixteen patients (52%) 
achieved stable disease with a mean duration of response of 2.86 months. 67  MLN8237 is the 
first oral AURKA selective inhibitor to enter Phase III trials and is currently being tested in 
patients with relapsed or refractory peripheral T-cell lymphoma (NCT01482962). ENMD2076, 
developed by EntreMed, is another potent inhibitor that displays preferential inhibitory effects 
towards AURKA (IC50 of 14 nM) to AURKB (IC50 of 350 nM). This compound is also a potent 
inhibitor of Flt3 (IC50 of 1.86 nM) and also inhibits 15 other oncogenic kinases with IC50 values 
of less than 100nM, including VEGFR2/KDR, VEGFR3, FGFR1, FGFR2, and PDGFRα which 
are involved in angiogenesis. 68  It is currently undergoing phase II trials (NCT01639248). 
AZD1152 is a potent and selective inhibitor for AURKB, included here for possible comparison 
purposes. It is a pro-drug, which undergoes phosphatase-mediated cleavage to release 
barasertib-hQPA, the selective AURKB inhibitor. 69 It was shown to induce apoptosis of acute 
myeloid leukaemia and acute lymphoblastic leukemia cells. 70  In leukaemia clinical trials, 
AZD1152 has shown some adverse effects, including neutropenia and stomatitis/mucosal 
inflammation. 71 
 
At the molecular level, the binding positions of VX680 and MLN8054 inhibitors to the 
AURKA catalytic domain were shown to be around the hinge region, confirmed by crystal 
structures (PDB: 3E5A and PDB: 2X81 72 ). There are currently no available co-crystal 
structures of MLN8237 and ENMD2076 bound to AURKA. However, due to the structural 
similarity of MLN8237 and MLN8054, it is predicted that MLN8237 may occupy similar 
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space. Figure 1.13 presents the interacting surface area and ligand interactions of MLN8054 and 
residues of the catalytic domain of human AURKA. 
 
 
 
 
Figure 1.13. Interactions of MLN8054 with AURKA catalytic domain (PDB: 2X81). 
1.13a. Surface interaction 
maps of MLN8054 in 
AURKA generated by 
MOE. MLN8054 (C atoms 
in green). Hydrophobic 
area (grey), polar areas (red 
and cyan).  
1.13b. Ligand interaction 
maps of MLN8054 in 
AURKA generated by 
MOE.  
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Bayliss et al. in 2010 published the crystal structure of MLN8054 complexed to an AURKA 
mutant that mimicked AURKB (triple-point mutant: L215R, T217E and R220K to mimic the 
catalytic domain of AURKB). They reported that binding of MLN8054 to the AURKA mutant 
induced a change in the conformation of the activation loop, called DFG-up. The binding 
switched a polar pocket in the active site to hydrophobic, similar to what is observed when a 
molecule binds to AURKA and induces DFG-out conformation. 29 
 
In summary, oncogenic functions of AURKA are indicated in the process of proliferation, 
survival and invasion of tumour cells, thus it is a target for cancer therapy. Recently developed 
AURKA inhibitors have been shown to exhibit anticancer effects including suspension of 
tumour growth and induced apoptosis of cancer cells in clinical trials. However, the prime 
obstacle for the successful application of AURKA inhibitors remains to be its adverse effect of 
high toxicity. The reported number of toxicities were associated with AURKB inhibitors, 
including VX680 and AZD1152. The promising clinical results of AURKA selective inhibitor, 
MLN8237 encourage further efforts on the development of AURKA selective inhibitors. At the 
molecular level, most of the AURKA inhibitors have been shown to exploit the hinge region, 
the hydrophobic pockets and may reach the solvent accessible region. However, few explored 
the region below the ribose-binding pocket and phosphate binding region and activation loop. It 
is open for investigation that whether there will be any benefit in terms of inhibitory effect and 
selectivity from interactions with those regions. 
  
1.4. Biochemical findings 73 
 
 
 
 
 
 
 
 
 
 
The following biochemical findings from Prof. Gout’s group are the premise to this research 
project. The key findings are summarised below: 
 
(1) Preliminary screening of CoA’s activity against a panel of 117 kinases showed that 
CoA exhibited striking selective activity. 74 (Figure 1.14) (Table 1.2) ADP, binding to 
3’ phosphate 
Coenzyme A (CoA)  
Pantetheine tail 
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the hinge region of the catalytic domain, provides unselective inhibition of kinases. The 
addition of a pantheine tail to ADP moiety provides specificity in inhibitory effects 
towards 10/107 kinases. A further addition of the 3’phosphate group (as in CoA 
structure) or a combination of ADP and 3’phosphate increase the specificity towards 
AURKA, Src and YES1 kinases. These results show that both 3’phosphate and 
pantetheine are likely to be contributing to the specificity of CoA towards AURKA.  
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(1) ERK8; (2) S6K1; (3) AURKA; (4) MARK3; (5) 
CK2; (6) IKKb; (7) Src; (8) YES1; (9) BTK; (10) 
FGFR1 
No of kinases inhibited >50 % 
3/117 
 
 
10/117 
 
 
72/117 
 
 
Figure 1.14. Selectivity towards kinase inhibition of CoA, dephospho-CoA (dpCoA) and ADP. 
[ADP] = 100 µM, [CoA] = 100 µM. The screening was done by International Centre for Kinase 
Profiling. The screening data for CoA were the average of 3 independent experiments. ADP and 
dpCOA were done once.  74 
 
 
 
 
 
CoA  
dpCoA  
ADP  
AURKA 
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Table 1.2 – Screening assays of ATP, ADP, dpCoA and CoA against active and inactive 
AURKA  
Binding assay: Lanthascreen (Invitrogen), TR-FRET assay. Kinase activity was assayed by measuring incorporation 
of 33P ATP into myelin basic protein (Sigma). Purified protein (100ng) was incubated at room temperature for 30min 
in a total volume of 25µl containing 50mM HEPES pH 7.5, 150mM NaCl, 10mM MgCl2,1mM EGTA, 0.05% Brij, 
0.5mg/ml myelin basic protein, and 5μM γ33P-ATP (100-10,000dpm/pmol). The reaction was stopped by spotting the 
reaction mixture onto squares of P81 Whatman phosphocellulose ion exchange paper which were then immersed in 
1.5% phosphoric acid. After washing twice in 1.5% phosphoric acid followed by two washes in distilled water, the 
papers were air dried and radioactivity was counted by a scintillation counter and recorded by Quantasmart ver2.03. 
 
Compound AURKA (active) IC50 
(µM) (Binding assay)† 
AURKA (inactive) IC50 
(µM) (Binding assay)† 
AURKA IC50 (µM) 
(Activity assay)† 
ATP 208 2990 - 
ADP 117 1280 54.4 ± 9.3 
dpCoA ~0.294 ~7 x 1017 16.9 ± 8.1‡ 
CoA ~0.082 283 4.4 ± 2.2 
dpCoA: dephospho-CoA (dpCoA, removal of 3’ PO42- group). Experiments done under [ATP] = 5 µM. † Number of 
experiments (n) = 4; for dpCoA ‡ n = 3. Binding assays were done once. 
 
(2) Dr. Y. Tsuchiya from Professor Gout’s group showed that Coenzyme A (CoA) 
displayed a good inhibitory effect towards AURKA (IC50 of 4.4 µM). (Table 1.2) 
Further ATP competitive assay experiments showed that CoA acted as an ATP-
competitive inhibitor in the ATP binding site of AURKA. Table 1.2 showed that CoA 
also bound to active AURKA much better than to inactive AURKA. It also showed that 
dephospho-CoA (dpCoA), lacking the 3’ phosphate, was also less potent than CoA 
(IC50 of 17 µM) and did not bind to AURKA as strongly as CoA did. This suggests 
some interactions around the 3’ phosphate binding region may be beneficial for 
AURKA inhibition.  
 
(3) When TPX2 was included in assay buffer, no inhibition of CoA against AURKA was 
recorded. It suggests that TPX2 modified the catalytic domain to prevent CoA binding. 
This is confirmed when comparing the two AURKA structures. (Figure 1.11) Pre-
incubating CoA and AURKA prior to the addition of TPX2 to the medium restored 
inhibitory activity of CoA. Furthermore, at 5 µM of [ATP], in the presence of a 
reducing agent, DTT, IC50 (CoA) is 47 µM whereas in the absence of DTT, it is 4.4 
µM. This suggested that there are likely two steps for CoA binding to the catalytic 
domain of AURKA: (i) CoA binds to the hinge region of AURKA. The binding is weak 
intermolecular interactions/H-bonding; (ii) CoA rearranges itself in the active site and 
such arrangement makes it possible for a covalent bond to be formed.  
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(4) From the screening panel, CoA inhibited AURKA but not AURKB whereas dpCoA 
inhibited both. AURKA and AURKB share similar active site pocket with a difference 
in T217. This suggested some interactions between 3’ phosphate of CoA and T217 
region and such interactions contributed to the selectivity in inhibition. T217 has 
previously been shown to be important for AURKA sensitivity to the benzazepine-
based Aurora inhibitor MLN8054 and the close analogue MLN8237. This residue was 
regarded as poorly accessible to a small molecule inhibitor. 72 Such hypotheses can be 
examined further through in silico experiments. (Chapter 2)
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1.5. Thesis proposal 
 
 
 
 
 
                                        
 
 
Figure 1.15. CoA scaffold for development of an AURKA selective inhibitor. 
 
Based on the biochemical findings, coupled with in silico experiments and synthetic chemistry 
the project is focused on two areas: 
(1) The possible binding mode of CoA in the ATP binding pocket of AURKA and an 
explanation of the selectivity of CoA towards AURKA. 
(2) CoA scaffold is utilised for the development of an AURKA selective inhibitor. 
 
CoA molecular weight is well over 500 (molecular weight of MLN8237 is 518.92) and does not 
satisfy Lipinski’s rule of 5. 75  It contains a phosphate and pyrophosphate linkage with the 
negative charge, making it unable to cross the cell membrane. Modification is needed to 
improve the drug-likeness and pharmacokinetic properties of CoA. As a result, the concept of 
“CoA scaffold” was established to design a selective inhibitor of AURKA. The CoA scaffold 
mentioned was defined by three components: a heteroaromatic head group, mimicking the 
adenosine group of CoA, a linker, mimicking the pyrophosphate of CoA and a pantetheine-
mimicking tail. The initial ideas were to replace ADP moiety with a known hinge region-
binding core and the pyrophosphate linker with a polar uncharged linker. The design would be 
assisted by computational modelling. The first design of the heteroaromatic head group was 
decided to follow that of VX680, with the aim to increase the binding at the hinge region 
compared to adenosine of CoA. It is described in detail in the first generation of compounds in 
Section 1.5.1. The synthesis of VX680 head group encountered problems and the initial 
computational predictions were found to contain some errors. This led to the decision to focus 
on verifying the biochemical findings and understanding the interactions of CoA in the 
AURKA catalytic domain more in detail before re-design of more inhibitory candidates. This 
“proof of concept” approach (Approach B) is the main content of this thesis.  
 
Heteroaromatic head group –  
ATP binding pocket 
Pantetheine binding pocket 
  
Linker  
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1.5.1. Approach A – The first generation of compounds 
As mentioned, in the first half of the project, much effort was spent on Approach A to design an 
AURKA selective inhibitor based on the idea of “CoA scaffold” and VX680. In approach A, 
the project was initially divided thus: 
(i) Computational analysis was done by our former collaborator, Dr. Lalitha 
Guruprasad. Unfortunately, this result was later found to be invalid. The synthetic 
target 2 was decided based on this work. (Section 2.4) 
(ii) Two synthetic structures (1st generation of compounds) were split into parts, which 
my colleague, Fiona Bellany and I, were responsible for preparing. (Figure 1.16) 
My colleague synthesised the head group whilst I focused on the synthesis of the 
linker and pantothenamide end. (Chapter 3) 
 
                                        
 
 
                                        
  
 
 
Figure 1.16. Structures of the first generation of compounds, 1 and 2. 
 
The main target of this approach was compound 2. However, due to the high price of the linker, 
a test compound, compound 1 was set to be synthesised first to establish the synthetic route 
with the linker 3-aminocyclohexane-1-carboxylic acid available commercially as a mixture of 
cis- and trans-3-aminocyclohexane-1-carboxylic acid with >95% cis-3-aminocyclohexane-1-
carboxylic acid. In this approach, as mentioned above, I focused on the synthesis of the linker 
and pantothenamide tail (i.e. pantetheine mimics) parts of the 1st generation of compounds 
(Figure 1.16) although some work was done on the investigation for synthesis of the head group 
(Figure 1.17), based on the preliminary docking of compound 1 and 2 and testing results of core 
structures prepared by my colleague, Fiona Bellany. (Table 1.3)  Those synthetic results are 
  
Linker  
Head group –  
ATP binding pocket 
Pantetheine binding pocket 
Head group –  
ATP binding pocket 
Linker  Pantetheine binding pocket 
  
2 
1 
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described in Chapter 3. The polar end –SH of the pantetheine tail of CoA was replaced by a –
CH3 group. It was suggested by the computational work done by Dr. Guruprasad that 
compound 1 and 2 would still fit well in the catalytic domain of AURKA and show significant 
potency. However, the biochemical results from Dr. Tsuchiya suggested that such change might 
reduce the potency of the compound. The initial plan was to establish a synthetic route to 
compounds 1 and 2, and then later a pantetheine end might be added to the compound to 
compare the effect of the –SH end. 
                      
 
Figure 1.17. Initial heteroaromatic analogues for AURKA inhibition.  
 
Table 1.3 – Preliminary biological testing results of initial analogues for AURKA 
inhibition 
 
 
 
Compound IC50 values in µM  
AURKA AURKB 
5 500 320 
6 1137 1031 
7 88 170 
8 166 240 
AURKA activity was assayed by a radiometric filter binding assay using myelin basic protein as a 
substrate. (See Table 1.2 legend for details). Experiments were carried out once (n = 1). Due to the poor 
inhibitory activity, exact IC50 values were not pursued. 
 
 
3 4 
5 6 7 8 
46 
 
1.5.2. Approach B – The second generation of compounds 
 
 
 
Figure 1.18. An example of the second generation of compounds 
 
Having difficulty in designing and synthesising an AURKA selective inhibitor through 
Approach A, it was decided that more focus would be needed on synthesis of compounds to 
verify the biochemical and computational findings (“proof of concept”). As a consequence, the 
core of this thesis involves three aspects: 
(i) Computational study of the selectivity of CoA towards AURKA. (Chapter 2) 
(ii) Based on an understanding of the interactions between CoA and protein residues in 
the AURKA catalytic domain obtained, the in silico design of new inhibitor(s) was 
investigated. (Chapter 2) 
(iii) The organic synthesis of newly designed candidates. (Approach B) These designs 
serve as the “proof of concept” for the biochemical and computational findings and 
establish the foundation for further design of a selective inhibitor for AURKA. The 
derived synthetic plan employed an adenosine head, a triazole-ring as a linker 
together with the previously established synthesis of pantothenamide tail in 
Approach A. (Chapter 4) 
  
Pantetheine binding pocket 
Linker  
ATP binding pocket 
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2. Computational study and design 
2.1. Backgrounds on proteins and methods of modelling 
2.1.1. Backgrounds 
Understanding the structure-activity relationship of protein-ligand is essential in structure-based 
drug design. The striking selectivity of CoA towards AURKA made obtaining its structural 
binding information to AURKA desirable. It may also provide valuable structural information 
regarding the conformation of the activation loop of AURKA, which has not been well 
described.  
The two most common experimental methods for structure determination are X-ray 
crystallography and NMR. Since effort on preparing crystal structures of CoA in AURKA has 
not been realised, the first step in modelling of CoA molecule in AURKA would be evaluation 
of an AURKA structure with a particular focus on the activation loop of AURKA. A 
background on protein structure and how to evaluate protein structure for modelling is given 
below. Once a structure is selected, docking and scoring of conformations of CoA in AURKA 
model will be carried out. The results will be analysed and compared with the previous 
biochemical results obtained by Dr. Tsuchiya, UCL to evaluate if they can explain those 
experimental observations. If the model is able to explain these biochemical results, it will be 
used to design compounds (CoA’s analogues) to further assist the determination of CoA’s 
conformation in AURKA and to explore possible areas for designing selective inhibitors of 
CoA. The model will be used to predict the behaviours of these designed compounds which will 
be verified later with biochemical experiments. If good agreements between the model and 
biochemical results are achieved, the model will continue to be used for design of an AURKA 
selective inhibitor. In circumstances where there is a lack of experimental information, 
theoretical methods such as homology modelling may be performed. It is only possible to build 
a confident homology model if there exist homologous proteins which have similar bioactive 
conformations of the desired structural region. The templates should share at least 40 % 
identical residues with the targets and the root-mean-square displacement (RMSD) values 
between final positions of Cα in the model and templates are less than 1.5 Å. If the sequences of 
two related proteins have 50% or more identical residues in an optimal alignment, the structures 
are likely to have similar conformations over more than 90% of the model. 76 
 
Protein structure 77 
Proteins are constructed from monomeric subunits, amino acids. The 20 common amino acids 
are α-amino acids, having a carboxyl group and an amino group attached to the same C atom 
(Cα). (Figure 2.1) Amino acids can be classified by R- group. The constituent amino acid 
residues in protein molecules are exclusively L stereoisomers.  
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Figure 2.1. The 20 common amino acids of proteins. The structural formulae show the state of 
ionisation that would predominate at pH 7.0. The shaded portions are the sidechain R groups. 
Although the R group of histidine is shown uncharged, at pH 7.0 a small but significant fraction 
of the imidazole ring of the R group is positively charged. 
 
Two amino acid residues can be linked together covalently through an amide bond to form a 
dipeptide. A polypeptide consists of many amino acids joined together. Some proteins such as 
lipoproteins, or glycoproteins may permanently contain chemical groups other than amino acid 
residues (e.g. lipids, sugars). A protein is commonly defined by four levels of structure. Its 
primary structure is a description of a sequence of amino acid residues linked together in a 
polypeptide chain. The spatial arrangement of amino acid residues that are adjacent in a 
Serine Threonine Cysteine 
Asparagine 
Glutamine 
Polar, uncharged R group 
Phenylalanine 
Tyrosine Tryptophan 
Aromatic R group 
Aspartate 
Glutamate 
Negatively charged R group 
Lysine 
Arginine 
Histidine 
Positively charged R group 
Glycine Alanine 
Valine 
Isoleucine 
Leucine 
Proline 
Methionine 
Non polar R group 
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segment of a polypeptide constructs the secondary structure of a protein. As Pauling and Corey 
suggested in 1951, 78 a common protein secondary structure is a helical structure, α-helix. In 
this arrangement, the polypeptide backbone is wound around an imaginary axis drawn 
longitudinally through the middle of the helix, making the R-groups protrude outward. The 
peptide plane is roughly parallel with the helix axis. The repeat unit is a single turn of the helix 
of 5.4 Å (3.6 residues). This arrangement maximises the use of internal hydrogen bonding. 
Another common protein secondary structure is β sheet, a more extended conformation of 
polypeptide chains. The adjacent polypeptide chains in a β sheet can have the same or opposite 
amino-to carboxyl orientations (parallel or anti-parallel respectively) and linked together by 
different hydrogen bonding patterns. The interstrand hydrogen bonds are essentially in-line in 
antiparallel β sheets and not in-line for the parallel ones. The repeat period is 6.5 Å for parallel 
conformation and 7 Å for antiparallel variant. The third type of secondary structure is β turns, 
which are the connecting elements that link successive runs of α helices and β conformations. 
The tertiary structure of a protein refers to the overall 3-D arrangement of all atoms in a protein, 
which includes longer range aspects of amino acid sequence compared to the secondary 
structure. Globular proteins have a very compact structure. Most of the charged sidechains are 
on the surface or interacting with other polar groups. The sidechains of the protein core are 
usually non-polar or hydrophobic as found in insulin. Hydrophobic interactions are commonly 
found in the core residues of the proteins. Solvent molecules may be trapped inside cavities and 
form hydrogen bonding with protein residues. The folding of protein molecules can be 
explained as the consequences of the Second Law of Thermodynamics, which suggests that 
spontaneous processes always give rise to an increase of entropy of randomness, which in this 
case refers to the randomness of the solvent. The quaternary structure refers to the spatial 
arrangement of two or more polypeptide subunits of a protein. For example, insulin exists as 
dimers and hexamers. 
The amide (peptide) (-HNC=O) bond of a protein backbone is planar due to π-electron 
delocalisation. The carboxyl bond of the amide bond is 1.24 Å long, which is very short 
compared to the length of the carbon-oxygen single bond of 1.43 Å. The carbon-nitrogen bond 
of the amide bond of 1.33 Å is also shorter than the carbon-nitrogen single bond of 1.47 Å. 
Peptide conformation is defined by three dihedral angles called φ (phi), ψ (psi) and ω (omega), 
reflecting rotations about each of the three repeating bonds in the peptide backbone. The φ 
angle describes rotation around N-Cα bond and ψ angle describes rotation around C-Cα bond. 
(Figure 2.2) Due to the nature of the peptide bond, ω angle is restrained to value of 0o (cis-
peptide) or 180o (trans-peptide). Cis-peptides are generally rare for steric reasons and may 
occur if the next residue is a proline (restricted rotation). Hence values of ω usually offer little 
validation checks. The φ and ψ angles are much less restricted and can take up values between –
180o and +180o. However, due to steric hindrance, only specific combinations of the dihedral 
angles are allowed. The φ/ψ diagram or Ramachandran plot 79 describes these relationships.  
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Figure 2.2. The planar peptide group. Three bond separate sequential Cα atoms in a 
polypeptide chain. 77 (Reproduced from Figure 4-2a Reference 77. Used by Permission of the 
publisher.) 
 
Protein-protein and protein-ligand interactions 80 
The functions of many proteins are modulated by the reversible binding of other molecules 
called ligands and by protein-protein interactions. The two major factors determine these two 
interactions are geometrical and chemical complementarity between interacting parts. Geometry 
refers to the complementarity of the molecular surfaces of the two molecules/proteins involved 
and the chemical complementarity refers to the chemical interactions between the proteins and 
ligands/proteins. The generally reversible protein-ligand interactions and/or protein-protein 
interactions are governed by weak noncovalent interactions. These include the hydrophobic 
effect, hydrogen bonds, electrostatic interactions and van der Waals interactions.  
In protein folding, the hydrophobic effect provides the thermodynamic drive for the overall 
structure of the proteins. The hydrophobic effect stabilises structures that exclude water from 
the interface because the entropy of the water is reduced when being exposed to hydrophobic 
surfaces. As in protein folding, the hydrophobic effect is essential for protein-protein 
interactions. Tsai et al. in 1997 reported from the data sets of 362 structurally non-redundant 
protein-protein interfaces and of 57 symmetry-related oligomeric interfaces that all protein-
protein interfaces were hydrophobic. 81 When examining the hydrophobic effect in the data sets 
of 264 subunit-subunit, 59 receptor-ligand and 39 enzyme-inhibitor interfaces, they also found 
that the enzyme-inhibitor exhibited a stronger hydrophobic effect. This may be explained by the 
fact that the inhibitors which block the enzyme active sites are unlikely to dissociate as easily as 
the general protein-ligand bindings. 
The hydrogen bond is another important class of molecular interaction in biology. It provides 
directionality and specificity to the protein folding, protein-protein and protein-ligand 
interactions. A hydrogen bond is defined as the electrostatic attraction between two polar 
groups, formed when a proton covalently bonded to a highly electronegative atom such as N or 
O (H-bond donor) experiences the electrostatic field of another electronegative atom such as N 
or O nearby (H-bond acceptor). 82 (Figure 2.3)  
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Figure 2.3. A schematic representation of the geometry of a hydrogen bond. D, donor atom; A, 
acceptor and H, hydrogen. 
 
The amide and carbonyl groups of the peptide backbone in proteins as well as the polar 
functional groups (hydroxyls, amines, amides and carboxyls) of the sidechains can act as 
hydrogen bond donors and acceptors. In a study of various types of hydrogen bonds in protein-
ligand complexes based on 4535 high quality protein−ligand complex structures by Liu et al. in 
2008, 83 they showed that the optimal distance for a hydrogen bond between carbonyl oxygen 
and amide nitrogen was 2.5 – 3.5 Å, with a sharp peak at 2.9 Å. The angles at the donor and 
acceptor are greater than 90o. In particular, Baker and Hubbard in 1984 reported that the donor 
angle was between 130o and 170o and the acceptor angle was approximately 150o. (Figure 2.3) 
The bond is strongest when linear. In general, the strength of a single hydrogen bond ranges 
from 8 to 42 kJ.mol-1.  In proteins, the strength of a single hydrogen bond is usually between 20 
and 25 kJ.mol-1. 84  Apart from the hydrogen bond, other electrostatic interactions include the 
salt bridge. For example, the interaction between the –NH3+ group of the sidechain of lysine and 
the oxygen of a carboxylic acid group. Van der Waals interactions are another type of dipolar 
interactions. They usually refer to the weak and short-range attractive forces between uncharged 
molecules, as a result of the interaction of permanent or transient dipole moments. The distance 
over which van der Waals interactions occur is less than 7 Å between atom centres and is 
limited by electron repulsion range of 3.9 Å between atom centres according to the Pauli 
Exclusion Principle.  
 
Covalent bonds are strong and lack the reversibility, and hence dynamics, of the weaker non-
covalent bonds described above. Consequently, they are scarce in protein-protein and protein-
ligand interactions. An example of this type of bond is the disulfide bond in immunoglobulins. 
Another example is the glutamate-lysine crosslinks which are important in crosslinking fibrin, 
the protein responsible for the stabilisation of blood clots. The covalent bond can be found in 
enzyme-inhibitor binding and is a characteristic of irreversible inhibitors. However, the 
majority of protein-protein and protein-ligand interactions are non-covalent.  
 
Evaluating protein structure for modelling  85, 86 
Kleywegt summarised that a good model satisfies 6 requirements: 
- Chemical requirements such as bond lengths and bond angles and steric constraints. 
D H 
A R 
Donor angle 
Acceptor angle 
Distance 
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- Physical requirements such as favourable packing of the molecules in the crystal and 
sensible patterns of temperature factors. 
- Crystallographic requirements: the model adequately explains the experimental data. 
- Statistical requirement: the model is the best hypothesis to explain the data, with 
minimal assumptions. 
- Protein structural requirement such as reasonable Ramachandran plot. 
- Biological requirement: the model explains previous observations (e.g. with respect to 
activity, specificity, effect of mutations or inhibitors) and the model should enable you 
to make predictions that can be tested experimentally. 
Crystal structures are the most common source of structural information for drug design. In 
order to obtain the best possible accuracy in modelling, the quality of protein crystal structure 
deposited in the database (e.g. RCSB PDB) needs to be assessed. An initial model built into an 
electron density map will need to go through model refinement and quality control to provide 
improvement in accuracy. When assessing a protein crystal structure, several refinement and 
quality control factors are taken into account. It is reviewed that a typically acceptable 
resolution is less than or equal to 2.5 Å. 87 A 2.5 Å resolution refers to the diffraction from sets 
of equivalent parallel planes of atoms spaced as closely as 2.5 Å in the unit cell. Other 
parameters to assess the precision of atomic positions in crystallography include R-factor and 
R-free. These are measures of the correlation between the model and the experimental data. The 
R-factor is calculated as follows: 
  
𝑅 =  
∑||F𝑜𝑏𝑠| − |F𝑐𝑎𝑙𝑐||
∑|F𝑜𝑏𝑠|
 
where |F𝑜𝑏𝑠| is the measured intensity of a refection in the diffraction pattern and |F𝑐𝑎𝑙𝑐| is the 
intensity of the same reflection calculated from atomic model. Values of R-factors range from 0 
to approximately 0.6. An R-factor value of 0.63 represents a totally random set of atoms and a 
perfect fit is represented by an R-factor of 0. The R-free value introduced by Brünger is a less 
biased way to examine the correctness of a model. R-free is calculated in similar way as R-
factor but only uses a small randomly chosen set of intensities, test set (e.g. 5% of experimental 
data), which are not used during refinement. At any stage of refinement, R-free measures how 
well the atomic model predicts the test set that was not included in the refinement. R-free values 
are usually slightly higher than those of R-factor. Anderson suggested that in drug design, R-
free value should be less than 0.28 and R-factor should be less than 0.25.  Kleywegt, G. J. and 
Bergfors, T. et al. reported an example of the poor performance of the conventional R-factor as 
an indicator of the correctness of a model. 88  They described that the structure of cellular 
retinoic acid-binding protein type II (previously solved at 1.8 Å resolution) was intentionally 
traced backward and refined using data from 3 Å resolution. The conventional R-factor came 
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down as low as 0.214 which refers as ‘excellent’ but the R-free value came up at 0.67. They 
suggested that good data sets provided differences between R and R-free of approximately 0.02 
and when resolution is low the difference may be as high as 0.05 - 0.08. Brünger also suggested 
that the precision of R-free values also depends on the size of the test set and ranges from about 
0.5% at high resolution to 3 - 5% at low resolution. 89 However, R-free factor relates to the 
mean absolute phase error, hence local errors in a model may well go undetected if only R-free 
is used to assess the correctness of a model. Jones, T.A and Kleywegt, G. J. suggested that a 
low resolution model could not yield a precise model but that did not mean that one cannot 
produce an accurate model. 85 Precision is related to the level of detail and accuracy refers to 
how close to the truth something is. The knowledge of stereochemistry such as bond lengths, 
bond angles and violations of dihedral restraints may help increase the accuracy of a model in 
quality control. In particular the Ramachandran plot mentioned above would provide a 
description of the allowed residue conformations and outliers in a model. It usefully provides a 
quality assessment of a particular region of the protein, for example the activation loop of 
AURKA in this case. In other words, Ramachandran plot may be used to assess the 
stereochemical quality of a protein structure locally. Models that show poor clustering and 
many outliers are bound to be poor. Temperature factor, or B-factor is another parameter of 
quality control. Resolution presents the average uncertainty for all atoms whereas B-factor 
quantitates the uncertainty for each atom. It is a measure of the extent to which the atom is 
disordered within the structure, due to static or dynamic disorder within the crystal. 86 The B-
factor of an atom i is calculated as follows: 
𝐵𝑖 = 8𝜋
2𝑈𝑖
2  ≈ 79𝑈𝑖
2  
where  𝑈𝑖
2 is the mean square displacement of the atom i from its resting position in Å2. For a 
value of 𝐵𝑖  of 79 Å
2, 𝑈𝑖
2   is approximately 1.0 Å2 hence the RMSD of the atom i due to 
vibrations is 1.0 Å. Deviations from ideal bond lengths should be equal or less than 0.015 Å or 
3o for bond angles. For macromolecule model, the best main chain deviations should be equal 
or less than 0.4 Å and sidechain deviations is less than 1 Å which translates into B-factor values 
of equal or less than 15 Å2 and 79 Å2 respectively. If there is no satisfactory protein structure 
available for modelling, a homology model from existing homologous proteins can be 
considered. Nevertheless a good model should satisfy the six requirements stated above, which 
include being able to explain biochemical experimental results and to make predictions that can 
be tested experimentally.   
 
In this project, the main purpose of modelling is to probe the binding mode of CoA to AURKA, 
which hopefully provides an explanation of the selectivity of CoA towards AURKA kinase and 
to assist the design of new selective inhibitors for AURKA which may be based on the structure 
of CoA. I used bioinformatics techniques such as sequence and structural alignment and in 
silico mutant experiments to investigate the selectivity of CoA towards AURKA, and used a 
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docking programme in order to probe the binding mode of CoA to AURKA and to design 
analogues of CoA. 
 
2.1.2. Materials and methods of modelling 
2.1.2.1. Structural alignment 
Sequence alignment of protein sequences is a procedure of comparison of two or more protein 
sequences by searching for a series of individual characters or character patterns that are in the 
same order in the sequences. It provides useful structural, functional and evolutionary 
information for protein sequences. Alignment of two sequences is performed using the fast 
algorithm programmes FASTA 90 and BLAST (Basic Local Alignment Search Tool) 91. Global 
multiple sequence alignment can be performed using CLUSTALW 92. CLUSTALW is capable 
of providing an adequate alignment of a large number of related sequences and is a reliable 
indication of the domain structure of the examined sequences. 
One of the “rules of thumb” is that if the sequences have more than 25% identical residues, they 
are likely to have a similar general folding pattern and if two proteins have more than 45% 
identical residues in their optimal alignment, they will have very similar structures. The patterns 
recognised in multiple sequence alignment may hold important information such as: 
- Conserved sets of residues are likely to be part of the active site and may suggest some 
information about the structural-function relationship. 
- The conservation patterns facilitate identification of other homologous sequences and 
classification of subfamilies within a set of homologues. 
The multiple sequence alignment technique allows greater accuracy in alignment of distantly 
related sequences. Most structure-prediction methods are more reliable if based on a multiple 
sequence alignment. From 50,000 protein structures known, it is acknowledged that members of 
a protein family maintain the same basic folding pattern over ranges of sequence similarity 
from near identity down to well below 20% conservation. Families of related proteins tend to 
retain common folding patterns. Consequently, when comparing two or more protein structures, 
determination of residue-residue correspondences via structural superposition of two or more 
proteins is a more accurate method than sequence alignment for detecting homology and 
aligning the sequences of distantly related proteins. 76 
 
Method 
In this project, biological screening of CoA activity against a panel of kinases demonstrated that 
CoA is particularly selective towards AURKA (Kinase activity remaining is 14% at [CoA] of 
100 µM, IC50 of 4.4 µM). (Table 1.2) In order to investigate CoA selectivity for AURKA, 
structural alignment then comparison of AURKA to other kinases in the screening panel was 
carried out, particularly in the ATP binding region and the activation loop. Using the kinome as 
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a structural reference, a selection of kinases with different % Kinase activity remaining at 
[CoA] of 100 µM in response to CoA was chosen for structural alignment. (Table 2.1) The 
kinome suggested that the closest structure to Aurora kinases was YANK kinases (YANK1, 2, 
3), which are Ser/Thr kinases of the AGC family. 12 However, there is only one structure of 
YANK1 deposited in RCSB PDB, which is 4FR4 93 (of Homo sapiens species, Resolution 2.29 
Å, R-factor 0.204, R-free 0.244). Moreover, there was no experimental data of % Kinase 
activity remaining at [CoA] of 100 µM for YANK1. The next candidate which shared the most 
similar structure to Aurora kinases and was included in the screening panel was PKA of AGC 
family. Hence, PKA was selected for structural alignment and comparison. Other kinases in the 
screening panel were from different families such as TK and CMCG and CK1. They were 
selected based on the different values of % Kinase activity remaining at [CoA] of 100 µM. 
Those kinases were Src and FGFR1 of TK family and CDK2 of CMCG family. 
 
Table 2.1 – Preliminary screening results of % kinase activity remaining at [CoA] and 
[ADP] of 100 µM 
Kinase (homo sapiens 
species) 
% Kinase activity remaining at [ligand] of 100 µM 
CoA† ADP‡ 
AURKA 14 ± 4 38 
Src 44 ± 7 32 
AURKB 55 ± 25 48 
FGFR1 60 ± 10 42 
CDK2 93 ± 9 27 
PKA 99 ± 6 28 
In vitro assays done by International Centre for Kinase Profiling. [ligand] = concentration of ligand; 
Ligand: CoA, ADP.† number of experiments (n) = 3; ‡ n =1. [ATP] = 20 µM except for AURKA: [ATP] 
= 5 µM. 
 
For 3-D structural comparison, crystal structures of the proteins are selected from the databases 
such as RCSB PDB, Kinase SARfari and/or Molecular Operating Environment programme 
(MOE) and aligned and visualised in MOE. The criteria for selection of the appropriate protein 
structure follows the six requirements for a good model mentioned above, including the 
evaluation of the refinement and quality-control factors such as the resolution, R-factor, R-free, 
B-factor and Ramachandran plot. In this project, the focus was on the comparison of the 
selected kinase structures around the highly conserved hinge region and the variable activation 
loop. In order to verify the quality of the protein structure of AURKA, virtual mutant 
experiments on T217 of the selected structure of AURKA was also carried out in MOE. 
 
56 
 
2.1.2.2. Docking programme 94 
In general, molecular docking programmes are used to model the interactions between a small 
molecule and a protein at the atomic level, which allow us to characterise the behaviour of 
small molecules in the binding site of target proteins as well as to elucidate fundamental 
biochemical processes. The theory of docking is to give a prediction of the protein-ligand 
interactions using computational methods. Fundamentally, the process of docking involves 
identifying a specific binding site, predicting the possible conformations of the ligand in the 
binding site of the protein by a search algorithm and then ranking these conformations via a 
scoring function. Ideally, the docking algorithms should be able to reproduce the experimental 
binding mode and the scoring function should also rank it highest among all generated 
conformations.  The docking programme used in this project is GOLD 5.4.0, developed by 
Cambridge Crystallographic Data Centre (CCDC), to examine poses of non-covalently and 
covalently bound ligands. GOLD (Genetic Optimisation for Ligand Docking) is a genetic 
algorithm for docking flexible ligands into protein binding sites (predicting poses of ligands). It 
is generally used in structural prediction and in structural development of small molecule 
inhibitors. The GOLD scoring function, CHEMPLP (Piecewise Linear Potential), is an 
empirical scoring function optimised for pose prediction. In empirical scoring functions, the 
binding energy is a sum of several energy components, such as hydrogen bond, ionic 
interactions, hydrophobic effect and binding entropy. Each component is multiplied by a 
coefficient (weight) and then added together to give a final score (fitness score). Coefficients 
are obtained from regression analysis fitted to a test set of ligand-protein complexes with 
known binding affinities. 
 
Piecewise Linear Potential (fPLP) is used to model the steric complementarity between protein 
and ligand, while for CHEMPLP additionally the distance- and angle-dependent hydrogen and 
metal bonding terms are considered (fchem-hb, fchem-cho, fchem-met). It is used for modelling 
the steric complementarity between a protein and a ligand as well as additionally considering 
the distance- and angle-dependent H-bonding terms.  
 
fitnessPLP = -(wPLP . fPLP + Wlig-clash . flig-clash + wlig-tors . flig-tors +fchem-cov + wprot . fchem-prot + 
wcons . fcons) 
fitnessCHEMPLP = fitnessPLP -(fchem-hb + fchem-cho + fchem-met) 
 
fitnessCHEMPLP = fitnessPLP -(fchem-hb + fchem-cho + fchem-met) 
flig-clash : The internal score of the ligand consists of the heavy-atom clash potential  
flig-tors : The torsional potential  
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wPLP : Weight of PLP contributions 
Wlig-clash : Weight of ligand clash potential 
wlig-tors : Weight of ligand torsion potential 
wprot : Weight of ChemScore protein potential 
wcons : Weight of constraint contributions 
 
The scoring function is capable of covalent docking (fchem-cov), considering flexible side-
chains (fchem-prot) and explicit water molecules as well as handling constraints (fcons). The 
scoring calculations (fitness scores) are unit-less. 
 
GOLD will dock each ligand several times, starting each time from a different random 
population of ligand orientations. The results of the different docking run are ranked by fitness 
score by CHEMPLP. By default the number of dockings to be performed on each ligand is 10. 
If the same pose is found in different docking runs, it is usually a strong indicator that it is the 
right pose. For a single ligand with default 10 dockings, GOLD will provide a list of ranked 
fitness scores. The largest fitness score of a ligand may indicate a higher chance of finding that 
pose in reality than other lower fitness scored poses of that ligand. However, for comparison 
between ligands, particularly ligands with significant different structures, the fitness scores are 
not a reliable measure. Validation test of GOLD on a set of 305 protein-ligand complexes in 
2002 showed that it worked particularly well on kinases and isomerases with the success rates 
of 86% and 99% respectively on pdb files of 2.5 Å. 95 Astex scientists in 2007 have tested the 
reliability of GOLD docking in the prediction of protein-ligand interactions on their Diverse Set 
of 85 protein-ligand complexes of 11 kinases, 9 nuclear receptors, 5 serine proteases, and 3 
members of the phosphodiesterase family. 96 They found that relatively unbiased protocols gave 
success rates of approximately more than 80% for redocking into native structures of large site 
(10 Å) and it is possible to get success rates of over 90% with some protocols. FLEXX is 
another automatic docking tool used for large data sets but the success rates reported have been 
lower than GOLD. 97 In a recent validation test on  Astex Diverse Set of 85 protein-ligand 
complexes, CHEMPLP was found to give the highest average success rates (81%) for both pose 
prediction and virtual screening experiments against the other three GOLD scoring functions: 
GoldScore (69%), ChemScore (76%) and ASP (72%) and was set as the default scoring 
function in GOLD. 98 
 
Method 
Based on the literature statistics, in this project, in order to probe the conformation of CoA 
inside AURKA, GOLD CHEMPLP was used for docking of CoA into the appropriate AURKA 
protein structure. The first step was to test if the docking function, CHEMPLP, was able to 
reproduce the conformation of ADP in AURKA, which was available in the crystal structure. If 
58 
 
it was able to predict accurately the conformation of ADP in AURKA, it would be then used to 
dock CoA in AURKA. The ranked docking conformations by GOLD CHEMPLP were then 
visualised and analysed in MOE to select the best predicted conformation of CoA in AURKA. 
GOLD docking programme was also used to predict the conformations of analogues of CoA, 
which were designed to assist the evaluation of the conformation of CoA in AURKA and to 
develop a new AURKA selective inhibitor. 
 
Examination of appropriate kinase protein structure of AURKA 
All the available crystal structures of the examined kinase protein are downloaded through 
MOE database, and/or RCSB PDB and examined by superimposing them together (same spatial 
coordinations).  In this project, 72 protein structures of Aurora kinases were downloaded from 
MOE database.  
Based on the objectives of the project, a set of criteria was set to select the appropriate crystal 
structure. CHEMPLP was re-validated by docking the original ligand back into the protein 
crystal structure to see if the same result as X-ray crystal structure can be obtained. In this 
project, there were three criteria to select an appropriate AURKA kinase crystal structure: 
(i) It is in the phosphorylated form of AURKA where T287 and T288 were 
phosphorylated and TPX2 was not bound. DFG-in conformation of classic kinase 
binding site. 
(ii) The presence of C290 residue of the activation loop in the structure. 
(iii) Examination of the quality of the crystal structures using global parameters such as 
resolution, R-factor, R-free factor and local parameters such as Ramachandran plot 
and B-factor. 
 
Validation of docking programme and scoring function 
GOLD CHEMPLP programme was used to redock the co-crystallised molecules back into the 
original protein structures (in this project, AURKA); for example, molecule AK8 in 3EFW 
(organism: Homo sapiens), 99 YPH in 4JBP (Homo sapiens) 100 and ZZL in 2WTV (Homo 
sapiens) 29. The molecules chosen were of the inhibitors with highest molecular weights in 
RCSB database, which are likely to expand a larger space compared to those with lower 
molecular weights. The reason for this was because CoA is of high molecular weight (compared 
to the general small molecule ligands with MW of less than 500 Da) and occupies a significant 
amount of space within the ATP binding site. The use of different expression systems was to 
test the general ability of ChemPLP to reproduce the X-ray conformations. (Table 2.2) 
ChemPLP should successfully produce the binding conformations of these molecules in the 
binding sites of the proteins judged by the largest scored conformations. 
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Table 2.2 - Some current crystallised inhibitors of AURKA and AURKB. 
PDB Ligand structure IC50 
[AURKA] 
nM 
IC50 
[AURKB] 
nM 
GOLD 
highest 
score 
 
3EFW 
 
 
 
1 
 
1 
 
89.8 
4JBP 
 
41 17 113.9 
2WTV 
 
4 172 87.5 
 
Setting up protein and ligand for docking  
The ligands such as CoA were set up in their lowest energy conformation with hydrogen atoms 
added and were saved in .mol2 file format. For the protein files, water molecules were removed 
as they were not in the catalytic domain (binding site) and hydrogen atoms were added. The 
binding site was the catalytic domain of the kinase (AURKA), extending from the hinge region 
to the activation loop. Protein flexibility was not addressed in this test set. 
Non-covalent and covalent dockings of the investigated ligands such as CoA or any designed 
compounds in Section 2.3 were done using GOLD CHEMPLP. Covalent docking is possible if 
you specify which ligand atom is bonded to which protein atom. The docking results were 
visualised and analysed in MOE.  
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Analysing the docking results 
The ranked conformations of the ligand in the protein-ligand complexes by CHEMPLP were 
visualised and analysed in MOE. The filters to detect suspect entries included: 
- Binding of adenosine head group outside of the hinge region 
- Presence of severe clashes between protein and ligand (CoA) 
- Unlikely geometry of the ligand (CoA)   
In summary,  
In order to explain the selectivity of CoA towards AURKA in the screening panel (the 
structural-activity relationship), a set of kinases including, human AURKA, AURKB, Src, 
FGFR1, CDK2 and PKA, which exhibited different values of % Kinase activity remaining at 
[CoA] of 100 µM, was selected. The methods used included sequence and structural alignment 
and in-silico mutant experiment using CLUSTALW and MOE respectively. In order to probe 
the binding mode of CoA to AURKA, an evaluation of the appropriate AURKA structure was 
carried out followed by docking of CoA and its analogues into that structure using GOLD 
CHEMPLP. The planned process of structure-based drug design in this project is summarised 
below. 
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Figure 2.4. The planned process of structure-based drug design for an AURKA selective 
inhibitor based on CoA. (n/a: not available) 
 
 
 
 
 
 
 
 
 
+ 
Analyse X-ray crystal structure(s) of CoA in AURKA 
Homology 
modelling? 
N/A 
Select an appropriate protein structure 
Analyse scored conformations of CoA in AURKA 
Design compounds to assist the analysis 
of CoA’s conformation in AURKA 
Synthesise designed compounds to assist the 
analysis of CoA’s conformation in AURKA 
Goal 2: Design and synthesise selective inhibitors 
based on the analysis of CoA’s conformation in 
AURKA and its selectivity towards AURKA 
Modelling NMR (n/a in this project) 
  
Biochemical experiments 
Goal 1 - Selectivity of CoA towards AURKA (Binding mode of CoA 
in AURKA, particularly the interactions with the activation loop) 
Dock and score conformations of CoA in AURKA 
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2.2. Backgrounds on computational tools 
2.2.1. PROCHECK for Ramachandran plot 101 
For a pdb file, a Ramachandran plot (φ angle in x-axis against ψ angle in y-axis) is available 
calculated with PROCHECK programme. Morris et al. in 1992 86 defined that the 
colouring/shading on the plot represents the different regions with the darkest areas usually 
refer to the "core" regions, which represent the most favourable combinations of φ/ψ values. 
Ideally, one would hope to have over 90% of the residues in these "core" regions.  
 
2.2.2. MOE for molecular visualisation and amino acid alignment and modification 102 
MOE (Molecular Operating Environment) programme, version 2015.10, developed by 
Chemical Computing Group (CCG), is a comprehensive molecular modelling package. It was 
used to visualise the docking solutions by GOLD and to perform structural alignment and 
modification (in silico mutant experiment) of different protein kinases. (Such experiments are 
presented in Section 2.2.2) 
MOE platform allows analysis of further docking poses of ligands inside the specified docking 
site of the receptors, including contact statistics, electrostatic and interacting surface area map. 
Other functions of MOE, which were not used are not mentioned. 
 
2.2.3. Other bioinformatics tools 
LIGPLOT 103 
LIGPLOT, now superseded by new version, LigPlot+, is a graphical front-end to the LIGPLOT 
and DIMPLOT programs written by Andrew Wallace and Roman Laskowski.  
This programme generates schematic diagrams of protein-ligand interactions for a given PDB 
file. Similar function is available in MOE Ligand Interactions command. 
ChEMBL database 104 
ChEMBL is a service part of the European Molecular Biology Laboratory (EMBL), providing 
an open data resource for binding, functional and ADMET (Absorption Distribution 
Metabolism Excretion and Toxicological) bioactivity data.  
PDBsum 105 
PDBsum is a pictorial database that provides an overview of the contents of each 3D structure 
deposited in the Protein Data Bank (PDB).  
It shows the molecule(s) that make up the structure (ie protein chains, DNA, ligands and metal 
ions) and schematic diagrams of their interactions. Extensive use is made of the freely available 
RasMol molecular graphics program to view the molecules and their interactions in 3D. 
SAS (Sequence Annotated by Structure) 106 
When searching for other pdb files of a particular protein with a known good pdb file, SAS is 
used. SAS is a tool for applying structural information to a given protein sequence. It uses 
FASTA to scan a given protein sequence against all the proteins of known 3D structure in the 
63 
 
Protein Data Bank (PDB). The resultant multiple alignment can be coloured according to 
different structural features and the matching 3D structures can be superimposed and viewed in 
MOE/PyMOL. 
RCSB PDB 107 
RCSB PDB is an information portal for 117882 biological macromolecular structures. This 
archive contains information about the 3D structures of large biological molecules, including 
proteins and nucleic acids of many different species. 
CHEMDRAW 108 
CHEMDRAW/CHEMOFFICE Professional is a complete drawing tool used to create 
scientifically intelligent drawings for molecules (2-D and 3-D) and to provide information on 
the chemical properties of the molecules such as molecular weight and clogP value. 
Octanol-water partition coefficient logP is used as a measure of molecular hydrophobicity. It is 
defined as the ratio of concentrations of the unionised compound between organic (e.g. octanol) 
and aqueous phases at equilibrium. . Its representing equation is as follows: 
log 𝑃 = (
[𝑠𝑜𝑙𝑢𝑡𝑒]𝑜𝑐𝑡𝑎𝑛𝑜𝑙
𝑢𝑛𝑖𝑜𝑛𝑖𝑠𝑒𝑑
[𝑠𝑜𝑙𝑢𝑡𝑒]𝑤𝑎𝑡𝑒𝑟
𝑖𝑜𝑛𝑖𝑠𝑒𝑑 ) 
Hydrophobicity affects drug absorption, bioavailability, hydrophobic drug-receptor interactions, 
metabolism of molecules, as well as their toxicity. In the simplest term, the logP values are 
linked to the solubility in water of the molecules. A high value of logP is related to low 
hydrophilicity of the molecule in question. 
 The calculated logP (clogP) value in CHEMDRAW is based on a pool of fragments predefined 
in the logP calculator. 109 The clogP value of a molecule is the sum of the fragment values that 
are present in the molecule. 
 
2.3. Results and Discussion on the selectivity of CoA towards AURKA 
2.3.1. Structural alignment of selected protein kinases for structural comparison 
2.3.1.1. Selection of protein kinase structures for alignment and docking 
Selection of AURKA protein structures 
Firstly the crystal structures of AURKA and AURKB from all species in the protein database 
was downloaded through MOE Protein Kinase Database (Appendix 2.1). There are 72 
structures. All the crystal structures are structurally aligned in MOE for the purpose of 
structural comparison.  
The catalytic domain of AURKA is large and defined by five features: (Figure 2.5)  
(i) Hinge region (yellow): residues E211 – A213, extended to T217 region where 
many small inhibitors (e.g. MLN54, MLN8237 and VX680) bind to through H-
bonding. 
(ii) Flexible chain (green): residues L139 – V147 and A160 – K162 
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(iii) Back loop (purple): residues L178 – Q185 
(iv) Front “loop”/surface: residues (red) H254 – L263 extended to residues A273 – 
G276 (cyan), forming a front surface. 
(v) Activation loop (residues in pink) between ‘red’ and ‘cyan’ region: W277 – D294. 
 
Figure 2.5. Superimposed AURKA and AURKB crystal structures (72 structures from MOE 
database, Appendix 2.1). Hinge region (yellow), flexible chain (green), back loop (purple), 
front “loop”/surface (red and cyan), activation loop (pink, different conformations: circled). 
 
For the original 72 structures of crystallised Aurora A and B kinase structures of all species 
(human and non-human) available, the first criteria of selection applied was that the crystal 
structure of AURKA was in the active form where T287 and T288 were phosphorylated and 
TPX2 was not bound. This criteria was derived from the biochemical experimental results 
report by Dr. Tsuchiya (Section 1.4, key findings (2) and (3)) where CoA was reported to bind 
to AURKA in its phosphorylated form without TPX2.  This eliminated 63 structures. The 9 
structures that met the criteria were 1OL7, 19 4BN1, 110 2WTV.A, 2WTV.B and 2WTV.D 29 for 
AURKA, and 4C2V.A, 4C2V.B, 111 4C2W.A, 4C2W.B 111 for AURKB. The second criteria 
was the presence of C290 residue of the activation loop in the structure. As can be seen from 
Figure 2.6 this activation loop was missing or adopted variable conformations due to its 
flexibility in many pdb protein files making them impossible to be the candidates for docking. 
(Figure 2.5, circled) From the biochemical findings (Section 1.4, key finding (3)), it was found 
that at 5 µM of [ATP], in the presence of a reducing agent, DTT, IC50 (CoA) is 47 µM whereas 
in the absence of DTT, it is 4.4 µM. It was suspected that the sidechain –SH of C290 residue 
may form some interactions with the end –SH or CoA. Therefore a structure containing C290 
ADP 
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residue was desirable. Out of these 9 structures, three of them (2WTV.A, 2WTV.B and 
2WTV.D) had C290 modified, forming disulfide bond with –SCH2CH2OH. As a result, these 
three structures were excluded, leaving two structures, 1OL7 and 4BN1 left. The comparison of 
the quality of 1OL7 and 4BN1 was carried out in the following order: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Checking the overall global parameters for structural validation, 4BN1 was slightly better than 
1OL7 in term of quality. The resolution of the two pdb files, are 2.75 Å for 1OL7 and 2.50 Å 
for 4BN1). For R-factor value, that of 1OL7 is 0.257 and that of 4BN1 is 0.195. For R-free 
value, that of 1OL7 is 0.296 (free test size of 5%) and that of 4BN1 is 0.244 (free test size of 
4.8%). (Table 2.3)  
 
Table 2.3 – Comparison of global parameters to assess quality of protein structure of 
AURKA between 1OL7 and 4BN1 
Parameter 1OL7 4BN1 
Resolution/ Å 2.75 2.50 
R-factor 0.257 0.195 
R-free 0.296 0.244 
 
Both free test sizes are similar and on the high end. It was suggested that the R-factor should be 
less than 0.25 and R-free value should be below 0.28 for drug design. Those values of 1OL7 
were slightly out of range. However, a local investigation in the 3-D alignment of 1OL7 and 
4BN1 in MOE showed that the conformations of amino acids in the five regions of the catalytic 
domain of AURKA were mostly the same. Variations were found in the location of the 
sidechains of residues in the activation loop, the area of interest. One particular important 
Overall stereochemical quality (Resolution, R-factor, R-free) 
Local assessment of the catalytic domain of AURKA 
B-factors for the catalytic domain, 
particularly the activation loop. 
Ramachandran plot: outliers in the 
catalytic domain, particularly in the 
activation loop. 
Outliers of C290 
residue of the 
activation loop ? 
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exception was in C290 of the activation loop. In 1OL7 model, the sidechain –SH was reported 
to be missing whereas in 4BN1 model, it was built in a way that the –SH was pointing outwards 
of the activation loop. Ramachandran plots of 1OL7 and 4BN1 were examined for a local 
assessment of the stereochemical quality of the activation loop. (Figure 2.6 and Figure 2.7)   
 
Figure 2.6. Ramachandran plot of 1OL7. The darkest areas (red) refer to the "core" regions, 
which represent the most favourable combinations of φ/ψ values. The regions are labelled as 
follows: A - Core alpha, L - Core left-handed alpha, a - Allowed alpha, l - Allowed left-handed 
alpha, ~a - Generous alpha, ~l - Generous left-handed alpha, B - Core beta, b - Allowed beta, 
~b - Generous beta,      p - Allowed epsilon, ~p - Generous epsilon. 
The general statistics of Ramachandran plot of 1OL7 is as follows: 
                                         No. of 
                                        residues     %-tage 
                                         ------      ------ 
Most favoured regions      [A,B,L]          193       82.5%*   
Additional allowed regions [a,b,l,p]         38       16.2%           
Generously allowed regions [~a,~b,~l,~p]      2        0.9%           
Disallowed regions         [XX]               1        0.4%*   
                                           ----      ------ 
Non-glycine and non-proline residues        234      100.0% 
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End-residues (excl. Gly and Pro)              1 
 
Glycine residues                             15 
Proline residues                             14 
                                           ---- 
Total number of residues                    264 
 
Figure 2.7. Ramachandran plot of 4BN1. The darkest areas (red) refer to the "core" regions, 
which represent the most favourable combinations of φ/ψ values. 
The general statistics of Ramachandran plot of 4BN1 is as follows: 
                                         No. of 
                                        residues     %-tage 
                                         ------      ------ 
Most favoured regions      [A,B,L]          211       90.6%           
Additional allowed regions [a,b,l,p]         16        6.9%           
Generously allowed regions [~a,~b,~l,~p]      2        0.9%           
Disallowed regions         [XX]               4        1.7%*   
                                           ----      ------ 
Non-glycine and non-proline residues        233      100.0% 
 
End-residues (excl. Gly and Pro)              2 
 
Glycine residues                             15 
Proline residues                             13 
                                           ---- 
Total number of residues                    263 
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The overall stereochemical quality of 4BN1 is better than that of 1OL7 with 90.6% of residues 
in most favoured regions compared to that of 82.5% in 1OL7. However, local assessment of the 
activation loop showed that 4BN1 contained more outliers in the activation loop (R285, S286, 
T287 and C290) compared to 1OL7 (T287). The C290 residue is a critical requirement in this 
model as the biochemical data provided by Dr. Tsuchiya suggested a possible interaction 
between CoA and this residue. As a result, it is unlikely that 4BN1 can be used. Another 
parameter to check is the B-factors. The B-factors of the five regions of the catalytic domain of 
AURKA of 1OL7 and 4BN1, especially those of the residues in the activation loop were 
compared. 1OL7 provided similar B-factors to 4BN1 for the hinge region, flexible chain 
(green), back loop (purple), front loops (red and cyan). For the activation loop, which was of 
particular interest in this project, the B-factors for that of 1OL7 is mostly 60 – 80 Å2 with the 
exception of T287 (80 – 100 Å2) and C290 (80 – 90 Å2). In comparison, the B-factors for that 
of 4BN1 is mostly 60 – 80 Å2 with the exception of T287 and T288 and C290 (100 – 130 Å2). 
The full details of B-factor values for 1OL7 and 4BN1 are presented in Appendix 2.2. Overall 
the B-factors value for both pdbs showed the flexibility of the activation loop, particularly at 
T287, T288 and C290 residues. In 1OL7 the –SH sidechain of C290 was missing and the 
average B-factor of the main chain was 88 Å2. In 4BN1, even though the –SH sidechain was 
included (pointing outwards of the activation loop), its B-factor is 135 Å2. For C290 of 4BN1, 
the average B-factor of C290 was 108 Å2 so the B-factor of –S atom of C290 was much higher 
than the average B-factor of C290. This presents a great uncertainty of the position of the –SH 
sidechain of C290. (Table 2.4) In summary, the B-factors of 1OL7 are lower than those of 
4BN1 in activation loop, particularly in the phosphorylated region: T287, T288 and in the area 
of interest C290. It means that 1OL7 model provided similar or better accuracy of the positions 
of the residues in the activation loop. As a result, 1OL7 was chosen among AURKA and 
AURKB crystal structures and the sidechain of C290 was constructed using MOE programme. 
1OL7 would also be used for modelling of CoA’s conformation in AURKA and to test whether 
the modelling results obtained able to explain biochemical observations provided by Dr. 
Tsuchiya.    
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Table 2.4 – Comparison of B-factor values of 1OL7 and 4BN1 
B-factor value/ Å2 1OL7 4BN1 
Average B-factor of activation loop W277 – 
D294 
68.8 76.4 
Average B-factor of T287 91 92 
Average B-factor of T288 89 122 
Average B-factor of C290 88 108 
B-factor of sidechain –S atom of C290 n/a 135 
 
In order to verify the quality of the structure of 1OL7 further, it was later used in docking 
programme to predict the conformations of CoA and its analogues in AURKA and in in-silico 
mutant experiement of the T217 residue of AURKA and to compare if the docking results can 
explain the biochemical findings. This was to confirm whether 1OL7 satisfied the “biological 
requirement” of a good model suggested by Kleywegt. 
 
Selection of protein structures for AURKB, Src, FGFR1, CDK2 and PKA to compare with 
AURKA 
The filtering of the protein structures followed similar process as that of the evaluation of Aur- 
A structure. The selected structures satisfied the crystallographic and statistical requirements 
such as resolution, R-factor and R-free as well as protein structural requirement (Ramachandran 
plot). They were in their phosphorylated/active form and contained a full activation loop or the 
most completed activation loop structure available.  For AURKB, there are currently no human 
AURKB crystal structures so the best alternative was that of Xenopus laevis. It is of 68% 
sequence identical to human AURKB, sharing identical residues in the hinge region and sharing 
highly similar residues in the activation loop. The crystal structures of AURKB of Xenopus 
laevis available were limited (11 structures) but of good overall quality. The best one was pdb 
4C2W 111 (Resolution 1.70 Å, R-factor 0.158, R-free 0.195, average B-factor of the hinge region 
E171 – E177 ~15 Å2, average B-factor of  the activation loop W237 – D267 ~20 – 30 Å2). For 
Src, the selected structure was pdb 2H8H (Resolution 2.20 Å, R-factor 0.207, R-free 0.272, 
average B-factor of the hinge region E339 – S345 ~ 30 – 40 Å2, average B-factor of the 
activation loop L407 – T440 ~50 – 60 Å2). 112 For FGFR1, the selected structure was pdb 
5AM6 (Resolution 1.96 Å, R-factor 0.215, R-free 0.251, average B-factor of the hinge region 
E562 – N568 ~ 35 Å2, average B-factor of  the activation loop L644 – T678 ~65 Å2). 113 For 
CDK2, the selected structure was pdb 4I3Z (Resolution 2.05 Å, R-factor 0.199, R-free 0.228, 
average B-factor of the hinge region E81 – D86 ~ 30 Å2, average B-factor of  the activation 
loop L148 – S181 ~35 – 45 Å2). 114 For PKA, the selected structure was pdb 2GU8 (Resolution 
1.96 Å, R-factor 0.215, R-free 0.251, average B-factor of the hinge region E121 – E127 ~ 40 
Å2, average B-factor of  the activation loop F187 – N216 ~40 – 50 Å2). 115   
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2.3.1.2. Structural comparison of AURKA, AURKB, Src, FGFR1, CDK2 and PKA  
In the first instance, structural alignment of AURKA, AURKB, Src, FGFR1, CDK2 and PKA 
showed that the hinge region and the flexible chain where ATP bound, the back loop and front 
loop were highly conserved among the 6 kinases. For the activation loop, the similarity of the 
residues dropped significantly. Only AURKA, AURKB and PKA showed some similarity to 
each other. (Figure 2.8)  
 
PDB 4I3Z|CDK2_HUMAN      PNIVKLLDVIHTEN-KLYLVFEF-LHQDLKKFMDAS 
PDB 2GU8|PKA_HUMAN       PFLVKLEFSFKDNS-NLYMVMEYVPGGEMFSHLRRI 
PDB 1OL7|AURKA_HUMAN     PNILRLYGYFHDAT-RVYLILEYAPLGTVYRELQKL 
PDB 4C2W|AURKB_X.laevis  PNILRLYNYFYDRR-RIYLILEYAPRGELYKELQKH 
PDB 5AM6|FGFR1_HUMAN     KNIINLLGACTQ-DGPLYVIVEYASKGNLREYLQKR 
PDB 2H8H|SRC_HUMAN       EKLVQLYAVVSE-E-PIYIVTEYMSKGSLLDFLKG- 
 
 
PDB 4I3Z|CDK2_HUMAN       IGEGTYGVVYKARNKL-------TGEVVALKKIRL 
PDB 2GU8|PKA_HUMAN        LGTGSFGRVMLVKHKE-------TGNHYAMKILDK 
PDB 1OL7|AURKA_HUMAN      LGKGKFGNVYLAREKQ-------SKFILALKVLFK 
PDB 4C2W|AURKB_X.laevis   LGKGKFGNVYLAREKK-------SHFIVALKVLFK 
PDB 5AM6|FGFR1_HUMAN      LGEGCFGQVVLAEAIGLDKDKPNRVTKVAVKMLKS 
PDB 2H8H|SRC_HUMAN        LGAGQFGEVWMATYN--------KHTKVAVKTMKP 
 
 
 
PDB 4I3Z|CDK2_HUMAN       VPSTAIREISLLKELNH-PNIVKLLDVIHTENKLYLV 
PDB 2GU8|PKA_HUMAN        IEHTL-NEKRILQAVNF-PFLVKLEFSFKDNSNLYMV 
PDB 1OL7|AURKA_HUMAN      VEHQLRREVEIQSHLRH-PNILRLYGYFHDATRVYLI 
PDB 4C2W|AURKB_X.laevis   VEHQLRREIEIQAHLHH-PNILRLYNYFYDRRRIYLI 
PDB 5AM6|FGFR1_HUMAN      DLSDLISEMEMMKMIGKHKNIINLLGACTQDGPLYVI 
PDB 2H8H|SRC_HUMAN        -VEAFLAEANVMKTLQH-DKL-VKLHAVVTKEPIYII 
 
 
 
PDB 4I3Z|CDK2_HUMAN       LLQGLAFCHSHRVLHRDLKPQNLLINTEGAIKLADFG 
PDB 2GU8|PKA_HUMAN        IVLTFEYLHSLDLIYRDLKPENLLIDQQGYIQVTDFG 
PDB 1OL7|AURKA_HUMAN      LANALSYCHSKRVIHRDIKPENLLLGSAGELKIADFG 
PDB 4C2W|AURKB_X.laevis   LADALMYCHGKKVIHRDIKPENLLLGLKGELKIADFG 
PDB 5AM6|FGFR1_HUMAN      VARGMEYLASKKCIHRDLAARNVLVTEDNVMKIADFG 
PDB 2H8H|SRC_HUMAN        IAEGMAFIEQRNYIHRDLRAANILVSASLVCKIADFG 
 
 
PDB 4I3Z|CDK2_HUMAN      LARAFGVPVRTYTH--------EVVTLWYRAPEILLGCKYYST 
PDB 2GU8|PKA_HUMAN       FAKRV-KGRTW--T--------LCGTPEYLAPEIILS-KGYNK 
PDB 1OL7|AURKA_HUMAN     WSVHAPSSRRT--T--------LCGTLDYLPPEMIEG-RMHDE 
PDB 4C2W|AUKBA_X.laevis  WSVHAPSLRRR--T--------MCGTLDYLPPEMIEG-KTHDE 
PDB 5AM6|FGFR1_HUMAN     LARDIHHIDYY------KKTTNGRLPVKWMAPEALFD-RIYTH 
PDB 2H8H|SRC_HUMAN       LARLIEDNEY-------TARQGAKFPIKWTAPEAALY-GRFTI 
 
 
Figure 2.8. Structural comparison of the catalytic domain of AURKA, AURKB, Src, FGFR1, 
CDK2 and PKA. Box: DFG motif prior to the activation loop. 
 
Hinge region 
Flexible chain 
Back loop 
Front loop 
Activation loop 
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Examining the hinge region in detail, the sidechains of E211 and A213 of AURKA point 
downwards and away from the hinge region. It was known in many crystal structures of 
AURKA and ATP/ADP that the ligands were bound to the hinge region by hydrogen bonding 
with the backbone of E211 and A213. The equivalent residues to E211 and A213 of AURKA in 
AURKB, Src, FGFR1, CDK2 and PKA also have the sidechains pointing away from the 
catalytic pocket. In fact, no sidechains of the residues in the hinge region of AURKA (E211 – 
T217) pointed into the catalytic pocket. The sidechains of the equivalent residues to E217 of 
CDK2, PKA and AURKB (D86 of CDK2, E127 of PKA and E177 of AURKB) pointed into the 
ATP binding site. Those of FGFR1 and SRC pointed away. Preliminary biochemical findings 
of the IC50 difference between CoA and dpCoA (4.4 and 17 µM respectively) suggested that 
there might be hydrogen bonding interaction between T217 and the 3’ phosphate of CoA. It 
suggested that a T or S residue with –OH sidechain might be able to form hydrogen bonding 
with the 3’ phosphate and account for the kinase sensitivity towards CoA. However, the 
structural alignment showed that although the T217 position was less conserved compared to 
other positions of the hinge region, it was difficult to conclude that there was hydrogen bonding 
between CoA and the residue at that position and such interaction was responsible for a kinase 
sensitivity towards CoA. The structural alignment showed that the –OH sidechain and the –NH 
mainchain of T217 pointed away from the catalytic region, making it unlikely that there would 
be any hydrogen bonding between T217 and 3’ phosphate of CoA. 
 
When examining the structural alignment of the activation loops of AURKA, AURKB, Src, 
FGFR1, CDK2 and PKA, the DFG motif prior to the activation loop was conserved among all 
investigated kinases but the activation loop residues varied. (Figure 2.9) The two kinases, 
AURKB and PKA, which shared the most residue similarity to AURKA in the activation loop, 
were examined in more details. For the activation loop of AURKA, only the sidechains of 
W277 and C290 were likely to point into the catalytic domain. For PKA, a number of 
sidechains pointed into the catalytic domain, including F187 (equivalent to W277 in AURKA), 
K189, T197 (phosphorylated site) and C199 (equivalent to C290 in AURKA). Among those 
residues, F187 and C199 were closest to the ATP binding site. For AURKB, W237 (equivalent 
for W277 in AURKA) and C250 (equivalent for C290 in AURKA) were also the closest 
residues to the ATP binding site with their sidechains pointing into the catalytic region. 
However, the exact positions of these residues (so as their distance from the ATP binding site) 
varied as the activation loop of the kinases adopted different conformation. None of the 11 
crystal structures of AURKB (of Xenopus laevis species) available shared similar 
conformations of the activation loop with 1OL7. The AURKB kinase was in fully activated 
form and the conformations of its activation loop resembled that of 1OL5 (TPX2-bound 
activated AURKA) more. For PKA, the structural alignment showed that PKA also contained a 
C199 which was at the same position as C290 of AURKA and PKA was not CoA sensitive. 
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Further search on the different conformations of PKA activation loop out of 172 structures in 
MOE Protein Kinase Database revealed that none was reported to adopt similar conformations 
as that of AURKA in 1OL7.  The activation loop of AURKA alone already showed varied 
conformations as presented in Figure 2.6. The conformation of the activation loop may be an 
important factor accounting for inhibitory selectivity of CoA towards AURKA. 
 
The observation of the flexible conformations of the activation loop also suggested that it might 
be very difficult to build an accurate homology model of the activation loop of AURKA or 
more precisely a more accurate model than which was obtained from X-ray crystallography. As 
mentioned, it is only possible to build a homology model if there exist homologous proteins 
which have similar conformations of activation loop of AURKA, then a model of the unknown 
activation loop can be constructed using amino acid alignment and the backbone structure of 
the known structures. The templates should share at least 40% homology with the targets and 
RMSD values between final positions of Cα in the model and templates should be less than 1.5 
Å. However, the activation loop appeared to be poorly conserved and is capable of adopting 
different conformations, which are unique for a particular kinase such as for AURKA, and 
essential for the activity of the kinase. This nature was not supportive to homology modelling.  
 
In summary, 
The hinge region was highly conserved in kinase structure so that the overall major effect that 
differentiated the fitting of CoA in AURKA catalytic domain over the catalytic domains of 
other kinases was likely to be the steric effect around T217 region. This steric effect around 
T217 region likely defines the pocket around the hinge region for CoA to fit in.  
The flexible and various conformations of the activation loop might be an important factor for 
CoA selectivity. AURKA kinase seemed to adopt a unique conformation of the activation loop 
that allowed interactions with CoA.  
 
2.3.2. Docking results and discussion of the conformation of CoA in AURKA 
 ADP 
The validation of CHEMPLP showed that CHEMPLP correctly predicted the binding 
conformation of the adenosine group of ADP (the original ligand) as that in the X-ray crystal 
structure. ADP bound at the hinge region of the ATP binding site, with the –NH2 of adenine 
ring forming H-bond with –CO backbone of E211. (Figure 2.9) For the flexible ribose and 
pyrophosphate groups, CHEMPLP predicted the binding position similar to that in the original 
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crystal structure. The ribose was predicted not having any hydrogen bonding interactions and 
this is in agreement with the binding shown in the original structure. The pyrophosphate group 
was predicted to form hydrogen bonding between P1=O and –NH2 sidechain of K162. This is in 
agreement with the original crystal structure. CHEMPLP predicted that the pyrophosphate 
group might take up another hydrogen bonding between P2=O and –NH backbone of F144. This 
was not indicated in the original crystal structure. Overall, CHEMPLP was able to predict 
accurately the binding of rigid structural part of ADP and was able to predict the position and 
binding of the flexible structural part of ADP to a reasonable extent.  
 
Figure 2.9. Re-evaluation of 1OL7. ADP docking result. a) ADP crystallised structure (C atoms 
in grey), ADP solution generated by CHEMPLP (C atoms in green). H-bonds (dashed lines). 
 
CHEMPLP was also able to predict the conformations of other co-crystallised molecules of 
other original protein structures (in this project, AURKA) of various expression systems; for 
example, molecule AK8 in 3EFW (expression system: Spodoptera frugiperda), 99 YPH in 4JBP 
(Homo sapiens), 100 and ZZL in 2WTV (Escherichia coli) 29. (Appendix 2.3) As CHEMPLP was 
able to predict the conformation of ADP in 1OL7 and the conformations of other binding 
ligands in other protein structures, it was then used to dock CoA and its analogues in the two 
models of 1OL7, original one with missing sidechain of C290 and modified one with the 
sidechain of C290 rebuilt by MOE. The aim was that the obtained conformation result of CoA 
would be able to explain the biochemical findings that CoA exhibited inhibition against 
AURKA in the absence of TPX2 and that IC50 (CoA) was increased (4.4 µM to 47 µM) in the 
presence of reducing agent DTT. 
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2.3.2.1. Noncovalent docking results of CoA and its analogue desulfo-CoA in AURKA 
 
 CoenzymeA  
Original crystal structure 1OL7 without C290 sidechain correction 
The result showed that the adenosine group of CoA bound to the kinase hinge region in a 
similar manner to ATP/ADP. Out of 10 docking solutions, there were 5 solutions where CoA 
sat in the binding site. The best 3 binding poses from CoA, determined by the largest docking 
scores, were saved and examined. 
The docking solutions can roughly fall into two binding modes of CoA in the catalytic domain 
of AURKA: binding mode I and II as illustrated in Figure 2.10. Out of the 5 docking solutions, 
four exhibited binding mode I and one exhibited binding mode II (defined in next sentences). 
In both binding modes, CoA bound to the hinge region through H-bonding in a similar fashion 
to ADP. The ribose sugar with 3’phosphate sat at the region below G140 and Lys141 of flexible 
chain and above T217 region. Binding mode I suggested that the 3’phosphate might form H-
bond with –NH backbone of K141 whilst binding mode II suggested that it might form an 
internal H-bond with –SH of CoA. In binding mode I (higher fitness score: 87.2, Figure 2.8a), 
the pantetheine tail sat in the back loop. Its direction was secured by H-bonds of –P2=O with –
NH backbone of K141 and –OH with –NH of N261 and –OH and –NH with –COOH sidechain 
D271. In binding mode II (lower fitness score: 79.3, Figure 2.8b), similar interactions between 
CoA and hinge were observed. The ribose sugar with 3’phosphate sat in similar location as in 
binding mode I but the 3’phosphate curved down, forming internal H-bonds with –OH of the 
ribose sugar and –SH of the pantetheine tail instead. The pantetheine tail curved to the front 
surface in order for the thiol group to form the H-bond with the 3’phosphate. 
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Figure 2.10. Two binding modes of CoA suggested by GOLD. a) Binding mode I (C atoms in 
green). b) Binding mode II (C atoms in orange). H-bonds (dashed lines). 
1OL7 with rebuilt C290 sidechain 
The non-covalent docking solutions of CoA suggested the flexibility of the pantetheine tail and 
a possibility for it to reach to the activation loop.  
Using this 1OL7 structure, GOLD docking was carried out with ADP, CoA and desulfo-CoA 
(CoA molecule without –SH group) to test any interactions between –SH of CoA and C290. 
Desulfo-CoA 
2.10a.  
2.10b.  
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Out of 10 docking solutions, there were 5 solutions where the conformations of CoA extended 
to the C290 residue. (Figure 2.11a) In other words, 50% of the best docked poses showed that 
there would be a potential for interaction between CoA (-SH) and C290 of AURKA (non-
covalent or covalent i.e. di-S bond). The best binding poses from CoA, determined by the 
largest docking scores, suggested possible disulfide linkages with C290 (Figure 2.11b) based on 
the close distance between the two sulfur atoms of CoA and C290 of 3.8 Å. 
 
 
2.11a.  
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Figure 2.11. Binding poses of CoA suggested by GOLD showing position of –SH around C290 
in AURKA ATP binding pocket. a) Highest scored docking pose (85) (C atoms in green). Other 
scored docking poses (C atoms in grey). b) Highest scored docking pose of CoA generated by 
GOLD. H-bonds: dashed lines. Clashes: orange rings. 
 
For desulfo-CoA, however, the best docking pose was curved to the front. Forty percent of the 
best docking poses had the tail around the C290 area (shown below), similar to the best pose of 
CoA. However, not having the –SH, there was no possibility for desulfo-CoA to form di-S 
bonding with C290 of AURKA. 
 
   
2.11b.  
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Figure 2.12. Best binding pose of desulfo-CoA suggested by GOLD showing the possible 
position of end–CH3 in AURKA ATP binding pocket. Highest scored docking pose (73.4) (C 
atoms in green). H-bonds (dashed lines). Clashes (orange rings). 
2.3.2.2. Covalent docking results of CoA and its analogue desulfo-CoA in AURKA 
This experiment was to test if a covalent bond was formed first whether CoA would fit inside 
the ATP binding pocket. It was hypothesised that when a covalent bond was formed first, CoA 
would NOT fit inside the ATP binding pocket of AURKA. The docking was done on 1OL7 
with rebuilt C290 model. 
Docking results 
Three out of 10 solutions and 3 out of 5 highest scored binding mode that suggested CoA might 
penetrate into the ATP binding pocket, particularly the hinge region. (Figure 2.13)  
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Figure 2.13. Binding poses of CoA inside AURKA ATP binding site suggested by GOLD 
when a di-S covalent bond is set between –SH (CoA) and C290.  a) Three scored docking poses 
of CoA that fit in the hinge region of the ATP binding pocket: best fit (cf. binding of ADP): 
docking score of 88.6 (C atoms in green). Other two scored poses (scored 91.8 and 87.4) (C 
atoms in grey). b) Best fit docking pose (C atoms in green). H-bonds (dashed lines). Clashes 
(orange rings). 
 
Out of the three solutions, only one showed a conformation at the adenosine head to be close to 
that of ADP in the hinge region. However, in order to accommodate such conformation when a 
di-S bond is formed between CoA and C290 first, the rest of the molecule curved out of the 
2.13a.  
2.13b.  
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pocket, creating bond tensions/clashes. In conclusion, in most cases, the adenine head of CoA 
did not manage to penetrate in ATP hinge region. (Figure 2.13b)  
2.3.2.3. Discussion of docking results 
In summary, the non-covalent docking results suggested that CoA was able to fit in the 
substrate binding site of AURKA, likely in an extended conformation with the adenosine head 
located in the hinge region through hydrogen bonding with E211 and A213 and the pantetheine 
tail located in the activation loop. There would be some interactions between the –SH of CoA 
and the sidechain –SH of C290 of the activation loop due to the close distance (3.8 Å) of these 
two when CoA was in the extended form. (Figure 2.11) This interaction with the activation loop 
may be important for the selectivity of CoA towards AURKA as later structural comparison of 
the activation loop of Aurora kinases to other kinases in the screening panel showed that the 
activation loop of Aurora kinases was significantly different from others and C290 residue was 
not been seen in equivalent conformation in any other kinases. This suggested conformation of 
CoA with possible interactions between –SH of CoA and C290 residue was able to explain the 
increase in IC50 (CoA) from 4.4 µM to 47 µM in the presence of DTT (a reducing agent to 
reduce disulphide bond). Furthermore, this conformation was also able to correlate with the 
inactivity of CoA in the presence of TPX2. In the TPX2-bound state, the activation loop of 
AURKA was pulled down as seen in crystal structure 1OL5 hence there would be no more 
interaction between –SH of CoA and C290. (Figure 2.14)  
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Figure 2.14. Comparison of the possible interactions between CoA and the activation loop of 
AURKA in the conformations of the TPX2-unbound state (1OL7) and TPX2-bound state 
(1OL5). 
 
Docking results also showed that when the –SH of C290 was removed (no interaction with 
C290), CoA adopted different conformations (suggested as binding mode I or II, Figure 2.10) 
and no longer interacted with the activation loop. These conformations might not be able to 
sustain CoA in the substrate binding site of AURKA. Moreover, using this extended 
conformation of CoA in covalent docking, the docking results suggested that it was unlikely 
that a di-S bond would form between –SH of CoA and C290 prior to the binding of adenosine 
head of CoA inside the hinge region. This is in agreement with the biochemical conclusion 
(finding (3), Section 1.4) where CoA was postulated to bind to the hinge region first before 
rearranging itself to form interactions at the activation loop. 
 
As this model was able to explain the biochemical findings, it was then used in the in-silico 
mutant experiment of T217 residue to investigate any possible interactions between CoA and 
T217 residue. 
2.3.2.4. In silico mutant experiment on AURKA T217 
The in-silico mutant experiment was done on 1OL7 structure with corrected C290 in MOE 
(using protein builder tool) and the preferred CoA’s mode of binding in this case (Figure 2.11b) 
1OL5 (TPX2-bound) 
1OL7(TPX2-unbound) 
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was used. The selected residue, T217 was mutated to T217N, T217V, T217E and T217C using 
protein builder tool. The possible interactions/clashes between those mutants and CoA were 
judged in electrostatic and steric terms. 
 
The results from the in-silico mutant experiment suggested that at the T217 position, steric 
effects likely accounted for the difference in IC50 between CoA and dpCoA instead of the 
hydrogen bonding.  A supplementary check on the possible interactions between the proposed 
extended conformation of CoA and some T217 mutants was carried out. It was shown that the 
3’ phosphate of the proposed extended conformation of CoA did not show to form any 
hydrogen bonding with T217. When comparing AURKA T217 mutants: T217N, T217E, 
T217C and T217V with the wild type AURKA (1OL7), it appeared that T217V and T217E 
mutants had the sidechain pointing inwards the binding pocket, hence creating steric hindrance 
against CoA fitting. The clashes were particularly clear in the case of T217E mutant. (Figure 
2.15b) 
 
 
Figure 2.15. Surface map between AURKA T217V and T217E mutants and CoA. a) AURKA 
T217V (C atoms in black). b) AURKA T217E (C atoms in dark green). Part of CoA preferred 
binding mode (C atoms in green). Surface interaction of CoA (mesh). 
 
For T217C and T217N mutants, however, the sidechains of T217C and T217N protrude 
outwards and away from the binding pocket, resulting in no steric clashes. As a result, although 
the length of the sidechain of N residue is similar to E, it would not obstruct CoA fitting. 
(Figure 2.16) 
2.15a.  2.15b.  
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Figure 2.16. Surface map between AURKA T217N and T217C mutants and CoA. a) AURKA 
T217N (C atoms in cyan). b) AURKA T217C (C atoms in pink). Part of CoA preferred binding 
mode (C atoms in green). Surface interaction of CoA (mesh). 
2.3.2.5. Overall conclusions 
The non-covalent and covalent docking experiments and in-silico mutant experiment confirmed 
that the 1OL7 model was able to explain the biochemical findings observed by Dr. Tsuchiya 
hence it was used further to design compounds with the aim to verify the CoA’s conformation 
in AURKA and to produce an AURKA selective inhibitor. The results also suggested that:  
(i) CoA was able to fit in the ATP binding pocket of AURKA in an extended 
conformation with the end –SH in close proximity to C290 of the activation loop. 
The length of CoA seems to be optimal for binding to AURKA ATP active site. 
Longer length seems to deplete the chance of contact with C290 of the activation 
loop. 
(ii) It was unlikely for CoA to form a di-S covalent bond first then rearrange itself to fit 
in the ATP active site of AURKA. Such procedure created too much strain to be 
compensated for by the formation of a covalent bond. 
2.3.2.6. Further suggestion of CoA analogues to investigate the conformation of CoA in 
AURKA 
Affinity probes, which are CoA analogues, were designed in order to further examine: 
(i) The upper limit of the length of a compound that would fit in AURKA catalytic 
domain. 
(ii) The possible location of CoA in AURKA without a crystal structure. 
(iii) The possible covalent bonding that can be generated around AURKA catalytic 
domain. 
2.16a.  2.16b.  
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Three common (chosen) examples: -azido benzoic acid (a photoreactive crosslinker),                       
-iodoacetimide and -maleimide analogues of CoA, were suggested for docking. Both non-
covalent and covalent docking were carried out for the three analogues. 
 
 
 
 
Backgrounds 116 
Crosslinking is the process of chemically joining two or more molecules by a covalent bond. 
Crosslinking reagents (or crosslinkers) are molecules that contain two or more reactive ends 
capable of chemically attaching to specific functional groups (primary amines, thiols, etc.) on 
proteins or other molecules.  
In this particular context, crosslinking is used for capturing and identify unknown protein 
interactors or interaction domains. The thiol group, –SH of the sidechain of C290 is the target 
site for crosslinking in this case. Examples of popular crosslinker reactive groups in this case 
are maleimide and haloacetyl (-bromo or –iodo) (10 and 11 analogues). It is also of interest to 
investigate other possible interactions between CoA analogues and the catalytic domain of 
AURKA. As a result, a photo-reactive crosslinker, azidobenzoic acid 9 44b analogue, was taken 
into consideration.  
 
 
9  
10 
11 
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Aryl azide (Azidobenzoic acid) reaction chemistry 
 
Figure 2.17. Photochemical conjugation between aryl azide reagent and primary amine of 
protein residues. 
Under exposure to UV light (250 – 350 nm), an aryl azide forms a nitrene group that can initiate 
addition reactions with double bonds or insertion into C-H and N-H sites or can undergo ring 
expansion to react with a nucleophile (e.g. primary amine). In the case where there is an 
exposed primary amine (from the side-chains of protein residues), the ring expansion reaction is 
favoured compared to other reactions. 
 
Maleimide reaction chemistry 
 
Figure 2.18. Thioether linkage reaction between a maleimide-containing reagent and a thiol 
group of a protein. 
In a pH medium of 6.5 – 7.5, the maleimide group of the reagent reacts specifically with thiol 
groups of a protein. This results in the formation of a stable thioether linkage that is irreversible. 
In more alkaline conditions (pH >8.5), the reaction favors primary amines and also increases 
the rate of hydrolysis of the maleimide group to a non-reactive maleamic acid. Maleimides do 
not react with tyrosines, histidines or methionines. 
 
Haloacetyl (-iodo) reaction chemistry  
 
Figure 2.19. Conjugation of iodoacetyl crosslinker and a thiol group of a protein. 
 
The most commonly used haloacetyl crosslinkers contain an iodoacetyl or a bromoacetyl group. 
At physiologic pH (>7.5) haloacetyls react with thiol groups, resulting in a stable thioether 
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linkage. The iodoacetyl group is able to react with other amino acids in the absence of free 
thiols, or if iodoacetyl group is used in large excess. Histidyl sidechains and amino groups react 
in the unprotonated form with iodoacetyl groups above pH 5 and pH 7, respectively. Iodoacetyl 
reactions and preparations are performed in the dark in order to limit free iodine generation, 
which has the potential to react with tyrosine, histidine and tryptophan residues.  
 
Non-covalent docking docking results  
Azidobenzoic acid analogue, 9 
All 10 solutions suggested that analogue 9 could not fit in the binding pocket in the same 
orientation as CoA. Only 2 out of 10 scored docking poses suggested the possibility of the 
adenine head of 9 to fit in the hinge region. Even in that case, the length forced the molecule to 
curve around and out of the pocket. The end of the molecule containing the phenyl azide 
reactive group was not in close proximity to C290 in any scored docking poses.  
 
Figure 2.20. Highest scored docking pose (82.9) of CoA’s azidobenzoic acid analogue, 9 
suggested by GOLD (C atoms in green) in non-covalent bonding setting. H-bonds (dashed 
lines). Clashes (orange rings). 
 
Iodoacetimide analogue, 10 
There is 60% chance of finding iodoacetimide analogue, 10 with the adenine head group in the 
ATP hinge region and three out of four best scored docking poses, including the highest scored 
docking pose, suggested that the tail, due to its length, would curve into the back of the ATP 
binding site and not be in close contact with C290. (Figure 2.21) 
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Figure 2.21. Binding poses of 10 inside AURKA ATP binding site suggested by GOLD in non-
covalent bonding setting.  a) Three best binding poses (out of 10) of CoA’s iodoacetimide 
analogue, 10 suggested by GOLD. Highest scored docking pose (73.7) (C atoms in green). 
Other scored docking poses (C atoms in grey). b) Highest scored docking pose. H-bonds 
(dashed lines). Clashes (orange rings). 
 
Maleimide analogue, 11 
There is only 1 out of 10 solutions (the highest scored docking pose) suggesting the binding of 
maleimide analogue, 11 to AURKA ATP binding pocket. However, due to the length, the 
2.21a.  
2.21b.  
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maleimide tail also had to curve to the front, out of the pocket and not in close proximity to 
C290. (Figure 2.22) 
 
Figure 2.22. Single valid scored docking pose (78.6) of CoA’s maleimide analogue, 11 
suggested by GOLD (C atoms in green) in non-covalent bonding setting. H-bonds (dashed 
lines). Clashes (orange rings). 
 
Covalent docking results 
The covalent docking results showed that the analogues have to come out of the binding pocket 
completely in order to accommodate the set covalent bond at C290. Even for iodoacetimide 
analogue, 10, the shortest among the three, none of the scored docking poses showed that it may 
be able to fit in the hinge region. Figure 2.23 showed the two highest scored docking poses 
(scored 105.8 and 99.0 respectively in Figure 2.23a and 2.23b) of A2 in this setting which are 
also the closest to the hinge region compared to the rest. However, those were not able to fit in 
the hinge region in the manner seen in ADP. 
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Figure 2.23. Two highest scored binding poses (out of 10) of CoA’s iodoacetimide analogue, 
10 suggested by GOLD when a di-S covalent bond was set between –SH (A2) and C290. a) 
Highest scored docking pose (105.8). b) Second highest scored docking pose (99.0) (C atoms in 
green). 
 
In summary, 
Out of the 3 examined proposed affinity analogues of CoA, it is shown by docking that the 
iodoacetimide analogue, 10 and azido benzoic acid analogue, 9 may be able to bind to ATP 
active site and hence suggested for synthesis. (The synthesis was carried out by my colleague, 
Fiona Bellany.) 
2.23a.  
2.23b.  
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2.4. Ab initio design of a new AURKA selective inhibitor 
2.4.1. Re-examination of preliminary docking results in the 1st generation of compounds 
There were three critical problems with the initial docking studies provided by Dr. Guruprasad. 
The crystal structure used, 2DWB, 117  lacks the full activation loop. It is also not in 
phosphorylated (activated) form. It also appeared that one of the docking solutions of CoA was 
used as a template to dock potential lead compounds. This assumption reduced the accuracy of 
computational docking results significantly. As such, re-examination of the docking results 
were carried out. The results showed that for the proposed synthetic candidates, 1 and 2, by Dr. 
Guruprasad, none of the scored docking poses indicated a good fit of the analogues inside the 
ATP binding site. For compound 1, the docking results showed that none of the 10 docking 
solutions showed a conformation where the heteroaromatic head group sat inside the hinge 
region. The highest scored docking solution (88.0) was in opposite direction to CoA. (Figure 
2.24) 
 
 
Figure 2.24. Binding poses of compound 1 in AURKA ATP binding site suggested by GOLD. 
Highest scored docking pose (88.0) of 1. ADP (C atoms in grey, surface area shown). 1 (C 
atoms in green). 
 
For compound 2, the docking results showed that the molecule adopted a conformation where 
the heteroaromatic head group was completely out of the binding hinge region (Figure 2.25) 
None of the 10 docking solutions showed a conformation where the heteroaromatic head group 
sat inside the hinge region in similar manner as the core of VX680 (Figure 1.10). 
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Figure 2.25. Binding poses of compound 2 in AURKA ATP binding site suggested by GOLD. 
Highest scored docking pose (90.2) of 2. ADP (C atoms in grey, surface area shown). 2 (C 
atoms in green). 
 
In addition, synthesis of the head group of proposed synthetic candidates 1 and 2 could not be 
achieved. Instead, the heteroaromatic head groups provided by my colleague allowed the 
synthesis of 12 and 13.  
 
 
Previous crystal structure of VX680 demonstrated that the N-1 and N-2 of the pyrazole ring 
were responsible for H-bonding with the hinge region. (Figure 1.10) As a result, it casts doubt 
on the bindings of compound 12 and 13 in AURKA catalytic domain. Nevertheless the 
computational dockings were re-examined for possible conformations of 12 and 13 in the 
binding site. For analogue 12, the suggested conformations of the ligand either came out of the 
hinge region or in opposite direction of ADP. (Figure 2.26) Figure 2.26a showed the highest 
12  
13 
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scored docking pose of 12 where the aromatic head came out of the hinge region. It was the 
closest distance to the hinge region suggested by all 10 poses. Other poses were either further 
away from the binding site or in the complete opposite direction as in Figure 2.26b. For 
analogue 13, similar poses were observed. The compound was predicted to not fit in the hinge 
region. Similar to analogue 12 it either came out of the pocket or in opposite direction of ADP. 
(Figure 2.27) The docking results were in agreement with later preliminary IC50 results, which 
of 12 is >7 mM and of 13 is >2 mM. For this reason, the analogues were not pursued further in 
synthesis. 
 
 
Figure 2.26. Binding poses of CoA’s analogue 12 in AURKA ATP binding site suggested by 
GOLD. a) Highest scored docking pose (85.6) of 12. b) Third highest scored docking pose 
(77.7) of 12. ADP (C atoms in grey, surface area shown). 12 (C atoms in green). 
2.26a.  
2.26b.  
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Figure 2.27. Binding poses of CoA’s analogue 13 in AURKA ATP binding site suggested by 
GOLD. a) Highest scored docking pose (95.2) of 13. b) Second highest scored docking pose 
(91.0) of 13. ADP (C atoms in grey, surface area shown). 13 (C atoms in green). 
 
2.4.2. Methods of new design for the 2nd generation of compounds 
As briefly stated in Chapter 1, the first generation of compounds was halted after the thorough 
review. In Section 2.4.1, I showed that the compounds recommended for synthesis by Dr. 
Guruprasad in the first generation of compounds were invalid candidates as AURKA inhibitors. 
Following the “proof of concept” direction (Section 1.5.2) I outlined the following 
computational method to design molecules for the purpose of validating biochemical and 
computational findings of CoA and to understand in detail the catalytic domain of AURKA. 
These are to set the foundation for designing an AURKA selective inhibitor. The method 
consists of 4 steps. Firstly, the surface area of AURKA (PDB: 1OL7) (Figure 2.28a) was 
examined. Crystal structures of known inhibitors were superimposed to examine ligand-
receptor interactions (mostly around hinge region). The possible binding modes (with and 
without the correction of C290 sidechain) of CoA were superimposed to explore ligand-
receptor interactions in the part that had not been exploited. (Figure 2.28b) After that, a part of 
2.27a.  
2.27b.  
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the ATP binding pocket was chosen to further design structure and investigate SAR. This was 
followed by screening an in-house database of inhibitor scaffolds of kinases to choose a 
scaffold to build up new structures that may offer desired ligand-receptor interactions. Finally, 
the designed structures were docked and evaluated for further modification/development. 
  
 
 
Figure 2.28. AURKA surface interaction map with and without CoA as ligand. 
 
Examining the surface area of AURKA showed that there are two aspects to consider with 
regards to the structure of AURKA ATP active site. The first aspect is the hinge region along 
with small hydrophobic back and front grooves that are commonly known and exploited in the 
2.28a. Protein surface map 
of AURKA generated by 
MOE. (PDB: 1OL7). 
Hydrophobic area (grey), 
polar areas (red and cyan).  
2.28b. Surface interaction 
maps of possible binding 
modes of CoA in AURKA 
generated by MOE. CoA 
binding mode with C290 
correction (Cα in green). 
CoA binding mode without 
C290 correction (Cα in 
cyan). Possible growing 
directions of new 
inhibitors: dashed arrows.  
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literature. The second aspect is the extended regions that are mostly unexplored, including: a 
back groove that was shown to accommodate one binding mode of CoA (C atoms in cyan), 
demonstrated by an orange arrow in Figure 2.28b; a front, less defined groove containing C290, 
demonstrated by another orange arrow in Figure 2.28b; and a front polar hump containing 
T217, E260 and N261. As examined in Figure 1.13, MLN8054 may be able to interact with this 
region. Taking CoA as the scaffold, the mentioned extended regions of the ATP active site were 
chosen for further SAR investigation. (Demonstrated by regions R1, R2 and R3 in Figure 2.29). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.29. AURKA ATP binding site divided into areas of investigation. R0: head group 
bound to hinge region, S: ribose region; R1: polar hump containing T217, E260 and N261; R2: 
phosphate binding site; R3: pantetheine binding region. (PDB: 1OL7) 
 
Due to time limitation and for the purpose of comparison, it was decided that R0 and S were 
first kept the same as in CoA. In other words, the first new designed compounds (the second 
generation of compounds) would contain an adenosine head group. 
2.4.2.1. Exploring the phosphate binding region, R2 
The phosphate binding region, linking the ribose and pantetheine region was first investigated. 
The idea was to choose a linker that is chemically robust and non-toxic to replace the 
pyrophosphate. The properties of being chemically robust is important as it allows generation of 
a large set of compounds in a short period of time, important for SAR study. Literature has 
suggested that triazole systems can be used as a phosphate mimic. 118 When applying this to a 
pyrophosphate system, there are two concerns: 
(i) The length and conformational flexibility of this chemical linkage compared to the 
pyrophosphate system. 
(ii) The reduction in the number of intermolecular hydrogen bonding compared to that 
provided by the pyrophosphate system. 
S 
R3 
R2 
R1 
R0 
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Whether these changes will increase or reduce the activity of CoA/designed compounds against 
AURKA is open for investigation. However it was decided to start synthesising a set of 
compounds that structurally differ from CoA in one part but similar in others (e.g. keeping 
adenosine head and pantetheine tail, replacing pyrophosphate linkage by triazole linkage) for 
comparison purposes.  
 
In summary, for the second generation of compounds, I chose an acetyl triazole group as the 
linker replacing the pyrophosphate of CoA. It should be noted that the acetyl triazole group is 
about 1.5 Å longer than the pyrophosphate. The length difference may not be significant for 
short molecules but may play a larger role in long molecules where the upper limit for the 
length to fit in the binding site is reached.  
                                                            
Through further in-house database 119 screening of inhibitor scaffolds of kinases and docking 
study using GOLD of several structures, it was realised that compounds with a phenyl group at 
the end with appropriate length could form π-π stacking interactions with F144 of AURKA 
ATP binding site. This interaction was favourable and molecules always seemed to rearrange 
themselves to accommodate it. F144 is the residue guarding the end of the phosphate binding 
region and the beginning of the pantetheine binding region. As a result, two compounds 14 and 
15 was proposed for docking and synthesis. (Figure 2.30) The synthesis was completed by me. 
                                               
Figure 2.30. Designed compounds to probe the interactions in the phosphate binding region. 
CHEMPLP suggested that six out of seven solutions showed a consistent binding mode in 
which the phenyl group was stacked under F144 residue. The acetyl triazole linker might form 
H-bonds with K162 to further secure the position as suggested by poses. Changing the –OBn 
end to –OMe resulted in a loss of consistent prediction of its conformation and much lower 
overall scoring. However 14 was not soluble in water. In order to improve the solubility of 14, 
Acetyl triazole linkage 
14 15 
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14 was modified to 15 (containing a urea group), which was later found to be soluble in water 
as predicted. Besides, all of the more successful Aurora kinase inhibitors present did not contain 
an ester bond. 15 was designed to contain no ester bond. 
 
 
 
2.31a.  
2.31b.  
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Figure 2.31. Conformation of 14 in AURKA ATP binding site. a) Scored docking of 14 in 
AURKA generated by GOLD. Highest scored docking pose (C atoms in green). Other scored 
docking poses (C atoms in grey). b) Highest scored docking pose (96.4) of 14. c) Ligand 
interaction maps of best scored docking pose of 14 in AURKA generated by MOE. 
 
Docking results of 15 showed comparable scoring to 14, all the valid solutions (8 out 10 
generated solutions) suggested consistent conformations where the phenyl ring was placed 
under F144. (Figure 2.32) 
 
 
2.32a.  
2.31c.  
14 
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Figure 2.32. Conformation of 15 in AURKA ATP binding site. a) Scored docking of 15 in 
AURKA generated by GOLD. Highest scored docking (C atoms in green). Other scored 
docking poses (C atoms in grey). b) Highest scored docking pose (99.1) of 15. c) Ligand 
interaction maps of best scored docking pose of 15 in AURKA generated by MOE. 
2.4.2.2. Exploring the pantetheine binding region, R3 
Using adenosine as the head group, and acetyl triazole as the linker to replace the 
pyrophosphate group, it would be informative to construct a pantetheine analogue group to 
compare the possible effect of the pantetheine group on the overall inhibitory activity of CoA 
and to explore the pantetheine binding site for further drug development. Compound 16 was 
designed based on this idea. (Figure 2.33) Docking results showed only 30% - 40% chance of 
16 to be fit in the hinge region and the –SH was not in as close proximity with C290 as that of 
CoA. The result suggested there were some good interactions between the triazole and K162 so 
2.32c.  
15 
2.32b.  
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it was suggested that the length of the tail should be cut down by 2 CH2 groups or the –
CH2COO group linked between the triazole and the tail needed to be removed. 
 
 
Figure 2.33. Conformation of 16 in AURKA ATP binding site. a) Best scored docking pose 
(91.7) of 16 (C atoms in green). b) Ligand interaction maps of best scored docking pose of 16 in 
AURKA generated by MOE. 
The effect of –SH group was investigated by designing 17, which is similar to 16 but the –SH is 
replaced by –CH3 group. 18 was proposed to be synthesised to investigate the effect of polar 
groups at the ribose. This will help deciding how to explore R1 region later. Docking suggested 
that there was only 30% of finding 17 inside AURKA ATP binding site. (Figure 2.34) The 
docking result for 18 showed that if the acetyl was introduced to protect –OH groups of the 
ribose, there would be little chance of finding 18 inside the binding site (<10%) hence no 
inhibition. (Figure 2.35) 
 
2.33a.  
2.33b.  
16 
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Figure 2.34. Conformation of 17 in AURKA ATP binding site generated by GOLD. a) Highest 
scored docking pose (90.7) of 17 (C atoms in green). b) Ligand interaction maps of best scored 
docking pose of 17 in AURKA generated by MOE. 
 
2.34a.  
2.34b.  
17 
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Figure 2.35. Conformation of 18 in AURKA ATP binding site. a) The single scored docking 
pose (73.7) suggested 18 in the ATP binding site, not the 5 highest scored docking poses (C 
atoms in green). Other scored docking poses (C atoms in grey). b) Ligand interaction maps of 
best scored docking pose of 18 in AURKA generated by MOE. 
 
In conclusion, it was suggested from docking results that 14 and 15 would likely show some 
inhibitory effect in an ATP competitive manner. 16 and 17 may provide some weak inhibition 
and based on the docking score, 16 may perform a little bit better than 17 but 18 will not exhibit 
any inhibitory effect. Later, a comparison between the IC50 of these compounds and the docking 
2.35a.  
2.35b.  
18 
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result, presented in Section 4.3 would provide a better direction for how to design further 
compounds for AURKA selective inhibition.  
2.4.2.3. Exploring the polar region containing T217, R1 
In order to explore the R1 region, the ribose was replaced by a maleimide moiety. This can act 
as a linker to link 3 groups: the head group (R0), the phosphate mimic (R2) and R1 group. Its 
chemistry and application has been extensively studied, facilitating the progress of developing 
the chemistry and generating large library. 
Screening a series of structures suggested 19 for initial synthesis, where the adenine head group 
and the phenyl urea (as in 15) were kept for the purpose of comparison. Docking results suggest 
a good inhibition with 70% chance of finding 19 inside the ATP binding site and possible 
interaction with the polar hump, which contains T217. (Figures 2.36 and 2.37) 
 
Figure 2.36. Docking result of 19 in AURKA ATP binding site. Highest scored docking pose 
(110.1) of 19 in AURKA generated by GOLD. 19 (C atoms in green). ADP (C atoms in pink). 
 
 
19 
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Figure 2.37. Conformation of 19 in AURKA ATP binding site generated by GOLD. a) Highest 
scored docking pose (110.1) of 19 (C atoms in green). b) Ligand interaction maps of highest 
scored docking pose of 19 in AURKA generated by MOE. 
 
 
2.37b.  
19  
2.37a.  
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2.5. Conclusion 
In summary, in approach A, which focused on the design and synthesis of an AURKA selective 
inhibitor based on the structures of VX680 and CoA, (Section 1.5.1) computational work done 
by Dr. Lalitha Guruprasad suggested four compounds, compound 1, 2, 12 and 13 for synthesis. 
(Figure 2.38) Compound 1 and 2 were unable to be synthesised. The syntheses of 12 and 13 are 
described in Chapter 3.  
 
 
 
 
Figure 2.38. Four main compounds in Approach A. 
 
Further computational work by me showed that none of the four compounds would exhibit any 
inhibitory effect against AURKA. This resulted in the shift in focus to Approach B. The main 
objective of Approach B was to validate the biochemical and computational findings of CoA 
and to understand in details the catalytic domain of AURKA. These are to set the foundation for 
designing an AURKA selective inhibitor. Six key designed molecules were synthesised. (Figure 
2.39) 
12  
13 
2 
1 
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Figure 2.39. Six key designed molecules in Approach B – the second generation of compounds. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
14 15 19 
16 17 18 
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3. Approach A syntheses 
3.1. Synthesis of the first generation of compounds 
As mentioned in Section 1.5.1 and 2.4, in Approach A, the designed compounds were based on 
“CoA scaffold” and VX680. This chapter includes the syntheses of compounds 12 and 13, 
where the synthetic focus was on the cyclic linker and pantothenamide end, and the initial 
synthetic attempts of VX680-heteroaromatic analogues, 3 and 4. (Figure 3.1) 
        
 
 
Figure 3.1. Synthetic targets of Approach A 
 
3.1.1. Literature research and synthetic plan of the 1st generation of compounds 
Given an example of the pantetheine-type structure with a linker, one approach to this type of 
compounds includes amide couplings and esterification reactions. (Figure 3.2) 
 
Figure 3.2. Synthesis approach to the first generation of compounds 
 
 
3 4 
12  
13 
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The structure suggests that there are three matters to consider in the synthesis of this part of the 
designed molecule: 
(i) Amide coupling reaction - Synthesis of pantothenamide tail (i.e. pantetheine 
analogue)  
(ii) Esterification 
(iii) Possible protecting group problem 
Amide coupling reaction - Synthesis of pantetheine analogues 
 
 
There are two ways to prepare the pantothenamide-type end 20, either by an amide coupling 
between pantothenic acid and an amine (Route 1) 120 or by the ring opening of D-pantolactone 
(Route 2) 121 . Virga et al. in 2006 120 reported the successful syntheses of several 
pantothenamide analogues by amide coupling between free-acid form of pantothenate and 
primary amines. (Figure 3.3)  
 
Figure 3.3. Amide coupling of pantothenic acid. (i) DPPA, DMF, 0oC; (ii) TEA, 24 h. 120 
Ring opening of D-pantolactone by amines was reported to be achievable by Kopelevich et al. 
in 1971 121a and Hoeper and Montforts in 1993 121b. This was adapted to provide another feasible 
way of preparing the pantothenamide-type analogues. (Figure 3.4)  
 
Figure 3.4. Examples of opening of D-pantolactone by amines. 121 
 
Route 1 
Route 1 (Figure 3.5) adapted from Virga et al. 120 started with the free-acid form pantothenic 
acid 22. This would provide a quick synthesis to a range of different pantothenamide-type 
compounds as the free acid can be obtained quickly from the commercially available sodium 
salts through Amberlite IR-120 resin column. 
 
20 
R = (CH2)2COOH 121a 
R = CH3 121b 
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Figure 3.5. Route 1 plan of 20. (i) Preparation of carboxylic acid in free form; (ii) amide 
coupling. 
In the reported synthesis by Virga et al., the hydroxyl groups of pantothenic acid 22 were not 
protected. Due to reactivity and steric reasons, it is likely that significant reaction in 
esterification at the desired primary alcohol would be achievable without protecting strategy. 
However, protection at -NH2 end of the linker is preferred and will be discussed in the next 
section, linker synthesis. At this point, there were three aspects to be investigated in the effort to 
make the coupling work: choice of coupling additives, solubility of reagents and/or choice of 
solvent and temperature. 
The amide bond formation can generally be achieved by using coupling additives, generating 
the active acylating reagent in situ in the presence of the amine. 122 A few common coupling 
reagents were selected. The first one to be considered was diphenylphosphorylazide, DPPA, 
reported in Virga et al. to successfully couple the pantothenic acid to a series of amines. 
Theoretically this allows the coupling to be achieved in high yield as the acyl azide is relatively 
unreactive to non-amine nucleophiles and Curtius rearrangement is relatively slow compared to 
the coupling. (Figure 3.6) 122, 123  
 
Figure 3.6. Amide coupling using DPPA 
Another selected choice was iso-tert-butyl chloroformate, to form an activating anhydride with 
the starting carboxylic acid. (Figure 3.7) The chloroformate was chosen for reactions where 
starting materials were soluble in organic solvent. 124  
 
Figure 3.7. Amide coupling using chloroformate 
Other choices of consideration were aminium salts, HBTU 125  and HATU 126 , which are 
commonly used in reactions, where starting reagents are partially soluble in common organic 
21 22 20 
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solvents other than DMF. (Figure 3.8) Esterification was first tried out using standard 
dicyclohexylcarbodiimide, DCC, as the coupling reagent. 127 
 
 
 
 
Figure 3.8. Amide coupling using aminium salts. 
Route 2 
Route 2 uses β-alanine as the starting material followed by an opening of the D-pantolactone 
ring forming the desired pantothenamide, which then undergoes an esterification, using a 
coupling agent such as DCC. (Figure 3.9) This approach, if successful, will allow the control of 
the length between two amide bonds. 
 
Figure 3.9. Planned route 2 of 20. (i) Protection of amino group, R1= protecting group; (ii) 
Amide coupling; (iii) Deprotection; (iv) Ring opening of D-pantolactone. 
 
3.1.2. Synthetic results of pantothenamide tail 
In synthetic route 1, which was adapted from Virga et al. (Figure 3.10), the free pantothenic 
acid can be obtained quantitatively by passing the commercially available sodium salt through 
Amberlite IR-120 resin column. The free acid form 22 was then coupled to propylamine using 
DPPA in the presence of triethylamine in dry DMF. Compound 20 was obtained successfully in 
96% yield in 2 g scale.  
 
 
Figure 3.10. Synthetic route 1 of 20. (i) Amberlite IR-120 resin, MeOH, water, quantitative;            
(ii) DPPA (1.5 eq), TEA (2.1 eq), DMF, 0oC, 45 min, propylamine (1.6 eq), 0oC to r.t, 20 h,  96 
%. 
HATU HBTU Activated species from HATU 
23 24 25 
26 
20 
21 22 20 
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In synthetic route 2 (Figure 3.11), the starting β-alanine was Boc-protected using Boc anhydride 
in sodium hydroxide and water with modified conditions from the literature to give N-Boc β-
alanine in 57% yield. 128 Amide coupling of N-Boc β-alanine to propylamine was achieved 
using isobutyl chloroformate to yield 29 in 58 % yield as a white powder. 129 Deprotection of 
the Boc group by TFA in CH2Cl2 provided the deprotected form of 29 quantitatively as a 
colourless oil. The product was then used directly to open the D-pantolactone ring using a 
procedure adapted from Kopelevich et al. 121a to obtain 20 as a colourless oil (total yield of 30% 
through 4 steps).  
 
Figure 3.11. Synthetic route 2 of 20. (i) Boc anhydride (1.0 eq), NaOH, water, r.t, 22 h, 57 %; 
(ii) iso-t-butyl chloroformate (1.2 eq), 28 (1.3 eq), NEt3 (1.4 eq), THF, 0oC to r.t, 20 h, 58 %; 
(iii) TFA: CH2Cl2 = 1:1, 15oC, 6 h, quantitative; (iv) 26 (1.0 eq), NHEt2 (xs), MeOH, reflux, 29 
h, 92 %. 
 
3.1.3. Synthesis of linkers and esterification 
5- and 6-membered ring linkers 
The first generation of compounds, 12 and 13, consists of a 5- or 6-membered ring linker. 
(Figure 3.1) Firstly an esterification was performed between (R)-2,4-dihydroxy-3,3-dimethyl-N-
(3-oxo-3(propylamino)propyl)butanamide, 20 and commercially available (1R, 3R)-N-BOC 1-
aminocyclopentane 3-carboxylic acid, 30 using DCC, DMAP in THF, 45oC for 15 h. It was 
successful, yielding 31 (33 % yield). However, later attempts of removal of the -Boc group by 
TFA and acidic resin Amberlyst-15 were unsuccessful. Rubin in 1948 reported that sodium 
pantothenate stability dropped 40% after 48 h at 45oC in pH 4. 130  As such it was suspected that 
the pantothenamide tail might not be able to withstand strong acidic or basic conditions or high 
temperature. Consequently, it was envisaged that the Fmoc group, which can be removed under 
mild basic condition, would be more suitable. The temperature recorded (68oC, reflux 
condition) for esterification was reexamined and shown to be incorrect due to heating plate 
error. Several attempts showed that at temperature higher than 50oC, the pantothenamide, 20, 
degraded overnight. The esterification was successfully reproduced at around 45oC.  
28 
29 
20
 
 10 
26 
23 27 
112 
 
 
Figure 3.12. Attempted synthesis of 32. (i) DCC (2.0 eq), DMAP (0.4 eq), THF, 0oC to r.t, 2 h 
then 30 (1.0 eq), 45oC, 15 h, 33%; (ii) TFA, DMF.   
3-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)cyclohexane-1-carboxylic acid, 34 was 
synthesised from the commercially available 3-aminocyclohexane-1-carboxylic acid (cis- and 
trans- mixture with >95% cis-3-aminocyclohexane-1-carboxylic acid). The 6-membered ring 
linker was initially used as a model for the 5-membered ring linker due to competitive pricing 
and availability. 
 
Figure 3.13. Synthesis of 34. (i) FmocOSu (1.2 eq), NaHCO3 (1.7 eq), water, THF, r.t, 30 h, 
95%. 
The synthesis of  (1R,3R)-3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)cyclopentane-1-
carboxylic acid, 35 from the commercially available N-Boc protected carboxylic acid was done 
in two steps, deprotection of the -Boc group using TFA in CH2Cl2 followed by Fmoc protection 
using FmocOSu. 
 
Figure 3.14. Synthesis of 35. (i) TFA (xs), CH2Cl2, r.t, 15 h, quantitative; (ii) FmocOSu (1.3 
eq), NaHCO3 (1.7 eq), water, THF, r.t, 22 h, quantitative. 
 
The Fmoc-protected linkers were then linked to the pantothenamide tail, 20 using DCC and 
DMAP, affording 36 in 37% and 38 in 32%. The compounds were stored in the Fmoc-protected 
forms and deprotection to free amine forms was performed when the coupling reaction to the 
heteroaromatic core was ready, because the free amines 37 and 39 (the removal of Fmoc group 
was confirmed quickly by 1H-NMR) easily deteriorate.  
 
 
 
 
 
20 
30 
31 
32 
33 34 
35 30 
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Figure 3.15. Synthesis of 37. (i) DCC (2.6 eq), DMAP (0.6 eq), THF, 0oC, 1 h, 20 (1.4 eq), 
45oC, 18 h, 37 %; (ii) piperidine (xs), THF, 4 h, 67%. 
 
 
Figure 3.16. Synthesis of 32. DCC (2.2 eq), DMAP (0.2 eq), THF, 0oC, 1 h, 20 (1.2 eq), 45oC, 
24 h, 32 %; (ii) piperidine, THF, r.t, 3 h, 80%.  
 
The final coupling reaction of 32 to the heteroaromatic core 39 (which was provided by my 
colleague, Fiona Bellany) was carried out using HOAt, PyAOP, DIPEA in DMF to achieve 
product 40 in 17%. However purification of the next deprotection step of the -Troc protecting 
group using Zn dust and NH4OAc was not successful due to contamination in HPLC column. 
Nevertheless the crude compound was screened for biological activity. The final coupling 
reaction of 37 to the heteroaromatic core was carried out by my colleague, Fiona Bellany. The 
reaction was not repeated due to inactivity of compound 12 (IC50 >7 mM) and crude 13 (IC50 >2 
mM) and my re-assessment of the computational work resulted in a change of approach to this 
project. (Chapter 2) 
 
 
 
34 36 
37 
35 38 
32 
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Figure 3.17. Attempted synthesis of 13. (i) 32 (1.3 eq), HOAt (1.9 eq), PyAOP (3.6 eq), 
DIPEA, DMF, 0oC to r.t, 48 h, 17%; (ii) Zn, NH4OAc, THF : H2O = 8:1, r.t, 24 h, only crude 
obtained (<10%). 
 
 
 
Figure 3.18. Synthesis of 12. (i) 37, HOAt, PyAOP, DIPEA, DMF, 0oC to r.t, 48 h, 22%; (ii) 
Zn, NH4OAc, THF : H2O = 8:1, r.t, 24 h, 78%. 
 
39 41 
12 
39 40 
13 
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3.2. Heteroaromatic core 
3.2.1. Literature and preliminary research on synthesis of the heteroaromatic head 
group, the first generation of compounds 
                                                 
 
Based on the structure of VX680 and preliminary work by my colleague, Fiona Bellany (Table 
1.3), compounds 3 and 4 were initially set as two of the target heterocycles. The regiochemistry 
of 3-amino 5-methylpyrazole substituent (C-2 of pyrimidine ring in 3 and 4), which is different 
from VX680 (C-4 of pyrimidine ring), was set based on the main target 1 and 2.  
VX680 patented synthesis is shown in Figure 3.19. 58b The –SMe at C-2 of pyrimidine ring was 
oxidized to a better leaving group –SO2Me. Nucleophilic substitions allows formation of 44. It 
was not discussed in the patent whether a competition was observed at C-2 and C4 positions. 
Similarly, nucleophilc substitution of 3-amino 5-methyl pyrazole to C-4 position was reported 
to occur at the primary amine of the pyrazole ring system. No competition between N-1 of 
pyrazole ring and –NH2 at C-3 of pyrazole as nucleophiles was mentioned.  
 
Figure 3.19. Patented synthesis of VX680 by Vertex Pharmaceuticals. 58b 
 
Retrosynthesis 
The synthesis of the core structures was envisaged to involve a combination of SNAr reaction 
and Buchwald-Hartwig reaction 131. The retrosynthetic plan of 3 is shown in Figure 3.20. The 
2,4,6-trichloropyrimidine was chosen as starting material due to its commercial availability. 
Synthesis of 4 would be similar as that of 3. 
3 4 VX680 
42 43 44 
45 VX680 
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Figure 3.20. Retrosynthesis of 3 
The mechanism of SNAr reaction is shown in Figure 3.21 where the nucleophile (N-methyl 
piperazine) attacks the pyrimidine ring, forming the intermediate anions (Meisenheimer 
Complex). Pyrimidine readily undergoes SNAr at the C-2 and C-4/6 positions with 4/6 being 
generally more reactive. 132 The reformation of the aromatic system and the leaving of chloride 
anion results in the product. As such electron-withdrawing substituents increase the reactivity of 
ring system as they stabilize the intermediate carbanions. (-Cl > -Br >> -I) 
 
Figure 3.21. SNAr reaction mechanism of reaction between N-methyl piperazine and 
trisubstituted pyrimidine. 
In the case of weak nucleophiles where SNAr reactions do not work, the assistance of a catalyst 
may be needed and a Buchwald-Hartwig reaction may be considered. 
Reaction between the substituted pyrimidine ring and 3-amino 5-methyl pyrazole was predicted 
to be low yielding because of the possible competition between –NH2 substitutent at C-3 of 
pyrazole ring and N-1 of pyrazole ring as nucleophiles. As a result, it was set as the final step of 
the synthesis. (This was also to make sure that no competitive substitutions between C-2 and C-
4 positions of the pyrimidine ring needed to be considered). Consequently, a Buchwald-Hartwig 
reaction (palladium-catalysed coupling of heteroaryl amines and heteroaryl halides) was chosen 
for the reaction between the substituted pyrimidine ring and 3-amino 5-methyl pyrazole. 
3 46 
47 48 
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The proposed catalytic cycle of Buchwald-Hartwig coupling reaction from the literature 133 is 
shown in Figure 3.22.  
 
Figure 3.22. Proposed catalytic cycle of Buchwald-Hartwig coupling between amine and aryl 
halide. 133 
Buchwald et al. and Hartwig et al. 133 independently studied the coupling reactions between aryl 
halides and substituted amines using Pd catalysts, particularly the use of Pd(dba)2 and 
phosphine ligands. The type of phosphine used is essential for the success of the coupling and 
the reaction is also sensitive to the type of base used. In the literature, 134 sterically hindered and 
electron-rich ligands such as DavePhos was reported to catalyse the reaction between aryl 
chloride and diethyl malonate. Literature research also suggests that (dba)Pd(BINAP) catalyst 
135 may work particularly well with chloro-substituted pyrimidine systems. It is reported that 
under conditions of excess amine, amine will bind to Pd prior to oxidative addition of the aryl 
halide and (R(R’)NH)Pd(BINAP) proceeds faster than does oxidative addtition to Pd(BINAP). 
136  
Most of the literature work reports palladium-catalysed coupling between heteroaryl amines and 
heteroaryl bromides or aryl bromides. It is suggested that due to bond length that may affect the 
initial rate of oxidative coupling reaction, aryl or heteroaryl bromides may react better that aryl 
or heteroaryl chloride. On the other hand, aryl and heteroaryl chlorides are generally more 
commercially available than their bromo analogues. Moss et al. reported that Pd-catalysed 
coupling reaction between 3-amino 5-methylpyrazole system and pyrimidine systems might 
occur at r.t in moderate to high yield. They also demonstrated that 2-chloropyridine reacted in a 
comparable time and in similar yield to 2-bromopyridine, concluding that their conditions might 
not be limited only to aryl bromides. (Table 3.1) 137 
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Table 3.1 – Room temperature coupling of 3-amino-5-methylpyrazole with heteroaryl 
halides with t-BuXPhos precatalyst 137 
           X = halide (-Cl, -Br) 
Aryl Halide Time (h) Product Yield % 
 
4 
 
88 
 
6 
 
89 
Reaction conditions: 1.5-mmol scale, amine (1.0 eq), aryl halide (1.25 eq), NaOt-Bu (2.1 eq), t-BuXPhos 
precatalyst, L-Pd(0) (1 mol%) where L = t-BuXPhos ligand, t-BuXPhos ligand (1 mol%), t-BuOH (5 
mL), r.t. 
 
The conditions used in their report included t-BuXPhos ligand (a known effective catalyst in 
weakly nucleophilic heteroaryl system) however preliminary test by my colleague did not show 
promising results with this ligand. As a result, BINAP ligand was tested first before re-
investigating t-BuXPhos ligand. 
 
 
In terms of a Pd-catalysed coupling reaction between a 3-amino 5-methyl pyrazole system and a 
bromo pyrimidine system, Moss et al. 137 reported that no yield was isolated for cross coupling 
involving Br in 4/6-position of the pyrimidine ring. The reaction seemed to proceed best where 
Br was in the 5-position of the pyrimidine ring (yield of 92% isolated yield of 70%) followed 
by 2-position (isolated yield of 61%). (Table 3.2) 
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Table 3.2 – Room temperature coupling of 3-amino-5-methylpyrazole with heteroaryl 
bromides with t-BuXPhos precatalyst 137 
 
Aryl Bromide Time (h) Product Yield % 
 
6 
 
0 
 
4 
 
(92) 70 
 
6 
 
61 
Reaction conditions: 1.5-mmol scale, amine (1.0 eq), aryl bromide (1.25 eq), NaOt-Bu (2.1 eq), t-
BuXPhos precatalyst L-Pd(0) (1 mol%) where L = t-BuXPhos ligand, t-BuXPhos ligand (1 mol%), t-
BuOH (5 mL), r.t. 
 
3.2.2. Synthetic results 
3.2.2.1. Synthesis of 3 
Reaction between 2,4,6-trichloropyrimidine and N-methyl piperazine proceeds well at -25oC to 
give the desired product 2,4-dichloro-6-(N-methylpiperazin-1-yl)pyrimidine, 47 in 74% yield. 
138 
 
Figure 3.23. Synthesis of 3. (i) N-methyl piperazine (1.0 eq), NEt3 (1.1 eq), EtOH, -25 to 0oC,  
4 h, 74%; (ii) t-butyl 4-aminobutanoate (1.8 eq), DIPEA (xs), EtOH, r.t, 26 h, 72%; (iii) 3-
amino 5-methyl pyrazole (1.7 eq), (dba)Pd((R)-BINAP) (15 mol%), Cs2CO3, THF, microwave 
120 -140oC, 40 min, 80%. 
 
48 47 46 
3 
120 
 
tert-Butyl 4-aminobutanoate was added to 47 with DIPEA and EtOH under reflux conditions to 
give 46 in good yield (72%). The last coupling step with electron poor 3-amino-5-methyl 
pyrazole was carried out using Buchwald-Hartwig coupling. Several readily available ligands, 
solvents and bases (Table 3.3) were tried out. Refluxing proved unsuccessful but under 
microwave conditions the product was obtained in good yield with high mol% of catalyst (15 
mol%). The total synthesis of core structure 3 is summarised above. 
 
Table 3.3 
 
 (iii) Pd catalyst, ligand, base, solvent 
Entry Catalyst and 
ligand, mol% 
Base Solvent Time 
(h) 
Temperature  Yield % 
1 (dba)Pd(R-
BINAP), 1.3 137 
Cs2CO3 dioxane 25  thernal heat, 100 oC ✗ 
2 Pd2(dba)3, 
DavePhos, 3.8 139 
NaOt-Bu dioxane 17  thermal heat, 100oC ✗ 
3 (dba)Pd(R-
BINAP), 4 
NaOt-Bu dioxane 40  thermal heat, 95oC ✗ 
4 Pd(PPh3)4, R-
BINAP, 8 
NaOt-Bu toluene 27  thermal heat, reflux ✗ 
5 (dba)Pd((R) -
BINAP), 5 
Cs2CO3 THF 1.6 microw, 140oC 6% 
isolated 
product 
6 (dba)Pd((R)-
BINAP), 15 
Cs2CO3 THF 0.6 microw,  
120 – 140oC 
80% 
isolated 
product 
 
It was assumed that the primary amine would attach at the C-2 position of pyrimidine as the 
literature suggested. As the 1H-NMR was obtained in CD3OD, the peaks of -NH and -NH2 of 
the pyrazole could not be identified and structure 3 was therefore assumed to be correct. 
However, during the course of this research, the regioselectivity of similar reactions was 
investigated by X-ray crystallography by my colleague.  
 
 
46 3 
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Figure 3.24. Investigation on regiochemistry of 2-chloro substituted pyrimidine system and 3-
amino 5-methylpyrazole. a) SNAr conditions: (i) NaH, CH2Cl2, reflux; b) Buchwald-Hartwig 
coupling conditions: (i) Pd (0), DavePhos, reflux.  
 
Under strong base (NaH) conditions, SNAr reaction showed that the major product, 50 was 
obtained through the attack of secondary amine of 3-amino 5-methylpyrazole. (Figure 3.24a) 
Further investigation reported that in neutral conditions the attack of the primary amine was 
favoured. 140 Crystal structure of the product 53 where Pd conditions with DavePhos as a ligand 
was not obtained. (Figure 3.24b) The two NMRs (in CDCl3) were compared by my colleague. 
They were found to be identical so reasonably it was assumed that in both case, the wrong 
regioisomers where the secondary amine was attached to C-2 of pyrimidine, were obtained. No 
further investigation was made for regiochemistry of 3 due to re-examination of target 
structures. (Section 1.5) 
 
3.2.2.2. Progress towards syntheses of 4 
Synthesis of 4 was envisaged to follow the same route as the synthesis of 3. (Figure 3.25)  
 
Figure 3.25. Synthetic plan of core 4.  
The first step is the synthesis of 2,4-dichloro-6-(N-methylpiperazin-1-yl)pyrimidine, 47, as 
mentioned in synthesis of 3. Synthesis of 54 was attempted using 47 and commercially 
available di-tert-butyl D-glutamate hydrochloride or free-form available di-tert-butyl D-
glutamate but all had been unsuccessful. (Table 3.4)  
 
49 50 51 
52 53 
3.24a. 
3.24b. 
47 54 
4 
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Table 3.4 – Attempts towards synthesis of 54 
 
 
Entry Amine 
(1.5-2 eq) 
Base 
(+catalyst) (xs) 
Solvent Temperature Time 
(h) 
Yield % 
1 salt DIPEA n-BuOH 
and EtOH 
reflux 7 6% of crude 
54 
2 salt DIPEA n-BuOH reflux 40 ✗ 
3 salt DIPEA THF reflux 4 ✗ 
4 salt Et3N EtOH reflux 24 ✗ 
5 free DIPEA t-BuOH reflux 24 ✗ 
6 free DIPEA n-BuOH 
and EtOH 
reflux 72 ✗ 
7 salt Cs2CO3 
(+(dba)Pd((R)-
BINAP)) 
toluene microw, 
140oC 
25 ✗ 
8 salt Cs2CO3 
(+(dba)Pd((R)-
BINAP)) 
THF  
 
microw, 
140oC 
30 ✗ 
 
At the same time, 2,4,6-tribromopyrimidine  was synthesised 141 as an alternative to 2,4,6-
trichloropyrimidine. The bromo-substituted heterocycle was intended to be used in the case of 
difficult Buchwald-Hartwig reaction. Unfortunately the SNAr reaction prior to the Buchwald-
Hartwig coupling could not proceed.  This synthetic attempt is described in Figure 3.26. 
Compound 56 was converted to 2,4-dibromo-6-(4-methylpiperazin-1-yl)pyrimidine 57 in 56% 
yield. Heating under reflux of 57 with di-tert-butyl D-glutamate hydrochloride in the presence 
of DIPEA as base and n-BuOH as solvent also failed to yield any sufficient product. 
 
Figure 3.26. Synthetic attempt of 4 from 2,4,6-tribromopyrimidine. (i) POBr3 (4.0 eq), PhNMe2 
(1.9 eq), toluene, reflux, 3 h, 68%; (ii) N-methyl piperazine (1.0 eq), NEt3 (2.3 eq), EtOH, -30 
to -5oC, 3 h 56%; (iii) di-tert-butyl D-glutamate hydrochloride (1.2 eq), DIPEA (1.2 eq), n-
BuOH, 45oC, 2 h then reflux, 15 h. 
47 54 
55 56 57 58 
123 
 
 
The reason for the failure of the reaction between 47 and di-tert-butyl D-glutamate 
hydrochloride was postulated that steric hindrance from one or both t-Bu esters prevented the 
reaction from taking place. As selective deprotection at the δ-COOH would be required for later 
coupling to the linker and pantothenamide, the synthesis of Glu(OAllyl)Ot-Bu, 60, was 
attempted. Trials were carried out on L-glutamic acid. Allyl protection of glutamic acid 
proceeded well in moderate yield, 42%. 142 (Figure 3.27) However, later tert-butyl protection 
using perchloric acid (xs) and t-butyl alcohol as solvent under stirring condition at r.t for 72 h 
was not successful.  
 
Figure 3.27. Di-protection of L-Glutamic acid. (i) Allyl alcohol (xs), TMSCl (xs), 0oC to r.t, 26 
h, 42%; (ii) perchloric acid (8.3 eq), t-butyl alcohol (13.0 eq), r.t, 48 h. 
 
Another suggestion to be tested was to change the leaving group (-Cl, -Br) at C-6 or C-2 of 
pyrimidine to a better leaving group such as a tertiary amine salt or fluoride before attempting 
other nucleophilic substitutions. 
3.3.  Conclusion 
The main difficulty of Approach A synthesis lies in the heterocyclic chemistry, in particular the 
reaction between 3-amino-5-methyl pyrazole and 2,4,6-substituted pyrimidine. The heterocyclic 
chemistry was investigated in detail by my colleague. Unfortunately, revised computational 
docking showed that the binding mode of VX680-like head group changed completely with the 
addition of pantothenamide end. This disrupted the research on Approach A synthesis. The 
chemistry of the second generation of compounds is described in Chapter 4. 
 
 
 
  
59 60 61 
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4. Approach B syntheses 
In this chapter, work has been focused on using the triazole group as an artificial chemical 
linkage to replace the pyrophosphate link in CoA. As outlined in Chapter 1 (Section 1.5.2) and 
Chapter 2 (Section 2.4.2) this linker has been chosen for further study for four reasons: 
(i) The feasibility of forming the prerequisite alkynes and azides that are attached to 
pantothenamide tail and head group. 
(ii) The possibility of the desired stable products to be formed in aqueous media (from 
functional groups that may be orthogonal to those in CoA), under mild conditions 
with sufficient yield. 
(iii) The triazole ring system is chemically robust and non-toxic and it has a limited 
number of rotatable bonds, which would provide more accurate prediction in 
modeling. 
(iv) Allowing a robust synthesis to provide a set of compounds, containing a diverse 
range of functional groups and length, in a short period of time. 
With the aim to establish an understanding of the ATP binding pocket of AURKA, including 
the activation loop which is disordered, computational study determined 6 main compounds to 
synthesise (as mentioned in Figure 2.39):  
        14 15 19 
125 
 
 
 
4.1. Literature research and proposed approach 
The feasibility of forming the prerequisite alkynes and azides 
Retrosynthetic analysis suggested two approaches to prepare these analogues: Approach 1: 
Head-alkyne, X and Tail-azide and Approach 2: Head-azide, X and Tail-alkyne. (Figure 4.1) 
There were two aspects to be investigated: one was to test whether it is possible to prepare 
prerequisite alkynes and azides and the other was to test the feasibility of Click reaction 
between prerequisite alkynes and azides. 
 
Figure 4.1. Retrosynthesis of “triazole-linked compounds” 
Because the pantothenamide tail was only able to withstand mild reacting conditions (Section 
3.1), it was preferred that tail-azide/tail-alkyne is formed first (lower yield reaction) before the 
Cu (I)-catalysed alkyne-azide coupling (CuAAC) reaction. However if this route proves 
difficult, the other approach is to perform CuAAC reaction first, followed by esterification 
reaction to link with the pantothenamide tail.  
Approach 2 Approach 1 
16 17 18 
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The feasibility of Click reaction between the required  alkyne and azide 
The general proposed reaction mechanism of a CuAAC is presented in Figure 4.2. Cu (I) 
catalysed CuAAC reaction was reported to produce a 1,4-substituted triazole system. 143 
 
 
 
 
 
 
 
Figure 4.2. General mechanism of CuAAC reactions. 143 
It is notable that CuAAC reactions, particularly with biomimetic systems may take 24 to 48 
hours to proceed with significant yield. For the purpose of generating later a large library of 
analogues, there are 5 features to achieve when investigating this type of reaction. Reactions 
should proceed in aqueous media, under mild and simple conditions (preferably not oxygen-free 
condition), tolerable to different types of substrates and are able to generate significant yield 
with easy purification procedure. 
In order to achieve these features, there were two features from the literature to highlight before 
investigating the feasibility of CuAAC reaction in this case and its optimized conditions. The 
first one is catalysts. The common source of copper (I) catalyst is CuSO4, which can be reduced 
in situ by ascorbate to CuI. 144 Copper wire (Cu0) usually resulted in longer reaction time at r.t 
and was used for microwave-assisted Click reaction. 145 Preparation of reactive Cu (I) acetylide 
in situ (in the presence of an organic azide) is critical for the success. Formation of polymeric 
acetylide is detrimental for the reaction hence to be avoided. As a result, stabilising ligands e.g. 
TBTA and THPTA were used to prevent the formation of unreactive polynuclear Cu (I) 
acetylide and facilitate the coordination of the azide to Cu centre and increase the solubility of 
Cu complex. 146 The second highlighted feature is solvents. Water is an ideal solvent capable of 
supporting reactive Cu (I) acetylide. 
 
 
 
Step A: Exothermic, π-alkyne-Cu complex 
deprotondation, forming σ-acetylide 
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4.2. Synthetic results 
4.2.1. The feasibility of forming prerequisite alkynes and azides 
Out of the two approaches, Approach 1 proved to be more reliable and easier to follow, mainly 
due to the observation that the formation of tail-azides is more feasible than that of tail-alkynes. 
 
Approach 1 results 
“Tail-azide” synthesis 
The pantothenamide-linked azide was prepared from an esterification between pantothenamide, 
20 and 2-azidoacetic acid, 63 using DCC, DMAP or PyAOP, HOAt as coupling reagents. DCC, 
DMAP was chosen as the preferred method for economic reason although the reaction yield 
was lower than that using PyAOP and HOAt. 2-Azidoacetic acid, 63 was prepared using a 
method from literature procedure 147 from commercially available 2-bromo acetic acid, 62 in 
quantitative yield. (Figure 4.3) 
 
Figure 4.3. Synthesis of 64. (i) Sodium azide (xs), water, quantitative; (ii) 20 (0.7 eq), DCC 
(1.2 eq), DMAP (0.1 eq), THF, 0oC to r.t, 20 h, 44%; or 20 (1.0 eq), PyAOP (1.9 eq), HOAt 
(1.5 eq), DIPEA (1.1 eq), DMF, 0oC to r.t, 18 h, 57%. 
 
“Head-alkyne” synthesis 
In order to prepare 72 (Figure 4.5), the prerequisite alkyne for many of the targets, the route 
previously reported in the literature 148, 149 was first attempted. Ketalisation of the 2’ and 3’ –OH 
groups of commercially available adenosine 148 was followed by benzoyl protection of the 
adenine –NH2 group 149. However, subsequent attempts to selectively introduce the propargyl 
group under literature conditions 149 using sodium hydride, propargyl bromide and TBAI (phase 
transfer reagent) in THF to produce 68 failed. Instead, unwanted products, 69 and 70, ratio 1:2, 
were found in the product mixture. (Figure 4.4) As a result, non-protective strategy was carried 
out. This proved to be successful, giving 72 in similar yield to that reported in the literature in 
less synthetic steps. (Figure 4.5) 
 
 
 
 
 
 
 
 
62 63 64 
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Figure 4.4. Attempted synthesis of 68. (i) p-toluenesulfonic acid (xs), acetone, 0oC to 11oC, 20 
h, quantitative; (ii) TMSCl (xs), BzCl (1.3 eq), pyridine, r.t, 3.5 h then water, NH3 (xs), 0oC, 10 
min, 64%; (iii) NaH (1.1 eq), THF, 0oC, 2 h, then TBAI (0.3 eq), propargyl bromide (1.3 eq), 
0oC to r.t, 20 h. 
 
 
Figure 4.5. Synthesis of 72. (i) NaH (1.5 eq), propargyl bromide (1.5 eq), THF, 0oC to r.t, 24 h, 
41%; (ii) TFA (xs), t-BuOH, water, r.t, 24 h, quantitative. 
 
Approach 2 results  
“Tail-alkyne” 
 
For compound X, n=1, proposed retrosynthesis starts with but-3-ynoic acid and pantothenic 
acid (free form) as starting materials, coupled together by an esterification reaction. However 
synthesis of but-3-ynoic acid from its alcohol via oxidation using NaIO4, K2Cr2O7, HNO3 150 
was not successful. (Table 4.1) As it is the very first step of the long synthesis and the reaction 
did not clearly provide high yield and easy purification, this was not pursued further.  
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Table 4.1 – Tested oxidising conditions for but-3-yn-1-ol, 74 
 
Conditions Results 
NaIO4, K2Cr2O7, HNO3, water, r.t 150 polymerised 
 
Propiolic acid was readily available for purchase so it was used as an alternative to test 
esterification reaction in this case. However, attempts to push the reaction forward using both 
mild conditions (coupling reagents) and forcing conditions (acyl chloride), keeping in mind the 
sensitivity of pantothenamide tail were unsuccessful. Literature suggested that esters of 
propiolic acid required forcing conditions (reflux in benzene for 2 - 16+ hours with p-
toluenesulfonic acid) 151. The other option would be to perform “Click chemistry” first, forming 
the triazole ring system before coupling it to the pantothenamide tail. A simple triazole ring 
system, 78 was synthesized to test the idea. (Figure 4.6) The “Click” conditions adapted from 
the literature 152 allowed 78 to be formed in good yield. (Table 4.2) However, the following 
esterification to link the pantothenamide, 20 with 78 were unsuccessful.  
 
Figure 4.6. Attempted synthesis of 79. (i) Boc2O (1.0 eq), CH2Cl2, r.t, 24 h, quantitative; (ii) 
NaN3 (xs), (F3CSO2)2O (2.0 eq), CH2Cl2, water at 0oC, 2 h then work-up followed by 76, 
MeOH, K2CO3 (1.6 eq), CuSO4.5H2O (6 mol%), H2O, r.t, 24 h, 81%; (iii) propiolic acid (0.13 
M, 1.1 eq), CuSO4.5H2O (15 mol%), sodium ascorbate (68 mol%), t-BuOH : water = 1:2, r.t, 48 
h, 75% 153; (iv) 20 (1.0 eq), PyAOP (4.0 eq), HOAt (0.5 eq), DIPEA (xs), 0oC to 60oC, 18 h. 
 
Table 4.2 – Testing “Click” conditions for preparation of 78 
[Reactant] M Solvent ratio (A:B) Catalyst loading (mol%) Time 
stirring 
at r.t (h) 
Yield 
% 
 
 
t-BuOH water CuSO4.5H2O sodium 
ascorbate 
0.05 0.05 1 2 22 90 18 h 41 
0.12 0.13 1 2 5.6 24 48 h 75 
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4.2.2. The feasibility of Click reaction between alkyne 72 and azide 64 
Having successfully synthesised alkyne 72 and azide 64, investigation of CuAAC reaction 
between the two was carried out.  
Several attempts to couple alkyne 71 and azide 64 using similar conditions for synthesizing 78 
above were not successful. It was hypothesized that the concentration of the reactants and the 
ratio of them to catalyst loading might be crucial to the success. (Table 4.3)  
 
Table 4.3 – Initial tests for optimal Click conditions on alkyne and azide, 71 and 64 
Entry [Reactant] M 
 
64               71 
Solvent ratio 
(A:B) 
Catalyst loading (mol%) Time 
stirring at 
r.t (h) 
Yield 
% 
 t-
BuOH 
water CuSO4.5H2O sodium 
ascorbate 
1 0.1 0.06 1 1 4.8 20 48 h ✗ 
2 0.02 0.02 1 2 6.5 23.5 48 h ✗ 
 
Because the literature review 154, 155 suggested that it was difficult to perform to completion the 
CuAAC reaction of adenosine-containing compounds in particular and of biomimetic systems 
in general (long reaction time and heating was required), a series of test experiments was 
carried out. Firstly, CuAAC test reaction was carried out between 2-azidoacetic acid 63 and 71 
but no product was obtained. (Table 4.4) 
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Table 4.4 – Second trials for optimal Click conditions  
 
Entry  [Reactant] M Solvent ratio 
(A:B) 
Catalyst loading†(mol%) Time (h),  
T (oC) 
Yield 
% 
 63 
 
71 
 
t-BuOH water CuSO4.5H2O  sodium 
ascorbate 
1 0.06 0.05 1 1 1.8 9 48 h, r.t ✗ 
2 0.07 0.07 1 1 0.9 9 48 h, r.t ✗ 
3 0.06 0.05 1 1 0.9 18 48 h, r.t ✗ 
4 0.02 0.02 1 1 1.5 7.5 1 h, 
microw 
100oC  
✗ 
†Catalysts’ stock solution in water: [CuSO4.5H2O] = [sodium ascorbate] = 0.1 M for the first 3 entries 
and of 0.05 M for the last entry. 
 
The failure was thought to be due to the fact that 2-azidoacetic acid was soluble in water, much 
more than 71. This might cause difficulty to form complex IV (Figure 4.2). As such 2-
azidoacetic acid was converted into benzyl 2-azidoacetate, 156  which was then successfully 
coupled to 71 to form 82, the precursor of target compound 14. Ketal removal of 82 by TFA 
afforded 14 in good yield, 82%. (Figure 4.7) The choice of a benzyl group was suggested by 
modeling work that showed a possible π-stacking interaction of a phenyl ring of a ligand with 
Phe144 in the ATP binding pocket of AURKA. Besides, the benzyl protecting group is known 
to be removed by H2, Pd/C (mild conditions) if required. Catalyst loading was low in these 
trials and might be increased. The trials to obtain optimised conditions for CuAAC reaction 
between azide 81 and alkyne 71 were shown in Table 4.5 and 4.6. 
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Figure 4.7. Synthesis of 14. (i) Cs2CO3 (0.5 eq), MeOH, H2O, -3 to 0oC, 2 h then PhCH2Br (1.0 
eq), DMF, 0oC to r.t, 15 h, 72% 95; (ii) 71 (1.0 eq), CuSO4.5H2O, sodium ascorbate, t-BuOH : 
H2O = 1:1, r.t, 24 h, 83%; (iii) TFA (xs), t-BuOH : H2O = 1:1, r.t, 14 h, 82%. 
 
Table 4.5 presents CuAAC third trials between benzyl 2-azidoacetate, 81 and 71. Entry 1 
proved to be successful after two weeks stirring at r.t with a yield of 59%. However, the 
reaction did not go to completion. In entry 6, 61% of 71 was reacted, giving an isolated yield of 
56 %. Entry 6 also suggested that for 0.02 M concentration of the reactants, even a 0.2 mol% of 
CuSO4.5H2O would catalyse the coupling. This indicates that the reaction proceeds in the below 
condition at slow rate. A slight increase in the concentration of reactants may speed up the 
reaction. In entry 5, when the amount of azide was initially a third of that of the alkyne for the 
first 24 h, reaction could not proceed further to achieve similar yield as that in entry 1. The 
suggested explanation was that polymeric Cu (I) acetylide might have formed and hindered the 
progress of the reaction.  
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Table 4.5 – Third trials for optimal Click conditions 
 
Entry 
 
[Reactant] M Solvent ratio 
(A:B) 
Catalyst loading † (mol%) Time (h),  
T (oC) 
Yield % 
81 71 t-BuOH water CuSO4.5H2O  sodium 
ascorbate 
1 0.02 0.02 1 1 0.75 7.5 312 h, r.t 59 
2 0.02 0.02 1 1 0.75 15 20 min, 100oC 
microw 
Trace of 
product 
in LCMS 
3 0.02 0.02 1 1 0.75 15 1.3 h, 100oC 
microw 
Trace of 
product 
in LCMS 
4 0.02 0.02 1 1 0.75 15 1.3 h, 100oC, 
then 1 h, 
150oC microw 
Degraded 
✗ 
5 7 x 10-3 
then 
0.02 
0.02 1 1 0.8 7.3 264 h, r.t ‡ 25 
6 0.02 0.02 1 1 0.2 1.85 192 h, r.t 56 
†Catalysts’ stock solution in water: [CuSO4.5H2O] = [sodium ascorbate] = 0.05 M. ‡ 24 h, r.t at 7 x 10-3 
M of 81 then 240 h at 0.02 M of 81. 
In CuAAC fourth trials, the concentrations of the reactants were varied based on the above 
results yielded the optimised conditions for CuAAC reaction involved adenosine-alkyne (Table 
4.6).  
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Table 4.6 – Fourth trials for optimal Click conditions 
Entry 
 
[Reactant] M Solvent ratio 
(A:B) 
Catalyst loading † (mol%) Time 
(h),  
r.t 
Completion 
% 
81 71 t-BuOH water CuSO4.5H2O  sodium 
ascorbate 
1 0.06 0.06 1 1 0.8 7.5 26 h 90 
2 0.15 0.15 1 1 0.8 7.5 26 h 80 
3 0.06 0.06 1 1 0.8 7.5 24 h 96 
†Catalysts’ stock solution: [CuSO4.5H2O] = [sodium ascorbate] = 0.05 M. 
Monitoring the reactions by LCMS showed that at the same catalyst loading, solvent system 
and other conditions, 0.06 molar concentration of reactants provided a faster rate of reaction 
(formation of product : consumption of reactants) of 1.5 times compared to 0.15 molar 
concentration of reactants. A scale-up of the reaction in entry 1 to six times in entry 3 showed 
the same observations.  
In summary, the optimized conditions for CuAAC reaction involving adenosine-alkyne required 
the equimolar concentrations of azide and alkyne at 0.05 M or 0.06 M. The source of copper (I) 
was CuSO4.5H2O at 0.8 mol% and that of reducing agent was sodium ascorbate at 8 mol%, 
both from freshly made 0.05 M solutions. In case the coupling proved to be difficult, stabilising 
ligand, THPTA was used at 0.8 mol%. The temperature was r.t (20oC) and the solvent system 
was t-BuOH and H2O at ratio 1:1 or 1:2 respectively. 
The optimised conditions were then used for the coupling between alkyne 71 and 
pantothenamide azide 64 to form target compound 17. After 15 h, LCMS monitoring suggested 
that the reaction was 60% completed. Purification by flash column chromatography afforded 
product 17 in 56% isolated yield. 
 
Figure 4.8. Synthesis of 17. (i) 64 (1.0 eq), CuSO4.5H2O, sodium ascorbate, t-BuOH : H2O = 
1:1, r.t, 15 h, 56%. 
In case of 16, in the absence of a stabilising ligand, the reactions appeared to be slow (not up to 
80-90% completion after 24 h). Therefore THPTA was added as the stabilising agent. This 
allowed the reactions to be completed within 1 - 2 h. (Figure 4.9) The disadvantage was that it 
requires extremely inert conditions (O2-free) to avoid re-oxidation of Cu (I) to Cu (II). One 
solution to this was to keep adding reducing agent (sodium ascobate) to the reaction mixture or 
copper wire to promote disproportionation reaction to keep providing Cu (I) source for the 
71 17 
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reaction. During these reactions, sodium ascorbate was chosen to be added in the case where re-
oxidation of Cu (I) to Cu (II) occurred, as the reaction time was short. 
 
Figure 4.9. Synthesis of 16. (i) 64 (1.0 eq), CuSO4.5H2O, THPTA, sodium ascorbate, t-BuOH : 
H2O = 1:2, 2 h (O2-free condition), 90%. 
As discussed in Chapter 2, due to solubility problem of 14, in order to increase the solubility 
whilst retaining the reactivity, 15 was designed. Compound 15 was prepared by CuAAC 
reaction between alkyne 72 and azide 86. Preparation of 86 was achieved by amide coupling 
between 2-azidoacetic acid, 63 and tert-butyl (2-aminoethyl) carbamate, 85 in good yield, 70%. 
Synthesis of the carbamate, 85 was adapted from literature 157, 158 which reported that phenyl 
isocyanate reacted vigorously with aliphatic amine to provide the desired carbamate in excellent 
yield. Overall, synthesis of 15 starting from commercially available phenyl isocyanate afforded 
the product in 30% over 4 steps. (Figure 4.10) 
 
Figure 4.10. Synthesis of 15. (i) 76 (1.0 eq), CH2Cl2, 0oC to r.t, 20 h, 97%; (ii) TFA (xs), 
CH2Cl2, r.t, 4 h stirring then standing in fridge o/n, quantitative; (iii) 63 (0.9 eq), HOBt (1.1 eq), 
EDC (1.1 eq), Et3N (xs), CH2Cl2, 70%; (iv) 72 (0.9 eq), CuSO4.5H2O, THPTA, sodium 
ascorbate, t-BuOH : H2O = 1:1, 12 h (O2-free condition), 40%. 
 
For the synthesis of an analogue with pantetheine tail, 18, a modification of the synthesis was 
required. Coupling of D-pantethine and 2-azidoacetic acid using EDC and HOBt gave only the 
singly coupled product, 87 which was purified by HPLC. However the reaction was not in 
completion but the singly coupled product was purified by HPLC to bring to the next step. 
CuAAC reaction between azide 87 and alkyne 72 with THPTA stabilising ligand gave crude 88 
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(mixed with starting material 87). A mixture of starting material azide and product 88 was 
obtained by HPLC. This crude material was reduced using TCEP and purified by HPLC to 
obtain pure 18 (95% yield through 2 steps).  
 
Figure 4.11. Synthesis of 18. (i) D-panthethine (0.5 eq), EDC (1.2 eq), HOBt (1.2 eq), Et3N 
(2.0 eq), THF, CH2Cl2, 0oC to r.t, 16 h; (ii) 72 (1.0 eq), CuSO4.5H2O, THPTA, sodium 
ascorbate, t-BuOH : H2O = 1:1, 12 h (O2-free condition) (crude); (iii) TCEP (4.5 eq), H2O : 
Acetonitrile = 1.5 : 1, r.t, 2 h, 95% (over 2 steps). 
In addition to the 5 target compounds, for the purpose of verifying the importance of π-stacking 
interaction of a phenyl ring of a ligand with Phe144, demonstrated in compound 14 and 17, a 
methyl ester analogue of 14 was synthesised, 91. For the purpose of easy handling and storage, 
14 was converted to 89 by introducing protecting group TIPDS at 2’ and 3’ –OH of substituted 
adenosine ring. Literature search suggested TIPDSCl2, which would form a seven-membered 
ring with 2’ and 3’ -OH and can be taken off easily by NH4F in generally good/excellent 
isolated yield. 155, 159 The -OMe group was introduced when deprotection of -OCH2Ph group 
from 89 was carried out in methanol. Removal of the TIPDS protecting group of 90 afforded 91 
in good yield. (Figure 4.12) 
63 87 
88 
18 
137 
 
 
 
Figure 4.12. Synthesis of 91. (i) TIPDSCl2 (1.2 eq), pyridine, r.t, 18 h, 98% 95; (ii) H2, Pd/C 
10% w/w, MeOH : CH2Cl2 = 1:1, r.t, 24 h, 97%; (iii) NH4F (8.6 eq), MeOH, r.t, 2 h, 86%. 
 
4.3. Biological screening results of the second generation of compounds and Discussion 
In vitro testings by Dr. Tsuchiya provided the following IC50 of the six designed compounds: 
 
Table 4.7 – IC50 testing results of the second generation of compounds 
Compound AURKA mean IC50 (µM)  S.E.M n 
14 7.7 0.7 3 
15 16.7 2.3 3 
16 27.3 5.8 3 
17 202 n/a 1 
91 391 n/a 1 
18 1800 n/a 1 
AURKA activity was assayed by a radiometric filter binding assay using myelin basic protein as a 
substrate. (See Table 1.2 legend for details). [ATP] = 5µM. n = number of experiments. n/a: not 
applicable. For compounds that show no inhibition or very poor inhibitory activity in preliminary assay, 
the exact IC50 values were not pursued. S.E.M: Standard Error of Mean. 
 
The results were in good agreement with the prediction from docking results. It was found that 
changing the –OPhe group in 14 to –OMe in 91 diminished the inhibition (IC50 changed from 
7.7 to 391 µM) This together with the computational docking results further emphasised the 
importance of π-stacking interaction of a phenyl ring of a ligand with Phe144. Compounds 14 
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and 15 showed comparable IC50 to ADP, providing good indication that the acetyl triazole link 
can be used to replace the pyrophosphate. Comparing IC50 of 16 (27.3 µM) and CoA (4.4 µM) 
suggested the role of 3’ phosphate/the interactions with front polar hump in AURKA inhibition. 
Compared the IC50 result of compound 16 to compound 17 which structure was the same as 16 
but the –SH group was replaced by a –CH3 group, it was nine times more reactive. This 
suggests some protein-ligand interactions involved the –SH group. 
 
The overall conclusion would be: 
(i) Having an interaction with F144 can improve the binding of ligands in AURKA 
ATP binding site. 
(ii) Polar interactions with T217-E260-N261 may improve inhibitory effect and 
possible selectivity. 
(iii) In terms of large molecules that are able to reach the activation loop, having a polar 
end, or particularly –SH (to be investigated), may improve inhibition compared to a 
non-polar end. 
Recent stability tests for compound 14 to 18 showed that only 15 was stable for 24 h. This was 
postulated due to the lack of an ester bond in 15, which was present in other compounds and 
susceptible for hydrolysis. Therefore further development of inhibitors should avoid including 
ester bond in structures. The synthesis of 19 has not been carried out and the design needs a 
revision due to the presence of an ester bond in 19. The retrosynthesis of 19 is presented in 
Appendix 4.1. 
5. Future work 
The biological data suggested that the method of designing AURKA inhibitor was in the right 
direction. However, in order to design new selective inhibitors with IC50 in the low nM range, it 
is essential to separate this research from CoA scaffold investigation. 
 
The research on selectivity of CoA for AURKA should be carried out independently. Whilst 
this would provide valuable information on the structure of the ATP binding site and its 
mechanism of action, CoA itself cannot be the lead compound to design new selective 
inhibitors. It is proposed that the design of new selective inhibitors should start at the three 
regions, the hinge region, the polar region R1 and the phosphate binding region R2 and may 
grow to the pantetheine binding region R3 if appropriate. (Chapter 2). Computational work 
suggests to further carry out synthetic chemistry in three aspects: 
(i) Phosphorylation at 3’-OH. 
(ii) Changing the head group from adenosine to another chemical moiety known in 
kinase inhibitors shown in Chapter 2 to increase binding at the hinge region. 
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(iii) Extending the 3’-OH position to test for interaction with T217 through maleimide 
moiety. 
On the research of the selectivity nature of CoA for AURKA, due to the lack of X-ray crystal 
structures and sufficient information from electron desity map, more analogues of CoA should 
be generated in the aim to gather information about the binding mode of CoA inside the ATP 
binding pocket.  
6. Synthetic experimental 
All reactions were carried out under argon unless otherwise stated. Solvents and reagents were 
purchased from commercial suppliers and used without further purification. 
Tris(dibenzylideneacetone)dipalladium (Pd2(dba)3) was purchased from Acros Organics. 
Dry solvents were purchased from Acros Organics (AcroSeal). 
THPTA ligand was purchased from 2B Scientific. 
Amberlite® IR120 hydrogen form was purchased from Sigma-Aldrich. 
1H NMR and 13C NMR spectra were recorded on Bruker AMX400 (400 MHz), AMX500 (500 
MHz), AMX600 (600 MHz) instruments at ambient temperature. The chemical shifts are 
expressed in parts per million (ppm) referenced to TMS (tetramethylsilane). Data are reported 
as follows: δ, chemical shift, integration, multiplicity, coupling constants (J in Hertz, Hz), and 
assignment (aromatic, ar). For 1H NMR, the multiplicity used for assignment is indicated by the 
following abbreviations: s = singlet, d = doublet, t = triplet, q = quadruplet, quint = quintet, sext 
= sextet, m = multiplet, br = broad, dd = doublet of doublets and dt = doublet of triplets. For 13C 
NMR, the spectra were assigned based on the support information from 13C-DEPT135 and 
HSQC spectra.  
Deuterated chloroform (CDCl3), dimethylsulfoxide ((CD3)2SO) and methanol (CD3OD) were 
used as solvents (as stated) for all NMR analysis. For IR recordings, br= broad, m= medium, s= 
sharp, w= weak. A stereocentre is noted with *. 
31P NMR spectrum was recorded on Bruker AMX400. 
Infrared spectra were obtained on a Perkin Elmer Spectrum 100 FTIR Spectrometer operating 
in ATR mode. 
Melting points were measured with a Gallenkamp melting point apparatus. 
High and low resolution mass spectrometry was performed using a VG70 SE operating in 
modes ES, EI or CI (+ or -) depending on the sample. 
Normal phase silica gel 60 (0.04-0.063 mm, 230-400 mesh) (BDH) was used for flash column 
chromatography. All reactions were monitored by thin layer chromatography (TLC) unless 
otherwise stated. TLC plates pre-coated with silica gel 60 F¬254 on aluminium (Merck KGaA) 
and KMnO4) as chemical stain were used, for visualisation under UV (254 or 365 nm). 
Preparative HPLC was performed on a Dionex 580 HPLC system with PDA-100 photodiode 
array detector, a P580 pump and a model ASI-100 automated sample injector. A Phenomenex 
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Onyx C18 100 x 10 mm column was used. Elutions were monitored at 254 nm and 280 nm and 
carried out according to either of the following gradients. Chromatograms were analysed using 
Chromeleon Software version 2.0. 
 
Gradient 
number 
Composition (% of 
acetonitrile/water (0.1% TFA)) 
Duration 
(min) 
Flow rate (mL.min-1) 
1 0.5 to 1 6 2.0 
2 10 to 60 20 2.0 
3 7 to 37 30 2.0 
4 7 to 18 18 2.0 
5 10 to 98 20 2.0 
6 10 to 70 15 2.0 
7 15 to 40 30 2.0 
8 15 to 40 30 8.0 
9 15 to 20 10 8.0 
10 0.1 to 0.6 8 2.0 
 
r.t = 20oC 
 
6.1. Approach A syntheses 
6.1.1. Synthesis of the first generation of compounds 
Pantothenic acid, 22 160  
 
From sodium salt 
The free-form pantothenic acid, 22 was obtained by dissolving sodium pantothenate, 21 (0.70 g, 
2.90 mmol) in MeOH (20 mL) and passing the solution through an Amberlite IR-120 ion 
exchange column with distilled water until the pH reached 6.6 (approx. 1.5 L). The solvents 
(water and methanol) were removed in vacuo and the resulting colourless oil was dried under 
high vacuum to give 22 quantitatively.  
 
From D-pantolactone and β-alanine 
To β-alanine (1.69 g, 18.78 mmol, 1.20 eq) in MeOH (90 mL) was added NHEt2 (4 mL). The 
solution was heated under reflux for 5 h. D-Pantolactone (1.00 g x 2, 15.21 mmol) was then 
added at two 12-hour intervals. The reaction solution was heated under reflux overnight. The 
solvent was then removed in vacuo and the residue was re-dissolved in water (40 mL) and 
passed through an Amberlite IR-120 ion exchange column with distilled water until neutrality 
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was achieved. The obtaining solute was concentrated in vacuo to about 200 mL and extracted 
with CH2Cl2 (10 x 250 mL). The combined aqueous layer was then dried in vacuo to give 22 as 
a colourless oil (1.93 g, 58%). 
 
1H-NMR ((CD3)2SO, 600 MHz): 7.71 (t, 1H, J 6.0 Hz, NH), 5.42 (d, 1H, J 6.0 Hz, C*H(OH)-
CONH), 4.51 (t, 1H, J 6.0 Hz, OHCH2), 3.70 (d, 1H, J 6.0 Hz, C*HOH), 3.15-3.33 (m, 4H, 
CONHCH2CH2COOH, HOCH2), 2.41 (t, 2H, J 7.2 Hz, CH2CH2COOH), 0.79 (s, 3H, CH3), 
0.77 (s, 3H, CH3). 13C-NMR ((CD3)2SO, 150 MHz): 177 (CONH), 173 (COOH), 74.5 
(CH(OH)CONH), 39.6 (C(CH3)2), 34.2 (NHCH2CH2COOH, HOCH2), 33.9 
(NHCH2CH2COOH), 20.3 (CH3), 19.6 (CH3). MS (CI) m/z (%): 221 (14), 220 (100), 202 (20). 
HRMS C9H17NO5: calc. 220.11850, found 220.118001, error: 2.30 ppm. 
 
N-Boc-β-alanine, 27 161 
 
β-Alanine (1.79 g, 20.10 mmol) was dissolved in water (20 mL) and NaOH  (10 M, 10 mL) was 
added at 0oC. The solution was stirred at 0oC for 15 min and Boc2O (4.44 g, 20.3 mmol, 1.0 eq) 
was added. The reaction mixture was stirred at 15oC for 22 h. The solvent was then removed in 
vacuo to about 20 mL and then water (50 mL) was added. The mixture was extracted once with 
pentane (50 mL). The pH of the aqueous layer was then adjusted to 2 by HCl 9% solution. 
Extraction continued with EtOAc (3 x 100 mL). The combined organic layers were washed 
with brine (2 x 80 mL) and dried (MgSO4). The solvent was removed in vacuo to give 27 as a 
white powder (2.15 g, 57%). Mpt: 72 – 75oC. IR (νmax, cm-1): 3440 (m, NH), 2969 (br, OH), 
1738, 1702 (OC=ONH, C=OOH). 1H-NMR ((CD3)2SO, 500 MHz): 6.86 (s, 1H, NH), 3.10 (q, 
2H, J 6.9 Hz, CONH-CH2), 2.33 (t, 2H, J 6.9 Hz, CH2-COOH), 1.35 (s, 9H, (CH3)3C). 
(Identical by 1H-NMR to the literature 128a) 13C-NMR ((CD3)2SO, 125 MHz): 172.9 (CONH), 
155.5 (COOH), 77.7 (CH3)3C-O), 36.1 (CONH-CH2), 34.2 (CH2-COOH), 28.2 (CH3)3C). MS 
(CI) m/z (%): 190 (100), 134 (30). HRMS C8H15NO4: calc. 190.10793, found 190.107173, 
error: 4 ppm. 
 
tert-Butyl-(3-oxo-3-(propylamino)propyl)carbamate, 29 
 
N-Boc-β-alanine, 27 (1.07 g, 5.65 mmol) was dissolved in THF (11 mL) at 0oC. NEt3 (1.12 mL, 
8.04 mmol, 1.40 eq) was added to the solution followed by iso-tert-butyl chloroformate (0.91 
mL, 6.61 mmol, 1.20 eq). The reaction mixture was stirred from 0oC to 15oC over 3 h. 
Meanwhile, a solution of propylamine (0.6 mL, 7.30 mmol, 1.30 eq) and NEt3 (0.35 mL, 2.51 
mmol) in THF (5 mL) was stirred at 15oC over 1 h. After 3 h, the propylamine solution was 
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added into the reaction mixture and the whole mixture was stirred at 15oC for 17 h. The white 
precipitate was then filtered off and washed with EtOAc. The filtrate was reduced and 
underwent flash column chromatography (20 to 25% EtOAc in Hexane) to give 29 as a white 
powder (0.75 g, 58%). Rf: 0.53 (EtOAc : Hex = 1:1). Mpt: 59 – 60oC. IR (νmax, cm-1): 3324 (m, 
NH), 2930 (w, sp3-CH), 1688, 1641 (OC=ONH, C=ONH). 1H-NMR (CDCl3, 500 MHz): 5.74 
(br, 1H, NH), 5.13 (br, 1H, NH), 3.40 (t, 2H, J 6.0 Hz, C(t-Bu)OCONH-CH2), 3.21 (q, 2H, J 
7.1 Hz, CONH-CH2), 2.40 (t, 2H, J 6.0 Hz, C(t-Bu)OCONH-CH2-CH2-CONH), 1.49-1.56 (m, 
2H, CH2CH2CH3), 1.43 (s, 9H, (CH3)3C), 0.94 (t, 3H, J 7.3 Hz, CH2CH3). 13C-NMR (CDCl3, 
125 MHz): 171.7 (CONH), 156.5 (COOH), 79.7 (CH3)3C-O), 41.5 (CONH-CH2), 36.8 (C(t-
Bu)OCONH-CH2), 36.5 (C(t-Bu)OCONH-CH2-CH2-CONH), 28.2 (CH3)3C), 22.9 
(CH2CH2CH3), 11.5 (CH2CH3). MS (CI) m/z (%): 231 (21), 203 (18), 175 (54), 174 (32), 157 
(18), 131 (100). HRMS C11H22N2O3: calc. 231.17087, found 231.17120, error: 1.43 ppm. 
 
(R)-2,4-dihydroxy-3,3-dimethyl-N-(3-oxo-3(propylamino)propyl)butanamide, 20 120 
 
Route 1 
The free-form pantothenic acid, 22 (1.93 g, 8.81 mmol) was dissolved in dry DMF (10 mL) and 
the solution was cooled to 0oC. DPPA (3.0 mL, 13.50 mmol, 1.50 eq) was added to the solution, 
followed by NEt3 (2.5 mL, 18.10 mmol, 2.10 eq). The solution was stirred at 0oC for 45 min 
then propylamine (1.15 mL, 13.71 mmol, 1.60 eq) was added at 0oC. The reaction mixture was 
continued stirring at 0oC for 3 h then at r.t for 17 h. The solvent was then removed in vacuo to 
give a viscous orange yellow oil. Purification by flash column chromatography (0 to 2% MeOH 
in EtOAc) gave the product 20 as a colourless oil (1.02 g, 47%).  
 
Route 2 - 2 steps 
tert-Butyl (3-oxo-3-(propylamino)propyl)carbamate, 29 (0.29 g, 1.26 mmol) was deprotected 
by stirring with TFA (2.5 mL) in CH2Cl2 (10 mL) for 6 h at 15oC. The solvent was removed in 
vacuo to give a colourless oil that was dried in vacuo for 2 days. The deprotected product, 3-
amino-N-propylpropanamide was confirmed by NMR analysis and the yield was quantitative. It 
was then taken to the next step without further purification. 
To 3-amino-N-propylpropanamide (0.16 g, 1.26 mmol) in MeOH (13 mL) NHEt2 (2.0 mL, 19 
mmol, xs) was added. The solution was heated under reflux for 7 h then D-pantolactone, 26 
(0.16 g, 1.25 mmol, 0.99 eq) was added. The mixture was heated under reflux for 22 h. 
Purification by flash column chromatography (0 to 1.7% MeOH in EtOAc) yielded 20 as a 
colourless oil (0.24 g, 92 %). 
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Rf: 0.26 (10% MeOH in EtOAc). 1H-NMR (CDCl3, 600 MHz): 7.54 (br, 1H, NH), 6.42 (br, 1H, 
NH), 4.00 (s, 1H, CHOH), 3.54 (br and m, 2H, CH(OH)CONHCH2), 3.48-3.49 (m, br, 2H, 
OHCH2), 3.16 (q, 2H, J 6.7 Hz, CONHCH2CH2CH3), 2.42 (t, 2H, J 6.0 Hz, 
CH(OH)CONHCH2CH2), 1.51 (sext, 2H, J 7.2 Hz, CH2CH2CH3), 0.98 (s, 3H, C(CH3)2), 0.95 
(s, 3H, C(CH3)2), 0.88 (t, 3H, J 7.2 Hz, CH2CH2CH3). (Identical by 1H-NMR to the   literature 
120) 13C-NMR (CDCl3, 150 MHz): 173. 4 (CONH), 171.4 (COOH), 77.9 (CH(OH)CONH), 71.0 
(OHCH2), (OHCH2), 51.0 (CH(OH)CONHCH2CH2CONH), 41.5 (CONHCH2), 39.4 
(C(CH3)2), 35.8 (CH(OH)CONHCH2CH2CONH), 22.9 (CH2CH3), 21.6 (C(CH3)2), 20.6 
(C(CH3)2), 11.5 (CH2CH3). MS (CI) m/z (%): 259 (100). HRMS C12H24N2O4: calc. 259.1658, 
found 259.1658, error: 0.00 ppm. 
 
(R)-3-hydroxy-2,2-dimethyl-4-oxo-4-((3-oxo-3-(propylamino)propyl)amino)butyl (1R,3R)-
3-((tert-butoxycarbonyl)amino)cyclopentane-1-carboxylate, 31 
 
To a solution of commercially available (1R, 3R)-N-BOC 1-aminocyclopentane 3-carboxylic 
acid (0.42 g, 1.74 mmol, 1.1 eq) in THF (5 mL) at 0oC, was added DCC (0.66 g 3.17 mmol, 2.0 
eq). The mixture was stirred at 0oC and then allowed to gradually warm up to r.t for 2 h before a 
catalytic amount of DMAP (77 mg) was added. The mixture was then stirred at r.t for 30 min. 
(R)-2,4-dihydroxy-3,3-dimethyl-N-(3-oxo-3(propylamino)propyl)butanamide, 20 (0.41 g, 1.56 
mmol) in THF (7 mL) was added to the reaction mixture and the solution was stirred at 45oC 
for 15 h. The precipitate was filtered off and the filtrate was concentrated in vacuo. Purification 
by flash column chromatography (EtOAc : Hexane = 1:1, then EtOAc : Hexane = 3:1, 100% 
EtOAc then 0.5% MeOH in EtOAc) gave the product, 31 as colourless flakes upon drying in 
vacuo (0.25 g, 33 %). Rf: 0.53 (10% MeOH in EtOAc). Mpt: 38 – 40oC. IR (νmax, cm-1): 3310 
(m, NH), 2966 (m, sp3-CH), 1688, 1645 (OC=ONH, C=ONH). 1H-NMR ((CD3)2SO, 600 
MHz):  3.90-4.03 (br, m, 1H, H-18), 3.87 (s, 1H, CH, H-10), 3.41-3.51 (m, 2H, CH2, H-7), 4.05 
(d, 1H, CH2, J 10.65 Hz, H-13), 3.97 (d, 1H, CH2, J 10.65 Hz, H-13), 3.12 (t, 2H, CH2, J 7.0 
Hz, H-3),  2.96 (quint, 1H, CH, J 8.0 Hz, H-16), 2.42 (t, 2H, J 6.8 Hz, CH2, H-6), ), 2.15-2.29 
(m, 1H, CH2, H-19), 2.09-2.18 (m, 2H, CH2, H-17 and H-19), 1.74-1.84 (m, 2H, CH2, H-17 and 
H-20), 1.48-1.53 (m, 3H, CH2, H-20 and H-2), 1.43 (s, 9H, 3 x CH3, H-25), 0.97 (s, 3H, CH3, 
H-12), 0.95 (s, 3H, CH3, H-12), 0.90 (t, 3H, CH3, J 7.2 Hz, H-1). 13C-NMR ((CD3)2SO, 150 
MHz): 177.5 (C=O, C-22), 176.7 (C=O, C-15), 175.5 (C=O, C-9), 173.6 (C=O, C-5), 79.9 (C, 
C-24), 75.9 (CH, C-10), 71.3 (CH2, C-13), 53.1 (CH, C-18), 43.3 (CH, C-16), 42.2 (CH2, C-3), 
39.5 (C, C-11), 37.2 (CH2, C-7), 36.8 (CH2, C-19), 33.8 (CH2, C-20), 29.2 (CH2, C-17), 23.6 
(CH2, C-2), 21.7 (CH3, C-12), 21.6 (CH3, C-12), 21.0 (CH3, C-25), 11.8 ((CH3, C-1). MS (CI) 
m/z (%): 472 (15), 416 (12), 398 (12), 370 (44), 258 (52), 243 (63), 214 (36), 188 (46), 157 
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(58), 131 (97), 122 (100). HRMS C23H42N3O7: calc 472.30173, found 472.300985, error: 1.60 
ppm.  
 
3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)cyclohexane-1-carboxylic acid, 34 162 
 
To a mixture of commercially available 3-aminocyclohexane-1-carboxylic acid (cis- and trans- 
isomers with >95% cis-3-aminocyclohexane-1-carboxylic acid) (853 mg, 5.66 mmol) and 
NaHCO3 (820 mg, 9.76 mmol, xs) in water (20mL) at r.t, was added FmocOSu (2.38 g, 6.77 
mmol, 1.20 eq) in THF (35 mL). The reaction mixture is stirred at r.t for 30 h. THF was then 
removed in vacuo and a white precipitate started to crush out. EtOAc (150 mL) was added to 
the mixture then HCl (3 M, 70 mL) was added slowly to the solution whilst stirring. The white 
precipitate was dissolved into organic layer to form a milky organic layer, which was extracted 
out. The organic layer was washed twice with brine (2 x 200 mL). To the milky organic layer, 
was added THF (100 mL) to form a clear solution, which was then dried (MgSO4). The solvent 
was removed in vacuo to give the product as a white powder (2.06 g, 95%). Rf: 0.71 (10% 
MeOH in EtOAc). IR (νmax, cm-1): 3323 (m, NH), 3067 (br, OH), 2939, 2860(m, sp3-CH), 1679 
(s, OC=ONH and C=OOH), 1537 (s, OCONH).  1H-NMR (CD3OD, 600 MHz): 7.80 (d, 2H, 
Ar-H, J 7.80 Hz, H-15), 7.60 (d, 2H, Ar-H, J 7.80 Hz, H-18), 7.40 (t, 2H, Ar-H, J 7.20 Hz, H-
16), 7.31 (t, 2H, Ar-H, J 7.20 Hz, H-17), 4.36 (d, 2H, CH2, J 6.11 Hz, H-11), 4.21 (t, 1H, CH, J 
7.00 Hz, H-12), 3.40-3.42 (br, m, 1H, CH, H-4), 2.34-2.38 (br, m, 1H, CH, H-2), 2.12-2.16 (br, 
m, 1H, CH2, H-3), 1.83-1.92 (br, m, 2H, CH2, H-7), 1.12-1.40 (m, 5H, CH2, H-3 and H-5 and 
H-6). 13C-NMR (CD3OD, 150 MHz): 176.3 (C=O, C-1), 155.3 (C=O, C-9), 143 (Ar-C, C-13), 
139 (Ar-C, C-14), 128.8 (Ar-C, C-16), 128 (Ar-C, C-15), 126 (Ar-C, C-17), 121 (Ar-C, C-18), 
65.4 (CH2, C-11), 49.0 (CH, C-4), 46.8 (CH, C-12), 42.0 (CH, C-2), 35.4 (CH2, C-3), 32.1, 
28.1 and 25.2 (CH2, C-5, C-6 and C-7). HRMS C22H24NO4: calc 366.1705, found 366.1718, 
error: 3.60 ppm. 
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(R)-3-hydroxy-2,2-dimethyl-4-oxo-4-((3-oxo-3-(propylamino)propyl)amino)butyl 3-((((9H-
fluoren-9-yl)methoxy)carbonyl)amino)cyclohexane-1-carboxylate, 36 
 
To 3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)cyclohexane-1-carboxylic acid, 34 (390 mg, 
1.07 mmol) in THF (10 mL) at 0oC, DCC (590 mg, 2.83 mmol, 2.64 eq) and DMAP (80.0 mg, 
0.65 mmol, 0.60 eq) were added. The mixture was stirred at 0oC for 1 h before (R)-2,4-
dihydroxy-3,3-dimethyl-N-(3-oxo-3-(propylamino)propyl)butanamide, 20 (375 mg, 1.44 mmol, 
1.35 eq) in THF (8 mL) was added. The solution was then stirred at 45oC for 18 h before the 
solvent was removed in vacuo. Purification by flash column chromatography (Petroleum Ether : 
EtOAc = 3:1 to 1:1 then 0.5% MeOH in EtOAc) yielded the product as a light yellow solid (287 
mg, 37%). Rf: 0.50 (10% MeOH in EtOAc). 1H-NMR (CD3OD, 600 MHz): 7.80 (d, 2H, Ar-H, 
J 7.80 Hz, H-29), 7.60 (d, 2H, Ar-H,  J 7.80 Hz, H-32), 7.40 (t, 2H, Ar-H, J 7.20 Hz, H-30), 
7.31 (t, 2H, Ar-H, J 7.20 Hz, H-31), 4.34 (d, 2H, CH2, J 7.20 Hz, H-25), 4.20 (t, 1H, CH, J 
7.20 Hz, H-26), 4.05 (d, 1H, CH2, J 10.62 Hz, H-13), 3.92 (d, 1H, CH2, J 10.62 Hz, H-13), 3.87 
(s, 1H, CH, H-10), 3.41-3.50 (m, 3H, CH and CH2, H-18 and H-7), 3.11 (t, 2H, CH2, J 7.20 Hz, 
H-3), 2.39-2.42 (m, br, 3H, CH and CH2, H-16 and H-6), 2.12-2.15 (br, 1H, CH2, H-17), 1.83-
1.89 (br, 2H, CH2, H-21), 1.50-1.51 (m, 2H, CH2, H-2), 1.12-1.40 (m, 5H, CH2, H-17 and H-19 
and H-20), 0.98 (s, 3H, CH3, H-12), 0.94 (s, 3H, CH3, H-12), 0.89 (t, 3H, CH3, J 7.20 Hz, H-1). 
13C-NMR (CD3OD, 150 MHz): 176.5 (C=O, C-15), 175.4 (C=O, C-9), 173.6 (C=O, C-5), 
158.0 (C=O, C-23), 145.3 (Ar-C, C-27), 142.6 (Ar-C, C-28), 128.8 (Ar-C, C-30), 128 (Ar-C, 
C-29), 126 (Ar-C, C-31), 121 (Ar-C, C-32), 75.9 (CH, C-10), 71.2 (CH2, C-13), 67.5 (CH2, C-
25), 49.1 (CH, C-18), 48.8 (CH, C-26), 43.8 (CH, C-16), 42.2 (CH2, C-3), 39.6 (C, C-11), 36.8 
(CH2, C-7), 36.4 (CH2, C-6), 36.3 (CH2, C-17), 29 (CH2, C-19 and C-20), 27 (CH2, C-21), 23.6 
(CH2, C-2), 20.3 (CH3, C-12), 19.8 (CH3, C-12), 11.8 (CH3, C-1). HRMS C34H46N3O7: calc 
608.3336, found 608.3332, error: 0.66 ppm. 
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(R)-3-hydroxy-2,2-dimethyl-4-oxo-4-((3-oxo-3-(propylamino)propyl)amino)butyl 3-
aminocyclohexane-1-carboxylate, 37 
 
(R)-3-hydroxy-2,2-dimethyl-4-oxo-4-((3-oxo-3-(propylamino)propyl)amino)butyl 3-((((9H-
fluoren-9-yl)methoxy)carbonyl)amino)cyclohexane-1-carboxylate, 36 (30 mg, 0.05 mmol) was 
dissolved in THF (2.5 mL) at r.t and piperidine (1.0 mL, 0.01 mol, xs) was added. The solution 
was stirred at r.t for 4 h before THF and piperidine were removed in vacuo. The mixture 
triturated until no trace of UV active spot was observed in toluene. The light yellow oil left after 
toluene wash was the product, which was dried in vacuo (1.5 h) (12.0 mg, 67%) and was used 
immediately in the next step without further purification. Rf: 0 (30% MeOH in EtOAc + 
ammonia). 
 
(1R,3R)-3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)cyclopentane-1-carboxylic acid, 
35 163   
 
(1R,3R)-3-((tert-butoxycarbonyl)amino)cyclopentane-1-carboxylic acid (269 mg, 1.11 mmol) 
was suspended in CH2Cl2 (8.0 mL) and TFA (4.0 mL). The mixture was stirred at r.t for 15 h 
then dried in vacuo for 4 h before re-dissolving in THF (12 mL). To this mixture, were added a 
solution of NaHCO3 (163 mg, 1.94 mmol, 1.75 eq) in H2O (7 mL) and FmocOSu (489 mg, 1.39 
mmol, 1.25 eq). The reaction mixture was stirred at r.t for 22 h then THF was removed in 
vacuo. EtOAc (25 mL) was added along with HCl (3 M, 25 mL). The mixture was stirred at r.t 
until all the white precipitate was dissolved, forming two layers. After extraction with EtOAc (3 
x 25 mL), the combined organic layers were washed with brine once. It was then dried 
(MgSO4). The solvent was removed in vacuo to provide the crude product as a light yellow oil, 
which solidified gradually under high vacuum. The crude oil was then washed several time with 
Et2O and dried in vacuo to give the product as a white solid (391 mg, quantitative). Rf: 0.24 
(Petroleum Ether : EtOAc = 1:1). IR (νmax, cm-1): 3317, 3063 (br, -OH), 2956 (br, sp3-CH), 
1739, 1685 (s, C=O, OC=ONH).  1H-NMR (CD3OD, 600 MHz): 7.83 (d, 2H, Ar-H, J 7.80 Hz, 
H-14), 7.64 (d, 2H, Ar-H, J 7.80 Hz, H-17), 7.42 (t, 2H, Ar-H, J 7.20 Hz, H-15), 7.32 (t, 2H, 
Ar-H, J 7.20 Hz, H-16), 4.36 (d, 2H, CH2, J 6.60 Hz, H-10), 4.19 (t, 1H, CH, J 6.60 Hz, H-11), 
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4.00-4.01 (br, m, 1H, CH, H-4), 2.88-2.92 (m, 1H, CH, H-2), 2.12-2.13 (m, 1H, CH2, H-5), 
1.99-2.09 (br, m, 2H, CH2, H-3 and H-6), 1.76-1.83 (br, m, 2H, CH2, H-3 and H-5), 1.51-1.55 
(m, 1H, CH2, H-6). 13C-NMR (CD3OD, 150 MHz): 179 (C=O, C-1), 158 (C=O, C-8), 145.4 
(Ar-C, C-12), 142.6 (Ar-C, C-13), 129 (Ar-C, C-15), 128 (Ar-C, C-14), 126 (Ar-C, C-16), 121 
(Ar-C, C-17), 67.4 (CH2, C-10), 53.5 (CH, C-4), 49 (CH, C-11), 43.0 (CH, C-2), 37.1 (CH2, C-
5), 33.4 (CH2, C-6), 28.9 (CH2, C-3). (Identical by 1H- and 13C-NMR to the literature 163) 
HRMS C21H22NO4: calc 352.1549, found 352.1545, error: 1.1 ppm. 
 
(R)-3-hydroxy-2,2-dimethyl-4-oxo-4-((3-oxo-3-(propylamino)propyl)amino)butyl (1R,3R)-
3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)cyclopentane-1-carboxylate, 38 
 
To a solution of (1R,3R)-3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)cyclopentane-1-
carboxylic acid, 35 (268 mg, 0.76 mmol) in THF (9.0 mL) at 0oC, DCC (349 mg, 1.69 mmol, 
2.22 eq) and DMAP (20 mg, 0.16 mmol) were added. The reaction mixture was stirred at 0oC 
for 1 h. Then 20 (243 mg, 0.93 mmol, 1.22 eq) in THF (6.0 mL) was added and the reaction 
mixture was stirred at 45oC for 24 h. The precipitate was filtered. The filtrate was purified by 
flash column chromatography (Petroleum Ether : EtOAc = 3:1 then 100% EtOAc then 0.4 to 
0.8% MeOH in EtOAc) to give 38 as a white solid (145 mg, 32%). Rf: 0.61 (10% MeOH in 
EtOAc). 1H-NMR (CD3OD, 600 MHz): 7.80 (d, 2H, Ar-H, J 7.80 Hz, H-28), 7.64 (d, 2H, Ar-
H, J 7.80 Hz, H-31), 7.40 (t, 2H, Ar-H, J 7.20 Hz, H-29), 7.30 (t, 2H, Ar-H, J 7.20 Hz, H-30), 
4.36 (d, 2H, CH2, J 6.60 Hz, H-24), 4.20 (t, 2H, J 6.60 Hz, CH, H-25), 4.00-4.25 (m, 2H, CH 
and CH2, H-13 and H-18), 3.83-3.97 (m, 1H, 2H, CH and CH2, H-13 and H-10), 3.43-3.57 (m, 
2H, CH2, H-7), 3.10-3.13 (m, 2H, CH2, H-3), 3.00 (br, m, 1H, CH, H-16), 2.40-2.43 (m, 2H, 
CH2, H-6), 2.15-2.29 (m, 1H, CH2, H-19), 1.85-2.15 (m, 2H, CH2, H-17 and H-20), 1.65-1.85 
(m, 2H, CH2, H-17 and H-19), 1.48-1.53 (m, 3H, CH2, H-20 and H-2), 0.97 (s, 3H, CH3, H-12), 
0.95 (s, 3H, CH3, H-12), 0.90 (t, 3H, CH3, J 7.20 Hz, H-1). 13C-NMR (CD3OD, 150 MHz): 
176.7 (C=O, C-15), 175.4 (C=O, C-9), 173.6 (C=O, C-5), 158.3 (C=O, C-22), 145.4 (Ar-C, C-
26), 142.6 (Ar-C, C-27), 128.8 (Ar-C, C-29), 128 (Ar-C, C-28), 126 (Ar-C, C-30), 121 (Ar-C, 
C-31), 75.9 (CH, C-10), 71.3 (CH2, C-13), 69 (CH2, C-24), 53.5 (CH, C-18), 49 (CH, C-25), 
43.8 (CH, C-16), 42.2 (CH2, C-3), 39.6 (C, C-11), 37.6 (CH2, C-6), 37.4 (CH2, C-7), 37.1 
(CH2, C-19), 33.8 (CH2, C-20), 29.4 (CH2, C-17), 23.5 (CH2, C-2), 21.7 (CH3, C-12), 21.5 
(CH3, C-12), 11.7 (CH3, C-1). HRMS C33H43N3O7: calc 594.3136, found 594.3179, error: 7.2 
ppm. 
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(R)-3-hydroxy-2,2-dimethyl-4-oxo-4-((3-oxo-3-(propylamino)propyl)amino)butyl (1R,3R)-
3-aminocyclopentane-1-carboxylate, 32 
 
To a solution of 38 (276 mg, 0.46 mmol) in THF (15 mL) at r.t, was added piperidine (7.0 mL, 
xs). The reaction mixture was stirred at r.t for 7 h before THF and piperidine were removed in 
vacuo. The mixture was triturated with toluene until no trace of UV active spot was observed in 
toluene. The colourless oil left after toluene wash was the product, which was dried in vacuo 
(12 h) (138 mg, 80%) and was used straight to the next step without further purification. 
 
(R)-3-hydroxy-2,2-dimethyl-4-oxo-4-((3-oxo-3-(propylamino)propyl)amino)butyl (1R,3R)-
3-(4-((2-(3-methyl-5-(((2,2,2-trichloroethoxy)carbonyl)amino)-1H-pyrazol-1-yl)pyrimidin-
4-yl)amino)butanamido)cyclopentane-1-carboxylate, 40 
 
4-((2-(3-methyl-5-(((2,2,2-trichloroethoxy)carbonyl)amino)-1H-pyrazol-1-yl)pyrimidin-4-
yl)amino)butanoic acid, 39 (60mg, 0.13 mmol) was dissolved in DMF (2.2 mL) at 0oC. HOAt 
(33 mg, 0.24 mmol, 1.86 eq) and PyAOP (245 mg, 0.47 mmol, 3.60 eq) and DIPEA (0.12 mL, 
xs) were added to the reaction mixture followed by 32 (64 mg, 0.17 mmol, 1.30 eq) in DMF 
(2.5 mL). The reaction mixture was stirred from 0oC to r.t gradually and kept stirring at r.t for 
48 h. Purification by flash column chromatography (4 to 20% MeOH in CH2Cl2) yielded crude 
mixture (44 mg) (checked by LCMS: MW = 804 at 2.12 min). The crude mixture was purified 
by preparative HPLC Gradient 10, product peak at 3.80 min to afford the product as a white 
solid (18 mg, 17%). Rf: 0.46 (15% MeOH in CH2Cl2+DIPEA). 1H-NMR (CD3OD, 600 MHz): 
8.01 (d, 1H, Ar-H, J 6.00 Hz, H-6), 6.50 (s, Ar-H, H-10), 6.38 (d, Ar-H, J 6.00 Hz, H-5), 5.00 
(s, 2H, CH2, H-16), 4.18-4.20 (br, 1H, CH, H-25), 4.05 (d, 1H, CH2, J 6.00 Hz, H-32), 3.83-
3.97 (m, 2H, CH and CH2, H-32 and H-35), 3.42-3.53 (m, 4H, CH2, H-38 and H-20), 3.11 (t, 
2H, CH2, J 6.00 Hz, H-42), 2.92-2.94 (br, 1H, CH, H-27), 2.41 (t, 2H, CH2, J 6.00 Hz, H-39), 
2.28-2.30 (m, 5H, CH3 and CH2, H-12 and H-22), 2.13-2.15 (m, 1H, CH2, H-19), 1.95-2.02 (m, 
4H, CH2, H-21 and H26 (1) and H-28 (1)), 1.72-1.82 (m, 2H, CH2, H-26 and H-29), 1.43-1.53 
(m, 3H, CH2, H-28 and H-43), 0.97 (s, 3H, CH3, H-34), 0.95 (s, 3H, CH3, H-34), 0.91 (t, 3H, 
CH3, J 7.20 Hz, H-44). 13C-NMR (CD3OD, 150 MHz): 177.3 (C=O, C-30), 175.4 (C=O, C-36), 
174.9 (C=O, C-23), 173.6 (C=O, C-41), 164.1 (Ar-C, C-4), 158.2 (Ar-C, C-2), 155.2 ((Ar-C, 
C-6), 152.8 (Ar-C, C-9), 151.4 (C=O, C-14), 141.8 (Ar-C, C-11), 104.6 (Ar-C, C-5), 97.2 (Ar-
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C, C-10), 96.5 (C, C-17), 75.8 (CH2, C-16 and C-35), 71.3 (CH2, C-32), 51.9 (CH, C-25), 43.4 
(CH, C-27), 42.2 (CH2, C-42), 39.5 (C, C-33), 36.9 (CH2, C-29), 36.5 (CH2, C-38 and C-39), 
34.3 (CH2, C-22), 33.2 (CH2, C-28), 26.1 (CH2, C-26), 23.6 (CH2, C-43), 21.6 (CH3, C-21), 
20.8 (CH3, C-34), 20.6 (CH3, C-34), 11.4 (CH3, C-44). MS (ESI+) m/z (%): 806 (100), 549 (35) 
MS (ESI+) C33H49Cl3N9O8+: calc 806.2735, found 806.2883, error: 18 ppm. 
 
Failed synthetic attempts 
(R)-3-hydroxy-2,2-dimethyl-4-oxo-4-((3-oxo-3-(propylamino)propyl)amino)butyl (1R,3R)-
3-aminocyclopentane-1-carboxylate, 32 
(Figure 3.12) 
Procedure 1 
To a solution of 31 (60 mg, 0.18 mmol) in DMF (3.0 mL) at r.t, was added TFA (0.3 mL, 3.90 
mmol, xs). The reaction mixture was stirred at r.t for 15 h. No product was detected and starting 
material 31 degraded. 
 
Procedure 2 
Commercially available Amberlyst-15 was cleaned by soaking in MeOH (24 h) then in a 
solution of NH3 4 M in MeOH (1 h) followed by soaking in a solution of HCl 3 M in MeOH (2 
h). The clean acidified Amberlyst-15 (35 mg) was added to a solution of 31 (30 mg, 0.06 mmol) 
in THF (2.0 mL) at r.t. The reaction mixture was stirred at r.t for 15 h. TLC (10 to 15% MeOH 
in EtOAc) showed the degrading starting material but no clear signal of product. 
(R)-3-hydroxy-2,2-dimethyl-4-oxo-4-((3-oxo-3-(propylamino)propyl)amino)butyl (1R,3R)-
3-(4-((2-(5-amino-3-methyl-1H-pyrazol-1-yl)pyrimidin-4-
yl)amino)butanamido)cyclopentane-1-carboxylate, 13 
(Figure 3.17) 
To a solution of 40 (18 mg, 2.20 x10-2 mmol) in THF (4 mL) added NH4OAc (0.25 mL) and Zn 
dust (60 mg, xs). The mixture was stirred at r.t for 24 h before filtered through Celite and 
washed with THF. LCMS showed product peak at 1.30 min (Iodide tray) and 1.37 min (ES+). 
Solvent was removed to afford crude product (12 mg). Purification by preparative HPLC 
Gradient 8, product peak at 15 min unfortunately failed and only provided crude (1.2 mg). 
Despite seeing 1 peak on HPLC and MS clean NMR could not be obtained. Unpromising 
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biological test (IC50 >2 mM) and reassessment by computational suggested inactivity of this 
type of compound result in abandon of this compound. No further attempt to prepare 13 was 
made. HRMS C30H47N9O6: calc 630.3728, found 630.3729, error: 0.15 ppm. 
 
6.1.2. Heteroaromatic core 
2,4-Dichloro-6-(N-methylpiperazin-1-yl)pyrimidine, 47 164 
 
2,4,6-Trichloropyrimidine (0.3 mL, 2.53 mmol) in EtOH (5.0 mL) was cooled to -25oC and 
then NEt3 (0.39 mL, 2.80 mmol, 1.12 eq) was added to the solution. N-Methyl piperazine (0.28 
mL, 2.50 mmol, 1.00 eq) was then added dropwise at -25oC. The reaction mixture was stirred at 
-25oC to 0oC over 4 h.  A white precipitate was formed and then filtered off and washed with 
plenty of water and dried in vacuo to yield the product as a white solid (0.45g, 74%). Mpt: 121-
122oC. IR (ν cm-1): 2843, 2937 (w, sp3-CH), 1575 (s, ArC=C).  1H-NMR (CDCl3, 600 MHz): 
7.04 (s, 1H, Ar-H), 3.5-3.7 (br, 4H, 2 CH2-CH2-N), 2.36 (t, 4H, J 5.0 Hz, 2 CH2-N(CH3)), 2.21 
(s, 3H, CH3). 13C-NMR (CDCl3, 150 MHz): 162.8 (N-ArC(Cl)-N), 159.1 (ArC(N((CH2)(CH2))-
ArN), 158.5 (ArC(Cl)-ArCH), 100.8 (Ar-CH), 53.9 (CH2-CH2-N), 46.2 (CH2-N(CH3)), 45.5 
(CH3). MS (EI) m/z (%): 248 (63) (37Cl35Cl), 246 (100) (35Cl35Cl). HRMS C9H12Cl2N4: calc. 
246.04335, found 246.04336, error: 1.26 ppm. 
 
tert-Butyl 4-(2-chloro-6-(4-methylpiperazin-1-yl)pyrimidin-4-ylamino)butanoate, 46 
 
To a solution of 2,4-dichloro-6-(N-methylpiperazin-1-yl)pyrimidine, 47 (136 mg, 0.55 mmol) in 
n-BuOH (4 mL) was added DIPEA (0.55 mL, 3.92 mmol, xs) and tert-butyl-4-aminobutanoate 
(158 mg, 0.99 mmol, 1.80 eq). The reaction mixture was heated under reflux for 26 h and white 
precipitate was formed. The white precipitate was filtered off and washed with EtOAc. The 
combined filtrate was then concentrated in vacuo and redissolved in CH2Cl2. The organic 
solution was then washed with NaHCO3 20% (2 x 20 mL), and the combined organic layers 
were dried (MgSO4). The solvent was removed in vacuo. The residues were purified by flash 
column chromatography (CH2Cl2 with 0 to 2% MeOH) to give the product 47 as a light yellow 
oil (153 mg, 75%). Rf: 0.57 (10% MeOH in CH2Cl2). IR (ν cm-1): 2978 (w, sp3-CH), 1722 (m, 
C=O), 1576 (s, ArC=C). 1H-NMR (CDCl3, 600 MHz): 5.85 (s, 1H, Ar-H), 3.78-3.80 (br, 1H, 
N-H), 3.57-3.65 (br, 4H, 2 CH2-CH2-N piperazine), 3.35-3.39 (m, 2H, CH2-COOt-Bu), 2.43-
2.45 (br, 4H, 2 CH2-N(CH3) piperazine), 2.31 (s, 3H, N-CH3), 2.28 (t, 2H, , J 7.2 Hz, COOt-
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Bu-(CH2)2-CH2-NH), 1.80 (m, 2H, COOt-BuCH2-CH2-CH2NH), 1.41 (s, 9H, (CH3)3-C). 13C-
NMR (CDCl3, 150 MHz): 173.0 (C=O), 161.7 (NH-ArC-ArN), 161.2 ((ArC(N((CH2)(CH2))-
ArN), 91.1(Ar-CH), 80.8 (C(CH3)3), 55.3 (CH2-CH2-N piperazine), 46.1 (CH2-N(CH3) 
piperazine), 44.1 (CH2-N(CH3) piperazine), 40.8 (CH2-COOt-Bu), 33.1 (COOt-Bu-(CH2)2-
CH2-NH), 28.3 (CH3)3-C), 25.3 (COOt-BuCH2-CH2-CH2NH). MS (CI) m/z (%): 371 (19) 
(37Cl), 369 (56) (35Cl), 299 (28), 298 (26), 297 (14), 296 (77), 245 (26), 243 (75), 202 (23), 187 
(100). HRMS C19H28ClN4O2: calc. 369.19260, found 369.19299, error: 1.06 ppm. 
 
 (dba)Pd((R)-BINAP) 135 
To over-dried glassware which was then placed in vacuo and flushed with Argon several times, 
were added Pd2(dba)3 (37.6 mg, 0.04 mmol) in dry benzene (3.5 mL) and (R)-BINAP (52 mg, 
0.08 mmol, 2 eq). The purple solution was stirred at r.t for 2.5 h. The resulting dark orange 
solution was then filtered through Celite and the Celite was washed with toluene (15.0 mL). 
The solvent was removed in vacuo, and the oily residues were re-dissolved in diethyl ether (3.4 
mL). The orange precipitate forming over 4 h was then collected, washed with diethyl ether and 
then dried in vacuo overnight to give the product catalyst (31.8 mg, 81%). The catalyst is stored 
inside a desiccator. 1H-NMR (CDCl3, 400 MHz): 6.32-7.42 (m). 31P-NMR (CDCl3, 162 MHz): 
24.7-26 (br). (Identical by 1H- and 31P-NMR to the literature 135) 
 
tert-Butyl-4-(2-(3-methyl-1H-pyrazol-5-ylamino)-6-(4-methylpiperazin-1-yl)pyrimidin-4-
ylamino)butanoate, 3 
 
tert-Butyl 4-(2-chloro-6-(4-methylpiperazin-1-yl)pyrimidin-4-ylamino)butanoate, 46 (12.2 mg, 
0.03 mmol) was dissolved in dry THF (3.5 mL). 3-Amino 5-methyl pyrazole (5.00 mg, 0.05 
mmol, 1.70 eq) was added to the solution along with Cs2CO3 (15.0 mg, 0.05 mmol, 1.60 eq) and 
the catalyst (dba)Pd((R)-BINAP) (5.00 mg, 5.00 µmol, 15 mol%). The resulting orange solution 
was then heated under microwave at 120oC for 10 min followed by 140oC for 30 min. LCMS 
confirmed strong product peak and no starting material remained. The solid was filtered off the 
reaction solution and washed with THF. The combined filtrate was concentrated in vacuo and 
the residues were dried in vacuo. Flash column chromatography (Chloroform with 1 to 10% 
MeOH) yielded the product 3 as a light yellow oil (11.2 mg, 80%). Rf: 0.15 (10% MeOH in 
CH2Cl2). 1H-NMR (CD3OD, 600 MHz): 6.33 (s, 1H, Ar-H pyrimidine), 5.28 (s, 1H, Ar-H 
pyrazole), 3.68-3.80 (br and m, 5H, (pyrimidine)-N-H-(pyrazole) and 2 CH2-CH2-N 
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piperazine), 3.30 (t, 2H, J 7.2 Hz, COOt-Bu-(CH2)2-CH2-NH),  3.10 (s, 1H, aliphatic N-H), 
2.47-2,52 (m, 4H, 2 CH2-N(CH3) piperazine), 2.33 (s, 3H, N-CH3 piperazine), 2.31 (t, 2H, J 7.3 
Hz, CH2-COOt-Bu), 2.11 (s, 3H, CH3 pyrazole), 1.84-1.88 (quint, 2H, J 7.2 Hz, COOt-BuCH2-
CH2-CH2NH), 1.40 (s, 3H, (CH3)3-C). 13C-NMR (CD3OD, 150 MHz): 174.8 (C=O), 162.7 
(ArN-ArC(NH)-ArN pyrimidine), 162.5 ((ArC(N((CH2)(CH2))-ArN pyrimidine), 162.0 (ArCH-
ArC-NH((CH2)3COOt-Bu)), 152.6 (ArC-NH pyrazole, ArC-CH3 pyrazole), 90.1 (ArC-H 
pyrimidine), 81.5 (C(CH3)3), 79.6 (ArC-H pyrazole), 56.7 (CH2-CH2-N piperazine), 46.1 (CH2-
N(CH3) piperazine), 41.6 (CH2-COOt-Bu), 34.0 (COOt-Bu-(CH2)2-CH2-NH), , 28.4 (CH3)3-C), 
26.2 (COOt-BuCH2-CH2-CH2NH). MS (CI) m/z (%): 432 (37), 431 (100), 430 (26). HRMS 
C21H348N8O2: calc. 431.28830, found 431.28877, error: 1.09 ppm. 
 
2,4,6-Tribromopyrimidine, 56 165 
 
To an oven-dried, argon-filled flask, was added phosphorus (V) oxytribromide (5.00 g, 16.92 
mmol, 4.0 eq), dry toluene (15.0 mL), barbituric acid (0.57 g, 4.46 mmol) and N, N-
dimethylaniline (1.1 mL, 8.28 mmol, 1.9 eq). The mixture turned red and was heated under 
reflux for 3 h before cooling to r.t and then ice (20 g) was added. The mixture was then stirred 
to form a milky solution. The aqueous layer was separated and extracted with benzene (2 x 20 
mL). The combined organic layers were dried (MgSO4), filtered and re-dissolved in MeOH (60 
mL). The solvent was then removed in vacuo to give 56 as a yellow solid (0.96 g, 68%). Mpt: 
91 – 95oC. IR (ν cm-1): 1504 (s, ArC=C). 1H-NMR (CDCl3, 500 MHz): 7.74 (s, 1H, Ar-H). 13C-
NMR (CDCl3, 125 MHz): 153.1 (N-ArC(Br)-N), 150.8 (C-ArC(Br)-N), 128.2 (ArC-H). 
(Identical by 1H- and 13C-NMR to the literature 144) MS (CI) m/z (%): 321(28), 319 (96) 
(81Br81Br79Br), 317 (100) (79Br79Br 81Br), 315 (32).  
 
2,4-Dibromo-6-(N-methylpiperazin-1-yl)pyrimidine, 57 
 
2,4,6-Tribromopyrimidine, 56 (200 mg, 0.63 mmol) in MeOH (6.0 mL) was cooled to -30oC 
and then NEt3 (0.2 mL, 1.43 mmol, 2.3 eq) was added to the solution. N-methyl piperazine (70 
µL, 0.63 mmol, 1.0 eq) was then added dropwise at -30oC. The reaction mixture was stirred at   
-30oC to -5oC over 3 h. After that, the slightly yellow milky solution was allowed to gradually 
warm up to r.t and it turned transparent over time. The solvent was then removed in vacuo. 
Purification by flash column chromatography (CH2Cl2 with 0 to 7% MeOH) yielded a white 
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solid which was washed with cold water to give 57 (118 mg, 56%). Rf: 0.29 (10% MeOH in 
CH2Cl2) – as a salt with HN+Et3. Mpt: product decomposed at 257 – 260oC, not melted. IR (ν 
cm-1): 2939, 2805 (w, sp3-CH), 1566 (s, ArC=C). 1H-NMR (CDCl3, 600 MHz): 6.62 (s, 1H, Ar-
H), 3.73-3.85 (br, 4H, 2 CH2-CH2-N), 2.50-2.60 (br, 4H, 2 CH2-N(CH3)), 2.36 (s, 3H, CH3). 
13C-NMR (CDCl3, 150 MHz): 162.1(ArC(N((CH2)(CH2))-ArN), 150.9 (ArC(Br)-ArCH), 104.4 
(Ar-CH), 54.3 (CH2-CH2-N), 46 (CH2-N(CH3)), 31.1 (CH3). MS (EI) (%): m/z, 338 (47) 
(81Br81Br), 336 (100) (81Br79Br), 334 (50) (79Br79Br). HRMS C9H12Br2N4: calc. 333.94232, 
found 333.94255, error: 0.69 ppm. 
 
(S)-2-amino-(5-allyloxy)-5-oxo-pentanoic acid. HCl salt, 60 166 
 
Commercially available L-glutamic acid, 59 (10.60 g, 71.3 mmol) and TMSCl (23 mL, xs) was 
added to a solution of allyl alcohol (250 mL, xs). The reaction mixture was then stirred at 0oC 
for 20 min then at r.t for 24 h. Ice-cold diethyl ether was then added (800 mL) and a white 
precipitate formed. The solution was stirred for 1 h to obtain more precipitate. The precipitate 
was then filtered and washed with cold diethyl ether (2 x 100 mL) and dried in vacuo to give 
the product 60 as the HCl salt (6.73 g, 42%). Mpt: 119-123oC. IR (ν cm-1): 3154(m, NH), 2974, 
2907 (br, m, -OH and sp3-CH), 1739 (s, C=O ester), 1722 (s, C=O acid), 1610 (m, C=C). 1H-
NMR ((CD3)2SO, 500 MHz): 8.59 (br, 2H, NH2), 5.91 (m, 1H, CH2=CH), 5.29 (d, J 16.2 Hz, 
1H, CH2=CH), 5.20 (d, J 10.8 Hz, 1H, CH2=CH), 4.53 (br, 2H, CH2O), 3.89 (br, 1H, H-C(α)), 
2.62 (m, 2H, HC(γ)), 2.05-2.11 (m, 2H, H-C(β)). 1H-NMR (CD3OD, 500 MHz): 5.91-5.97 (m, 
1H, COOH), 5.32 (dd, 1H, J 17.2 and 1.5 Hz, CH2=CH), 5.22 (dd, J 12.9 and 1.3 Hz, 1H, 
CH2=CH), 4.85 (br, 3H, NH3), 4.60 (dd, 2H, J 7.7 and 0.9 Hz, CH2O), 4.05 (t, 2H, J 7.0 Hz, H-
C(α)), 2.60-2.66 (m, 2H, HC(γ)), 2.01-2.28 (m, 2H, H-C(β)). 13C-NMR (CD3OD, 125 MHz): 
173.3 (C=O(OAllyl)), 171.3 (C=O(OH)), 133.5 (CH2=CH), 118.5 (CH2=CH), 66.5 (CH2O), 
53.1 (H-C(α)), 30.5 (HC(γ)), 26.6 (H-C(β)). (Identical by 1H- and 13C-NMR to the literature 142) 
MS (CI) m/z, (%): 189 (22), 188 (100). HRMS C8H13NO4: calc. 188.09228, found 188.09261, 
error: 1.75 ppm. 
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Failed synthetic attempts 
tert-Butyl-4-(2-(3-methyl-1H-pyrazol-5-ylamino)-6-(4-methylpiperazin-1-yl)pyrimidin-4-
ylamino)butanoate, 3 
(Table 3.3) 
Table 3.3 
 
 (iii) Pd catalyst, ligand, base, solvent 
Entry Catalyst and 
ligand, mol% 
Base Solvent Time 
(h) 
Temperature  Yield % 
1 (dba)Pd(R-
BINAP), 1.3  
Cs2CO3 dioxane 25  thernal heat, 100oC ✗ 
2 Pd2(dba)3, 
DavePhos, 3.8 
NaOt-Bu dioxane 17  thermal heat, 100oC ✗ 
3 (dba)Pd(R-
BINAP), 4 
NaOt-Bu dioxane 40  thermal heat, 95oC ✗ 
4 Pd(PPh3)4, R-
BINAP, 8 
NaOt-Bu toluene 27  thermal heat, reflux ✗ 
5 (dba)Pd((R) -
BINAP), 5 
Cs2CO3 THF 1.6 microw, 140oC 6% 
isolated 
product 
6 (dba)Pd((R)-
BINAP), 15 
Cs2CO3 THF 0.6 microw,  
120 – 140oC 
80% 
isolated 
product 
 
Entry 1  
tert-Butyl 4-(2-chloro-6-(4-methylpiperazin-1-yl)pyrimidin-4-ylamino)butanoate, 46 (89.3 mg, 
0.24 mmol) was dissolved in dry dioxane (3.0 mL). 3-Amino 5-methyl pyrazole (28.0 mg, 0.28 
mmol, 1.17 eq) was added to the solution along with Cs2CO3 (113 mg, 0.34 mmol, 1.42 eq) and 
the catalyst (dba)Pd((R)-BINAP) (3.0 mg, 3 µmol, 1.3 mol%). The resulting solution was then 
46 3 
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heated at 100oC for 25 h. LCMS confirmed no product peak and starting material. Reaction 
failed. 
 
Entry 2  
tert-Butyl 4-(2-chloro-6-(4-methylpiperazin-1-yl)pyrimidin-4-ylamino)butanoate, 46 (10.6 mg, 
28.7 µmol) was dissolved in dry dioxane (1.5 mL). 3-Amino 5-methyl pyrazole (2.60 mg, 26.8 
µmol, 0.96 eq) was added to the solution along with NaOt-Bu (2.80 mg, 29.4 µmol, 1.02 eq) 
and the catalysts (dba)2Pd(dba)3 (0.9 mg, 0.98 µmol, 3.8 mol%) and DavePhos (2.0 mg, 7.11 
µmol). The resulting solution was then heated at 100oC for 17 h. LCMS confirmed no product 
peak. Reaction failed. 
 
Entry 3  
tert-Butyl 4-(2-chloro-6-(4-methylpiperazin-1-yl)pyrimidin-4-ylamino)butanoate, 46 (34.0 mg, 
92.0 µmol) was dissolved in dry dioxane (3.5 mL). 3-Amino 5-methyl pyrazole (13.0 mg, 0.13 
mmol, 1.41 eq) was added to the solution along with NaOt-Bu (16.0 mg, 0.17 mmol, 1.80 eq) 
and the catalysts (dba)2Pd(dba)3 (3.50 mg, 3.80 µmol, 4.0 mol%) and ((R)-BINAP (7.0 mg, 11.0 
µmol). The resulting solution was then heated at 95oC for 40 h. LCMS confirmed no product 
peak. Reaction failed. 
 
Entry 4 
tert-Butyl 4-(2-chloro-6-(4-methylpiperazin-1-yl)pyrimidin-4-ylamino)butanoate, 46 (17.5 mg, 
47.3 µmol) was dissolved in dry toluene (4.2 mL). 3-Amino 5-methyl pyrazole (5.10 mg, 52.5 
µmol, 1.11 eq) was added to the solution along with NaOt-Bu (12.0 mg, 0.13 mmol, 2.64 eq) 
and the catalysts Pd(PPh3)4 ( 6.0 mg, 5.19 µmol, 8 mol%) and R-BINAP (2.95 mg, 4.73 µmol). 
The resulting solution was then heated under reflux for 27 h. LCMS confirmed no product peak. 
Reaction failed. 
 
Entry 5  
tert-Butyl 4-(2-chloro-6-(4-methylpiperazin-1-yl)pyrimidin-4-ylamino)butanoate, 46 (66.0 mg, 
0.18 mmol) was dissolved in dry THF (4.0 mL). 3-Amino 5-methyl pyrazole (27.0 mg, 0.27 
mmol, 1.52 eq) was added to the solution along with Cs2CO3 (87.0 mg, 0.17 mmol, 1.52 eq) and 
the catalyst (dba)Pd((R)-BINAP) (8.00 mg, 8.00 µmol, 5 mol%). The resulting solution was 
then heated under microwave at 140oC for 1.60 h. LCMS confirmed product peak and starting 
material. The solid was filtered off the reaction solution and washed with THF. The combined 
filtrate was concentrated in vacuo and the residues were dried in vacuo. Flash column 
chromatography (Chloroform with 1 to 3% MeOH) yielded the product 3 as a light yellow oil 
(4.70 mg, 6%). 
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Di-tert-butyl (2-chloro-6-(4-methylpiperazin-1-yl)pyrimidin-4-yl)-D-glutamate, 54 
(Table 3.4) 
Table 3.4 
 
 
Entry Amine 
(1.5-2 eq) 
Base 
(+catalyst) (xs) 
Solvent Temperature Time (h) Yield % 
1 salt DIPEA n-BuOH 
and EtOH 
reflux 7 6% of 
crude 54 
2 salt DIPEA n-BuOH reflux 40 ✗ 
3 salt DIPEA THF reflux 4 ✗ 
4 salt Et3N EtOH reflux 24 ✗ 
5 free DIPEA t-BuOH reflux 24 ✗ 
6 free DIPEA n-BuOH 
and EtOH 
reflux 72 ✗ 
7 salt Cs2CO3 
(+(dba)Pd((R)-
BINAP)) 
toluene microw, 
140oC 
25 ✗ 
8 salt Cs2CO3 
(+(dba)Pd((R)-
BINAP)) 
THF  
 
microw, 
140oC 
30 ✗ 
 
Free-form di-tert-butyl D-glutamate 
Di-tert-butyl D-glutamate hydrochloride (178 mg, 0.60 mmol) was dissolved in water (pH = 
4.7). To the solution, was added saturated NaHCO3 solution and NaOH 10M until the pH 
reached 9.5. The solution was extracted by chloroform (3 x 40 mL). The combined extract was 
dried (MgSO4) and concentrated in vacuo to give the free-form di-tert-butyl D-glutamate as a 
colourless oil (146 mg, 94%). This was used directly in further experiments. 
 
 
 
47 54 
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Entry 1 
To a solution of 2,4-dichloro-6-(N-methylpiperazin-1-yl)pyrimidine, 47 (69.0 mg, 0.28 mmol) 
in n-BuOH (3 mL) and EtOH (5 mL), were added DIPEA (0.25 mL, 1.78 mmol, xs) and di-tert-
butyl D-glutamate hydrochloride (134 mg, 0.45 mmol, 1.60 eq). The reaction mixture was 
heated under reflux for 7 h. The reaction mixture was then concentrated in vacuo and purified 
by flash column chromatography (CH2Cl2 with 0 to 2% MeOH) to give a crude mixture 
containg product 54 (7.8 mg, 6%). 1H-NMR showed that only 20% of the crude was the 
product: 1H-NMR (CDCl3, 500 MHz): 6.40 (s, 1H, Ar-H), 3.30-3.40 (br, m, 4H, 2 CH2-CH2-N 
piperazine), 2.68-2.77 (br, m, 4H, 2 CH2-N(CH3) piperazine), 2.48 (s, 3H, N-CH3), 2.40-2.45 
(br, m, 1H, HN(C*H), underneath other peaks), 2.15-2.17 (m, 2H, -C*(H)-CH2-CH2-COOt-Bu) 
2.00-2.05 (m, 2H, -C*(H)-CH2-CH2), 1.50 (s, 18H, (CH3)3-C, underneath other peaks).  
 
Entry 2  
To a solution of 2,4-dichloro-6-(N-methylpiperazin-1-yl)pyrimidine, 47 (107 mg, 0.43 mmol) in 
n-BuOH (5 mL), were added DIPEA (0.50 mL, 3.59 mmol, xs) and di-tert-butyl D-glutamate 
hydrochloride (209 mg, 0.71 mmol, 1.65 eq). The reaction mixture was heated under reflux for 
40 h. LCMS did not detect any product. 
 
Entry 3 
To a solution of 2,4-dichloro-6-(N-methylpiperazin-1-yl)pyrimidine, 47 (21.4 mg, 86.6 µmol) 
THF (2 mL), were added DIPEA (0.30 mL, 2.15 mmol, xs) and di-tert-butyl D-glutamate 
hydrochloride (43.0 mg, 0.14 mmol, 1.62 eq). The reaction mixture was heated under reflux for 
4 h. LCMS did not detect any product. 
 
Entry 4  
To a solution of 2,4-dichloro-6-(N-methylpiperazin-1-yl)pyrimidine, 47 (53.5 mg, 0.22 mmol) 
in EtOH (4 mL), were added Et3N (0.60 mL, 4.26 mmol, xs) and di-tert-butyl D-glutamate 
hydrochloride (100 mg, 0.34 mmol, 1.55 eq). The reaction mixture was heated under reflux for 
24 h. LCMS did not detect any product. 
 
Entry 5  
To a solution of 2,4-dichloro-6-(N-methylpiperazin-1-yl)pyrimidine, 47 (72.0 mg, 0.29 mmol) 
in t-BuOH (5 mL), were added DIPEA (0.30 mL, 2.15 mmol, xs) and free-form di-tert-butyl D-
glutamate (110 mg, 0.42 mmol, 1.45 eq). The reaction mixture was heated under reflux for 24 
h. LCMS did not detect any product. 
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Entry 6 
To a solution of 2,4-dichloro-6-(N-methylpiperazin-1-yl)pyrimidine, 47 (56.0 mg, 0.23 mmol) 
in n-BuOH (2.5 mL) and EtOH (1.6 mL), were added DIPEA (0.20 mL, 1.43 mmol, xs) and 
free-form di-tert-butyl D-glutamate (85.4 mg, 0.33 mmol, 1.43 eq). The reaction mixture was 
heated under reflux for 72 h. LCMS did not detect any product. 
 
Entry 7 
To a solution of 2,4-dichloro-6-(N-methylpiperazin-1-yl)pyrimidine, 47 (52.5 mg, 0.21 mmol) 
in toluene (3.0 mL), were added di-tert-butyl D-glutamate hydrochloride (75.0 mg, 0.25 mmol, 
1.19 eq) along with Cs2CO3 (81.0 mg, 0.25 mmol, 1.19 eq) and the catalysts (dba)2Pd(dba)3 (45 
mg, 0.05 mmol, 22 mol%) and ((R)-BINAP (44.5 mg, 0.07 mmol). The reaction mixture was 
heated under microwave at 140oC for 25 min. LCMS did not detect any product. 
 
Entry 8  
To a solution of 2,4-dichloro-6-(N-methylpiperazin-1-yl)pyrimidine, 47 (51.0 mg, 0.21 mmol) 
in THF (3.5 mL), were added di-tert-butyl D-glutamate hydrochloride (88.5 mg, 0.30 mmol, 
1.42 eq) along with Cs2CO3 (99.7 mg, 0.31 mmol, 1.42 eq) and the catalysts (dba)2Pd(dba)3 (29 
mg, 0.03 mmol, 14 mol%) and ((R)-BINAP (40.0 mg, 0.06 mmol). The reaction mixture was 
heated under microwave at 140oC for 30 min. LCMS did not detect any product. 
 
Di-tert-butyl (2-bromo-6-(4-methylpiperazin-1-yl)pyrimidin-4-yl)-D-glutamate, 58 
(Figure 3.26) 
To a solution of 2,4-dibromo-6-(N-methylpiperazin-1-yl)pyrimidine, 57 (50.8 mg, 0.15 mmol) 
in n-BuOH (5.3 mL) at r.t, were added di-tert-butyl D-glutamate hydrochloride (53.0 mg, 0.18 
mmol, 1.20 eq) and DIPEA (26 µL, 0.19 mmol, 1.30 eq). The reaction mixture was heated 
under reflux over 5 h and monitored by TLC. After 5 h, only starting materials were detected. 
Further amounts of di-tert-butyl D-glutamate hydrochloride (33.0 mg, 0.1 mmol, 0.70 eq) and 
DIPEA (50 µL, 0.19 mmol, xs) were added. The reaction mixture was heated under reflux for 
15 h. LCMS did not detect any signals of the product. 
 
5-Allyl 1-(tert-butyl) L-glutamate, 61 
(Figure 3.27) 
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To a solution of (S)-2-amino-(5-allyloxy)-5-oxo-pentanoic acid. HCl salt, 60 (6.26 g, 28.0 
mmol) in perchloric acid 70% (17 mL) at 0oC, tert-butyl alcohol (50 mL, 0.37 mol, 13.0 eq) 
was added dropwise over 1 h. The reaction was allowed to gradually warm up to r.t whilst 
stirring for 48 h. After that, the reaction mixture was cooled to 0oC and NaOH (10 M, 87 mL) 
was added slowly to change the pH of the solution to 10. The reaction mixture was then 
extracted with EtOAc (2 x 80 mL). The combined extract was dried (MgSO4). TCL (10% 
MeOH in CH2Cl2) did not detected the formation of the product. 
 
6.2. Approach B syntheses 
2-Azidoacetic acid, 63 167 
 
To a solution of 2-bromoacetic acid (5.0 g, 36.0 mmol) in water (25 mL) at 0oC, was added 
sodium azide (10.0 g, 153.8 mmol, xs). The reaction mixture was stirred from 0oC to r.t for 24 
h. After that, a solution of HCl 37% was added (15 mL) until the colour of the mixture turned 
from peach to colourless. The combined organic layers were extracted with Et2O (3 x 100 mL) 
then dried (Na2SO4). The solvent was removed in vacuo to afford the product as a colourless 
liquid (3.65 g, quantitative). IR (νmax, cm-1): 3100 (br, OH), 2918 (m, sp3-CH), 2105 (s, azide), 
1716 (s, C=O acid). 1H-NMR (D2O, 600 MHz): 4.10 (s, 2H, CH2). (Identical by 1H-NMR to the 
literature 147) 13C-NMR (D2O, 150 MHz): 173.5 (C=O), 50.8 (CH2). MS (EI) m/z (%): 101 
(100). HRMS C2H3N3O2: calc. 101.0220, found 101.0215, error: 0.46 ppm.  
 
(R)-3-hydroxy-2,2-dimethyl-4-oxo-4-((3-oxo-3-(propylamino)propyl)amino)butyl 2-
azidoacetate, 64 
 
 
Procedure using DCC and DMAP 
To a colourless solution of 2-azidoacetic acid, 63 (152 mg, 1.50 mmol, 1.50 eq) in THF (4.0 
mL) at 0oC, was added DCC (385 mg, 1.80 mmol, 1.80 eq) to form a cloudy solution. DMAP 
(20 mg, 0.16 mmol, 0.16 eq) was added followed by (R)-2,4-dihydroxy-3,3-dimethyl-N-(3-oxo-
3(propylamino)propyl)butanamide, 20 (260 mg, 1.00 mmol) in THF (2.7 mL). A further 4.0 mL 
of THF was added and the reaction mixture was stirred from 0oC to r.t for 40 min before 
heating at 45oC whilst stirring for 20 h. The solvent was then removed in vacuo. Purification by 
flash column chromatography (Petroleum Ether to Petroleum Ether : EtOAc = 1:1 then 1:2 then 
100% EtOAc to 0.5 to 1% MeOH in EtOAc) gave the product 64 as a white solid (150 mg, 
44%). Rf: 0.20 (EtOAc). 
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Procedure using PyAOP and HOAt 
To a colourless solution of 2-azidoacetic acid, 63 (111 mg, 1.09 mmol, 1.02 eq) in DMF (9.0 
mL) at 0oC, were added PyAOP (1.03 g mg, 1.98 mmol, 1.85 eq), HOAt (206 mg, 1.51 mmol, 
1.41 eq) and DIPEA (0.20 mL, 1.15 mmol, 1.07 eq) followed by (R)-2,4-dihydroxy-3,3-
dimethyl-N-(3-oxo-3(propylamino)propyl)butanamide, 20 (280 mg, 1.07 mmol) in DMF (10 
mL). The reaction mixture was stirred from 0oC to r.t for 18 h. The solvent was then removed in 
vacuo and Petroleum Ether (10 mL) and CH2Cl2 (50 mL) were added. After filtration, the 
filtrate was concentrated in vacuo. Purification by flash column chromatography (Petroleum 
Ether : EtOAc = 3:1 then 2:1 then 100% EtOAc to 0.2 to 1% MeOH in EtOAc) gave the 
product 64 as a white solid (209 mg, 57%).  
 
IR (νmax, cm-1): 3319 (m, br, NH, OH), 2929 (m, sp3-CH), 2105 (s, azide), 1741 (s, C=O ester), 
1639 (s, C=ONH), 1527 (s, CONH). 1H-NMR (CDCl3, 600 MHz): 7.31 (t, br, 1H, N-H, H-8), 
6.02 (s, br, 1H, N-H, H-4), 4.20 (d, 1H, J 10.92 Hz, H-12), 3.99 (d, 1H, J 10.92 Hz, H-12), 3.93 
(s, 1H, CH, H-10), 3.92 (s, 2H, CH2, H-16), 3.52-3.55 (m, 2H, CH2, H-7), 3.16-3.19 (m, 2H, 
CH2, H-3), 2.41 (t, 2H, CH2, J 5.16 Hz, H-6), 1.47-1.53 (m, 2H, CH2, H-2), 1.03 (s, 3H, CH3, 
H-13), 0.98 (s, 3H, CH3, H-13), 0.94 (t, 3H, CH3, J 7.3 Hz, H-1). 13C-NMR (CDCl3, 150 MHz): 
172.4 (C=O, C-9), 172.3 (C=O), C-15), 171.6 (C=O, C-5), 71.7 (CH2, C-12), 75.1 (CH, C-10), 
50.6 (CH2, C-16), 41.6 (CH2, C-3), 38.4 (C, C-11), 35.6 (CH2, C-6), 35.4 (CH2, C-7), 22.8 
(CH2, C-2), 20.9 (CH3, C-13), 20.8 (CH3, C-13), 11.5 (CH2, C-1). MS (EI) m/z (%): 344 (100), 
345 (20). HRMS C14H26N5O5: calc. 344.1928, found 344.1931, error: 0.20 ppm. 
 
((3aR,4R,6R,6aR)-6-(6-amino-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-
d][1,3]dioxol-4-yl)methanol, 66 168 
 
To a mixture of adenosine (3.00 g, 11.22 mmol) in acetone (300 mL) at 0oC, was added p-
toluenesulfonic acid (21.8 g, 113 mmol, xs) in two equal portions. The mixture was stirred at 
0oC to 11oC for 20 h. Saturated NaHCO3 solution (300 mL) was then added to the mixture 
whilst stirring and acetone was removed in vacuo. NaOH 10 M was added to bring pH to 11. 
The combined organic layers were extracted with EtOAc (3 x 200 mL) then dried (NaSO4) and 
concentrated in vacuo to afford the product as a white solid (3.40 g, 99%). IR (νmax, cm-1): 3267, 
3106, 3061 (br, w, NH2, OH), 2986, 2937 (w, sp3-CH), 1682, 1570 (m, adenine C=C, C=N). 
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1H-NMR ((CD3)2SO, 600 MHz): 8.35 (s, 1H, Ar-H, H-8), 8.15 (s, 1H, Ar-H, H-2), 7.34 (br, 2H, 
N-H), 6.12 (d, 1H, CH, J 2.83 Hz, H-11), 5.34 (dd, 1H, CH, J 6.00 Hz and 2.77 Hz, H-12), 5.25 
(t, 1H, O-H, J 5.80 Hz), 4.96 (dd, 1H, CH, J 6.29 Hz and 2.42 Hz, H-13), 4.20-4.22 (m, 1H, 
CH, H-14), 3.49-3.58 (m, 2H, CH2, H-15), 1.54 (s, 3H, CH3, H-17’), 1.32 (s, 3H, CH3, H-17). 
(Identical by 1H-NMR to the literature 148) 13C-NMR ((CD3)2SO, 150 MHz): 156.2 (Ar-C, C-6), 
152.8 (Ar-C, C-2), 148.8 (Ar-C, C-4), 139.7 (Ar-C, C-8), 119.2 (Ar-C, C-5), 113.1 (C, C-16), 
89.7 (CH, C-11), 86.5 (CH, C-14), 83.4 (CH, C-12), 81.4 (CH, C-13), 61.6 (CH2, C-15), 27.2 
(CH3, C-17’), 25.2 (CH3, C-17). MS (ESI) m/z (%): 308 (100), 309 (25). HRMS C13H18N5O4: 
calc. 308.1359, found 308.1351, error: 2.60 ppm. 
 
N-(9-((3aR,4R,6R,6aR)-6-(hydroxymethyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-
4-yl)-9H-purin-6-yl)benzamide, 67 169 
 
 ((3aR,4R,6R,6aR)-6-(6-Amino-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-
yl)methanol, 66 (500 mg, 1.62 mmol) was added to pyridine (10 mL) and the solution was co-
evaporated before pyridine (9.0 mL) was added back to the mixture. TMSCl (1.05 mL, 8.27 
mmol, xs) was added whilst stirring at r.t for 30 min followed by BzCl (296 mg, 2.11 mmol, 
1.30 eq). The mixture was stirred at r.t for 3.5 h before cooling down to 0oC. Water (1.65 mL) 
was added whilst stirring for 10 min then ammonia 28% solution (3.3 mL) was added. The 
mixture was stirred at r.t for 45 min then evaporated. Purification by flash column 
chromatography (0 to 2.5% MeOH in CH2Cl2) gave the product 67 as a white solid (424 mg, 64 
%). Rf: 0.40 (10% MeOH in CH2Cl2). IR (νmax, cm-1): 3351, 3180, 3061 (br, w, NH2, OH), 2986, 
2923, 2853 (w, sp3-CH), 1707 (s, C=ONH), 1602, 1588, 1524 (m, adenine C=C, C=N and 
Ph(C=C)). 1H-NMR ((CD3)2SO, 600 MHz): 11.24 (s, 1H, N-H), 8.77 (s, 1H, Ar-H, H-8), 8.68 
(s, 1H, Ar-H, H-2), 8.05 (d, 2H, Ar-H, J 7.28 Hz, H-20), 7.66 (t, 1H, Ar-H, J 7.67 Hz, H-22), 
7.56 (t, 2H, Ar-H, J 7.70 Hz, H-21), 6.28 (d, 1H, CH, J 2.34 Hz, H-11), 5.45 (dd, 1H, CH, J 
6.20 Hz and 2.26 Hz, H-12), 5.16 (t, 1H, O-H, J 5.80 Hz), 5.01 (dd, 1H, CH, J 6.20 Hz and 
2.26 Hz, H-13), 4.27 (m, 1H, CH, H-14), 3.55-3.56 (m, 2H, CH2, H-15), 1.56 (s, 3H, CH3, H-
17’), 1.35 (s, 3H, CH3, H-17). 13C-NMR ((CD3)2SO, 150 MHz): 165.6 (C=O, C-18), 151.8 (Ar-
C, C-2), 150.5 (Ar-C, C-4), 143.2 (Ar-C, C-8), 134.3 (Ar-C, C-6), 133.3 (Ar-C, C-19), 132.5 
(Ar-C, C-22), 128.6 (Ar-C, C-20), 128.2 (Ar-C, C-21), 119.2 (Ar-C, C-5), 113.1 (C, C-16), 
89.3 (CH, C-11), 86.9 (CH, C-14), 83.7 (CH, C-12), 81.8 (CH, C-13), 61.5 (CH2, C-15), 27.2 
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(CH3, C-17’), 25.2 (CH3, C-17). (Identical by 1H- and 13C- NMR to the literature 149) HRMS 
C20H22N5O5: calc. 412.1621, found 412.1628, error: 1.70 ppm. 
 
N-(9-((3aR,4R,6R,6aR)-2,2-dimethyl-6-((prop-2-yn-1-yloxy)methyl)tetrahydrofuro[3,4-
d][1,3]dioxol-4-yl)-9H-purin-6-yl)benzamide, 68 149 (Attempted) 
(Figure 4.3) 
To a solution of 67 (974 mg, 2.36 mmol) in THF (20 mL) at 0oC, was added NaH (105 mg, 2.62 
mmol, 1.10 eq) slowly. The reaction mixture was stirred at 0oC for 1 h then TBAI (290 mg, 
0.78 mmol, 0.33 eq) and THF (20 mL) were added in followed by propargyl bromide 80% (390 
mg, 1.30 eq). The reaction mixture was stirred at r.t for 24 h. Purification by flash column 
chromatography (0 to 4% MeOH in CH2Cl2) gave the product 69 (240 mg) and 70 (440 mg) as 
white foams.  
N-(9-((3aR,4R,6R,6aR)-6-(hydroxymethyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-
4-yl)-9H-purin-6-yl)-N-(prop-2-yn-1-yl)benzamide, 69 
 
1H-NMR ((CD3)2SO, 600 MHz): 8.68 (s, 1H, Ar-H, H-8), 8.62 (s, 1H, Ar-H, H-2), 7.36-7.37 
(m, 3H, Ar-H, H-23 and H-25), 7.26 (m, 2H, Ar-H, H-24), 6.19 (d, 1H, CH, J 2.90 Hz, H-11), 
5.35 (dd, 1H, CH, J 6.20 Hz and 2.90 Hz, H-12), 5.13 (t, 1H, O-H, J 5.30 Hz), 5.07 (d, 2H, 
CH2, 2.50 Hz, H-18), 4.94 (dd, 1H, CH, J 6.20 Hz and 2.40 Hz, H-13), 4.22-4.25 (m, 1H, CH, 
H-14), 3.50 (t, 2H, CH2, J 5.30 Hz, H-15), 3.11 (t, 1H, CH, J 2.50 Hz, H-20), 1.53 (s, 3H, CH3, 
H-17’), 1.31 (s, 3H, CH3, H-17). 13C-NMR ((CD3)2SO, 150 MHz): 170.8 (C=O, C-21), 152.4 
(Ar-C, C-4 and C-6), 151.6 (Ar-C, C-2), 144.2 (Ar-C, C-8), 131.3 (Ar-C, C-22 and C-23), 
128.4 (Ar-C, C-24), 128.2 (Ar-C, C-25), 125.8 (Ar-C, C-5), 113.1 (C, C-16), 89.8 (CH, C-11), 
86.8 (CH, C-14), 83.5 (CH, C-12), 81.5 (CH, C-13), 79.6 (C, C-19), 74.3 (CH, C-20), 61.4 
(CH2, C-15), 37.1 (CH2, C-18), 27.2 (CH3, C-17’), 25.2 (CH3, C-17). 
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N-((E)-9-((3aR,4R,6R,6aR)-6-(hydroxymethyl)-2,2-dimethyltetrahydrofuro[3,4-
d][1,3]dioxol-4-yl)-1-(prop-2-yn-1-yl)-1,9-dihydro-6H-purin-6-ylidene)benzamide, 70 
 
1H-NMR ((CD3)2SO, 600 MHz): 8.53 (s, 1H, Ar-H, H-2), 8.14 (s, 1H, Ar-H, H-8), 8.00 (dd, 
2H, Ar-H, J 7.90 Hz and 1.30 Hz, H-23), 7.53 (t, 1H, Ar-H, J 7.26 Hz, H-25), 7.43 (t, 2H, Ar-
H, J 7.80 Hz H-24), 6.05 (d, 1H, CH, J 2.90 Hz, H-11), 5.24 (dd, 1H, CH, J 6.10 Hz and 2.64 
Hz, H-12), 5.07 (t, 1H, O-H, J 5.30 Hz), 5.00 (d, 2H, CH2, 2.40 Hz, H-18), 4.90 (dd, 1H, CH, J 
6.20 Hz and 2.40 Hz, H-13), 4.19-4.22 (m, 1H, CH, H-14), 3.54 (t, 2H, CH2, J 2.40 Hz, H-20), 
3.49 (t, 2H, CH2, J 5.30 Hz, H-15), 1.52 (s, 3H, CH3, H-17’), 1.31 (s, 3H, CH3, H-17). 13C-
NMR ((CD3)2SO, 150 MHz): 175.8 (C=O, C-21), 147.9 (Ar-C, C-2), 144.4 (Ar-C, C-6), 144.2 
(Ar-C, C-4), 139.2 (Ar-C, C-8), 131.8 (Ar-C, C-22 and C-25), 129.1 (Ar-C, C-23), 128.3 (Ar-
C, C-24), 120.9 (Ar-C, C-5), 113.1 (C, C-16), 90.0 (CH, C-11), 87.0 (CH, C-14), 84.0 (CH, C-
12), 81.3 (CH, C-13), 78.9 (C, C-19), 76.0 (CH, C-20), 61.4 (CH2, C-15), 37.8 (CH2, C-18), 
23.1 (CH3, C-17’), 19.3 (CH3, C-17). 
 
9-((3aR,4R,6R,6aR)-2,2-dimethyl-6-((prop-2-yn-1-yloxy)methyl)tetrahydrofuro[3,4-
d][1,3]dioxol-4-yl)-9H-purin-6-amine, 71 170 
 
To a solution of ((3aR,4R,6R,6aR)-6-(6-amino-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-
d][1,3]dioxol-4-yl)methanol, 66 (3.11 g, 10.0 mmol) in THF (75 mL) at 0oC, was added NaH 
60% weight (560 mg, 14.0 mmol, 1.40 eq). The reaction mixture was stirred at 0oC for 4 h 
before propargyl bromide 80% in THF (2.08 g, 14.0 mmol, 1.40 eq) was added. The reaction 
mixture was then stirred at 0oC and allowed to warm up to r.t for 20 h. The mixture was then 
filtered and the filtrate was concentrated in vacuo. Purification by flash column chromatography 
(0 to 2% MeOH in CH2Cl2) gave the product 71 as a light yellow oil (1.42 g, 41%). Rf: 0.25 
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(5% MeOH in CH2Cl2). IR (νmax, cm-1): 3280, 3130 (br, w, NH2 and alkyne C-H), 2981, 2932 
(w, sp3-CH), 1641, 1595, 1571 (m, adenine C=C, C=N). MS (ESI) m/z (%): 346 (100), 347 
(20), 242 (90). 1H-NMR ((CD3)2SO, 600 MHz): 8.30 (s, 1H, Ar-H, H-8), 8.17 (s, 1H, Ar-H, H-
2), 7.35 (br, 2H, N-H), 6.16 (d, 1H, CH, J 2.83 Hz, H-11), 5.41 (dd, 1H, CH, J 6.00 Hz and 
2.77 Hz, H-12), 4.98 (dd, 1H, CH, J 6.29 Hz and 2.42 Hz, H-13), 4.31 (br, 1H, CH, H-14), 
4.13-4.14 (m, 2H, CH, H-19), 3.55-3.56 (m, 1H, CH2, H-15), 3.44-3.45 (s, 1H, CH, H-21), 1.56 
(s, 3H, CH3, H-17’), 1.35 (s, 3H, CH3, H-17). (Identical by 1H-NMR to the literature 170) 13C-
NMR ((CD3)2SO, 150 MHz): 155.6 (Ar-C, C-6), 153.3 (Ar-C, C-2), 149.6 (Ar-C, C-4), 139.5 
(Ar-C, C-8), 120.0 (Ar-C, C-5), 114.4 (C, C-16), 91.4 (CH, C-11), 85.8 (CH, C-14), 84.9 (CH, 
C-12), 81.9 (CH, C-13), 69.9 (CH2, C-15), 59 (CH2, C-19), 27.2 (CH3, C-17), 25.4 (CH3, C-
17’). HRMS C16H20N5O4: calc. 346.1515, found 346.1516, error: 0.30 ppm. 
 
(2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((prop-2-yn-1-yloxy)methyl)tetrahydrofuran-
3,4-diol, 72 171 
 
To a solution of 9-((3aR,4R,6R,6aR)-2,2-dimethyl-6-((prop-2-yn-1-
yloxy)methyl)tetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-9H-purin-6-amine, 71 (725 mg, 2.10 
mmol) in t-BuOH (7 mL) and water (23 mL) at r.t, was added TFA (9 mL). The reaction 
mixture was stirred at r.t for 24 h and then concentrated in vacuo. The crude oil was redissolved 
in water and freeze-dried to afford the product as a colourless/white foam (639 mg, 
quantitative) which was used immediately in the next step. IR (νmax, cm-1): 3364 (m), 3282 (s, 
alkyne C-H and NH2), 3120 (m, OH), 2960 (m, sp3-CH), 1623-1669 (m, adenine C=C, C=N). 
1H-NMR ((CD3)2SO, 600 MHz): 8.48 (s, 1H, Ar-H, H-8), 8.33 (s, 1H, Ar-H, H-2), 5.94 (d, 1H, 
CH, J 5.18 Hz, H-11), 4.56 (dd, 1H, CH, J 5.18 Hz and 5.05 Hz, H-12), 4.20-4.21 (m, 2H, CH2, 
H-19), 4.16 (t, 1H, CH, J 4.65 Hz, H-13), 4.06-4.08 (m, 1H, CH, H-14), 3.73 (dd, 1H, CH2, J 
10.76 Hz and 3.72 Hz, H-15), 3.64 (dd, 1H, CH2, J 10.76 Hz and 4.91 Hz, H-15), 3.48 (t, 1H, 
CH, J 2.39 Hz, H-21). 13C-NMR ((CD3)2SO, 150 MHz): 158 (Ar-C, C-6), 153 (Ar-C, C-4), 149 
(Ar-C, C-2), 140.6 (Ar-C, C-8), 118.8 (Ar-C, C-5), 87.7 (CH, C-11), 83.2 (CH, C-14), 80.1 
(CH, C-20), 77.6 (CH, C-21), 73.7 (CH, C-12), 70.8 (CH, C-13), 69.6 (CH2, C-15), 57.9 (CH2, 
C-19). MS (ESI) m/z (%): 344 (20), 306 (100). HRMS C13H16N5O4: calc. 306.1202, found 
306.1200, error: 0.70 ppm. 
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tert-Butyl (2-aminoethyl)carbamate, 76 172 
 
A solution of Boc2O (5.10 g, 18 mmol) in CH2Cl2 (500 mL) was added dropwise to a solution 
of ethylenediamine (12.0 mL, 0.18 mol, 10 eq) in CH2Cl2 (120 mL) at r.t whilst stirring. The 
reaction mixture was continued stirring at r.t for 24 h. The white precipitate was filtered and 
discarded. The filtrate was concentrated in vacuo and saturated Na2CO3 solution (200 mL) was 
added. After extraction with CH2Cl2 (3 x 100 mL), the combined organic layers were dried 
(MgSO4) and concentrated in vacuo to afford the product as a colourless oil (2.88 g, 
quantitative). IR (νmax, cm-1): 3305 (m, NH), 2979, 2869 (m, sp3-CH), 1687 (s, OC=ONH), 
1519 (s, OCONH). 1H-NMR (CDCl3, 600 MHz): 4.93 (br, 1H, NH), 3.16-3.18 (m, br, 2H, CH2, 
H-3), 2.79 (t, 2H, CH2, J 6.0 Hz, H-2), 1.44 (s, 9H, 3 x CH3, H-8). (Identical by 1H-NMR to the 
literature 175) 13C-NMR (CDCl3, 150 MHz): 156.5 (C=O, C-5), 79.4 (C, C-7), 43.4 (CH2, C-3), 
42.0 (CH2, C-2), 28.5 (CH3, C-8).MS (CI) m/z (%): 201 (45), 161 (100), 105 (48). HRMS 
C7H17N2O2: calc. 161.1290, found 161.128974, error: 0.2 ppm. 
 
tert-Butyl (2-azidoethyl)carbamate, 77 173 
 
To a solution of sodium azide (6.40 g, 98.4 mmol, xs) in CH2Cl2 (40 mL) and water (40 mL) at 
0oC, was added (F3CSO2)2O (5.41 g, 19.2 mmol, 1.97 eq) dropwise. The reaction mixture was 
stirred at 0oC for 2 h then extracted with CH2Cl2 (2 x 20 mL). The combined organic layers 
were washed once with saturated NaHCO3 solution before added to a solution of tert-butyl (2-
aminoethyl)carbamate, 76 (1.56 g, 9.74 mmol), K2CO3 (2.20 g, 15.90 mmol, 1.63 eq), 
CuSO4.5H2O (28 mg, 0.11 mmol) in MeOH (50 mL) and water (40 mL). The total mixture was 
stirred at r.t for 24 h before water (50 mL) was added and pH of the solution was adjusted to 2 
using HCl 37% (aq). MeOH and CH2Cl2 were removed in vacuo followed by extraction with 
CH2Cl2 (3 x 150 mL). The combined organic layers were washed with water (300 mL) then 
dried (Na2SO4) and concentrated in vacuo to give the product as a colourless oil (1.48 g, 81%). 
Rf: 0.30 (CH2Cl2). IR (νmax, cm-1): 3336 (m, NH), 2978, 2933 (m, sp3-CH), 2094 (s, azide), 1686 
(s, OC=ONH), 1513 (s, OCONH).  1H-NMR (CDCl3, 600 MHz): 4.83 (br, 1H, N-H), 3.41 (t, 
2H, CH2, J 5.3 Hz, H-1), 3.29-3.31 (m, 2H, CH2, H-2), 1.44 (s, 9H, 3 x CH3, H-7). (Identical by 
1H-NMR to the literature 174) 13C-NMR (CDCl3, 150 MHz): 155.8 (C=O, C-4), 79.9 (C, C-6) 
51.4 (CH2, C-1), 40.2 (CH2, C-2), 38.5 (CH3, C-7). HRMS C7H15N4O2: calc. 187.11950, found 
187.119168, error: 1.80 ppm. 
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1-(2-((tert-Butoxycarbonyl)amino)ethyl)-1H-1,2,3-triazole-4-carboxylic acid, 78  
 
†This Click test reaction was not followed the general procedure but adapted from the literature procedure 
157 
To a solution of propiolic acid (318 mg, 4.54 mmol, 1.06 eq) in t-BuOH (6.0 mL), were added 
CuSO4.5H2O (60.0 mg, 0.24 mmol) and sodium ascorbate (200 mg, 1.02 mmol) in water (14 
mL). The reaction mixture was stirred vigorously and tert-butyl (2-azidoethyl)carbamate, 77 
(800 mg, 4.30 mmol) in t-BuOH (6.0 mL) followed by water (10 mL) were added to it. The 
reaction mixture was then stirred at r.t for 48 h before t-BuOH was removed in vacuo. As t-
BuOH was removed in vacuo, a white precipitate appeared. The precipitate was filtered and 
washed with cold water three times and dried in vacuo to give the product as white flakes (826 
mg, 75%). IR (νmax, cm-1): 3381 (s, NH), 3118 (s, triazole C-H), 2979, 2932 (m, sp3-CH), 1687 
(s, OC=ONH and C=OOH), 1525 (s, OCONH).1H-NMR ((CD3)2SO, 600 MHz): 13.06 (br, 1H, 
O-H), 8.58 (s, 1H, Ar-H, H-6), 6.99-7.01 (br, 1H, N-H), 4.43 (t, 2H, CH2, J 5.65 Hz, H-7), 
3.37-3.40 (m, br, 2H, CH2, H-8), 1.33 (s, 9H, 3 x CH3, H-13). 13C-NMR ((CD3)2SO, 150 MHz): 
161.8 (C=O, C-1), 155.6 (C=O, C-10), 139 (Ar-C, C-2), 129.2 (Ar-C, C-6), 78.0 (C, C-12), 
49.5 (CH2, C-7), 39.9 (CH2, C-8), 28.1 (CH3, C-13). MS (ESI) m/z (%): 258 (18), 257 (100). 
HRMS C10H17N4O4: calc. 257.1229, found 257.1250, error: 8.20 ppm. 
 
tert-Butyl (2-(3-phenylureido)ethyl)carbamate, 84 175 
 
To a solution of tert-butyl (2-aminoethyl)carbamate, 76 (501 mg, 3.13 mmol) in CH2Cl2 (11 
mL) at 0oC, was added phenyl isocyanate (372 mg, 3.13 mmol, 1 eq) in CH2Cl2 (4 mL) slowly. 
A white precipitate formed. The mixture was stirred vigorously from 0oC to r.t for 20 h. After 
that, half of the solvent was removed in vacuo. Hexane (22 mL) was added and the precipitate 
was filtered and washed several times with hexane before dried in vacuo to afford the product 
as a white solid (840 mg, 97%). Rf: 0.85 (EtOAc).IR (νmax, cm-1): 3305 (m, NH), 3108 (m, 
triazole C-H), 2980 (w, sp3-CH), 1680 (s, C=ONH carbamate), 1642 (HNC=ONH urea), 1540 
(m, Ph(C=C) and CONH). 1H-NMR ((CD3)2SO, 600 MHz): 8.53 (s, br, 1H, N-H, H-10), 7.36-
7.37 (m, 2H, Ar-H, H-12), 7.19-7.22 (m, 2H, Ar-H, H-13), 6.87-6.89 (m, 1H, Ar-H, H-14), 
6.86-6.87 (br, 1H, N-H, H-5), 6.15 (br, 1H, N-H, H-8), 3.09-3.12 (m, 2H, CH2, H-7), 2.97-3.00 
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(m, 2H, CH2, H-6), 1.37 (s, 9H, 3 x CH3, H-1). 13C-NMR ((CD3)2SO, 150 MHz): 155.8 (C=O, 
C-9), 155.3 (C=O, C-4), 140.3 (Ar-C, C-11), 128.7 (Ar-C, C-13), 121.1 (Ar-C, C-14), 117.7 
(Ar-C, C-12), 40.4 (CH2, C-6), 39.1 (CH2, C-7), 28.3 (CH3, C-1). (Identical by 1H- and 13C- 
NMR to the literature 160) MS (ESI) m/z (%): 302 (10), 281 (20), 280 (100). HRMS 
C14H22N3O3: calc. 280.1661, found 280.1668, error: 2.50 ppm. 
 
1-(2-Aminoethyl)-3-phenylurea hydrochloride, 61 hydrochloride salt, 85.HCl salt 176 
 
To a solution of tert-butyl (2-(3-phenylureido)ethyl)carbamate, 84 (251 mg, 0.96 mmol) in 
acetone (8.5 mL), was added HCl (6 M, 0.2 mL, 1.20 mmol, 1.25 eq). The reaction mixture was 
stirred at r.t for 4 h. A white precipitate started coming out of the colourless solution and the 
mixture was left standing at r.t overnight. The precipitate was then filtered and washed with 
cold EtOAc and Petroleum Ether before drying in vacuo to afford the product as a white solid 
(120 mg, 56%). IR (νmax, cm-1): 3324, 3231 (m, NH2), 2943 (m, sp3-CH), 1656 (m, 
HNC=ONH), 1526-1594 (m, Ph(C=C) and CONH). 1H-NMR (D2O, 600 MHz): 7.41-7.44 (m, 
2H, Ar-H, H-7), 7.33-7.35 (m, 2H, Ar-H, H-8), 7.20-7.23 (m, 1H, Ar-H, H-9), 3.54 (t, 2H, 
CH2, J 5.85 Hz, H-2), 3.18 (t, 2H, CH2, J 5.93 Hz, H-1). (Identical by 1H-NMR to the literature 
160) 13C-NMR (D2O, 150 MHz): 159.4 (C=O, C-4), 138.4 (Ar-C, C-6), 129 (Ar-C, C-7), 125 
(Ar-C, C-9), 122.3 (Ar-C, C-8), 40.6 (CH2, C-1), 38 (CH2, C-2).  MS (CI) m/z (%): 180 (100). 
 
1-(2-Aminoethyl)-3-phenylurea, 85 
 
To a suspension of tert-butyl (2-(3-phenylureido)ethyl)carbamate, 84 (161 mg, 0.61 mmol) in 
CH2Cl2 (7.5 mL), added TFA (1.5 mL, xs) dropwise. The reaction mixture was stirred at r.t for 
4 h before left standing in fridge overnight. The solvent was then removed in vacuo and the 
remaining colourless oil was dried in vacuo for 3 h to remove any TFA residue before using 
straight in next step reaction.  
 
2-Azido-N-(2-(3-phenylureido)ethyl)acetamide, 86 
 
To a solution of 2-azidoacetic acid, 63 (50 mg, 0.50 mmol, 0.90 eq) in CH2Cl2 (12.0 mL) at 
0oC, HOBt (83.50 mg, 0.62 mmol, 1.12 eq) and EDC (118 mg, 0.62 mmol, 1.12 eq) were 
added. The reaction mixture was stirred at 0oC for 15 min. Meanwhile, 1-(2-aminoethyl)-3-
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phenylurea, 85, prepared from tert-butyl (2-(3-phenylureido)ethyl)carbamate, 84 and TFA, was 
dissolved in CH2Cl2 (6.0 mL) then NEt3 (0.96 mL) was added. The mixture was sonicated for 
15 min to neutralise any TFA left. This solution was then added to the mixture containing 2-
azidoacetic acid. The combined reaction mixture was stirred from 0oC to r.t for 20 h before 
concentrated in vacuo. Purification by flash column chromatography (20 to 50% EtOAc in 
Petroleum Ether then EtOAc) gave the product 86 as a colourless oil (92 mg, 64%). Rf: 0.30 
(EtOAc). IR (νmax, cm-1): 3380, 3325, 3269 (m, NH), 2970, 3090 (w, sp3-CH), 2107 (s, azide), 
1648 (m, HNC=ONH and C=ONH amide), 1561, 1596 (m, Ph(C=C), CONH). 1H-NMR 
((CD3)2SO, 600 MHz): 8.54 (s, 1H, N-H, H-8), 8.21 (br, 1H, N-H, H-3), 7.37-7.39 (m, 2H, Ar-
H, H-10), 7.19-7.22 (m, 2H, Ar-H, H-11), 6.87-6.89 (m, 1H, Ar-H, H-12), 6.19-6.20 (br, 1H, 
N-H, H-6), 3.82 (s, 2H, CH2, H-1), 3.14-3.20 (m, 4H, 2 x CH2, H-4 and H-5). 13C-NMR 
((CD3)2SO, 150 MHz): 167.6 (C=O, C-2), 155.4 (C=O, C-7), 140.3 (Ar-C, C-9), 128.7 (Ar-C, 
C-11), 121.1 (Ar-C, C-12), 117.7 (Ar-C, C-10), 50.8 (CH2, C-1), 38.8 (CH2, C-4 and C-5). MS 
(CI with ammmonia) m/z (%): 280 (50), 263 (95), 252 (53), 237 (55), 235 (100). HRMS 
C11H15N6O2: calc. 263.12510, found 263.125090, error: 0.05 ppm. 
 
(3R,22R)-3,22,24-trihydroxy-2,2,23,23-tetramethyl-4,8,17,21-tetraoxo-12,13-dithia-
5,9,16,20-tetraazatetracosyl 2-azidoacetate, 87 
 
 
To a solution of 2-azidoacetic acid, 63 (80 mg, 0.79 mmol) in CH2Cl2 (14.0 mL) and THF (4.0 
mL) at 0oC, were added HOBt (131 mg, 0.97 mmol, 1.23 eq) and EDC (187 mg, 0.97 mmol, 
1.23 eq) and NEt3 (0.20 mL). The reaction mixture was stirred at 0oC for 15 min. Then D-
pantethine (220 mg, 0.40 mmol, 0.5 eq) and CH2Cl2 (10 mL) were added to the reaction 
mixture. The combined reaction mixture was stirred vigorously from 0oC to r.t for 16 h. 
Although LCMS showed that most of the starting material D-pantethine had not reacted, the 
reaction mixture was worked up. The solvent was removed and water (50 mL) and CH2Cl2 (50 
mL) were added. The organic layer was washed with water (2 x 30 mL) and the combined 
aqueous layer was reduced to 6 mL. Purification by preparative HPLC Gradient 2, product peak 
at 7.3 min gave the product 87 as a sticky yellow oil (13.3 mg). 1H-NMR (D2O, 600 MHz): 
4.15-4.18 (m, 3H, CH2, H-17(1) and H-1 (2)), 4.06-4.08 (m, 1H, CH2, H-17), 4.04  (s, 1H, CH, 
H-7’), 4.00 (s, 1H, CH, H-7), 3.50-3.58 (m, 9H, 5 x CH2, H-10 (2), H-14 (2), H-4 (1)), 3.41 (d, 
1H, CH2, J 11.24 Hz, H-4), 2.87 (t, 4H, 2 x CH2, J 6.31 Hz, H-15 and H-15’), 2.53 (t, 2 x CH2, 
J 6.51 Hz, H-11 and H-11’), 1.02 and 1.00 (s, 2 x CH3, H-6’), 0.94 and 0.91 (s, 2 x CH3, H-6). 
13C-NMR (D2O, 150 MHz): 175.8 (C=O, C-8), 175.3 (C=O, C-8’), 174.6 (C=O, C-12 and C-
12’), 171.2 (C=O, C-2), 76.4 (CH, C-7’), 75.4 (CH, C-7), 71.8 (CH2, C-17), 69 (CH2, C-4), 
51.0 (CH2, C-1), 39.6 (C, C-5’), 39.2 and 38.7 (CH2, C-10 and C-14), 38.4 (C, C5), 37.1 (CH2, 
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C-15), 36.0 (CH2, C-11), 21.3 and 20.2 (CH3, C-6’), 19.7 and 20.2 (CH3, C-6). HRMS 
C24H44N7O9S2: calc. 638.2636, found 638.2636, error: 0.11 ppm. 
 
General procedure for Click reaction forming 1,2,3-triazole ring system 
CuSO4.5H2O = 0.8 mol%, Sodium Ascorbate = 8 mol% from freshly made 0.05 M solutions in 
water. 
To a solution of the alkyne in t-BuOH or water or both (according to solubility), were added 
CuSO4.5H2O 0.05 M and sodium ascorbate 0.05 M stock solutions with the ratio 0.8 mol% and 
8 mol% respectively followed by a solution of the azide (1.0 eq) in t-BuOH or water or both 
(according to solubility) (not in inert conditions). The overall concentration of the azide/alkyne 
was 0.05 M or 0.06 M and the ratio of t-BuOH : H2O =1:1 or 1:2. The reaction mixture was 
stirred at r.t and monitored by LCMS. In case the progress of the reaction was slow, inert 
condition was applied (O2-free) and ligand THPTA = 0.8 mol% was added. The reaction 
mixture was then concentrated in vacuo and purification by either flash column 
chromatography or preparative HPLC afforded the product. 
 
Benzyl 2-(4-((((3aR,4R,6R,6aR)-6-(6-amino-9H-purin-9-yl)-2,2-
dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methoxy)methyl)-1H-1,2,3-triazol-1-
yl)acetate, 82 
 
9-((3aR,4R,6R,6aR)-2,2-dimethyl-6-((prop-2-yn-1-yloxy)methyl)tetrahydrofuro[3,4-
d][1,3]dioxol-4-yl)-9H-purin-6-amine, 71 (588 mg, 1.70 mmol), CuSO4.5H2O (0.26 mL of 0.05 
M stock solution, 13 µmol, 0.8 mol%), sodium ascorbate (2.46 mL of 0.05 M stock solution, 
123 µmol, 8 mol%), and benzyl 2-azidoacetate, 81 (329 mg, 1.72 mmol, 1.01 eq) were 
dissolved in t-BuOH (14 mL) and water (14 mL). After stirring at r.t for 24 h, LCMS indicated 
96% completion of the reaction. The reaction mixture was then concentrated in vacuo and 
purification by flash column chromatography (2 to 3.3% MeOH in CH2Cl2) afforded the 
product as a colourless oil, forming foam upon drying in vacuo (757 mg, 83%). Rf: 0.30 (2% 
MeOH in CH2Cl2). IR (νmax, cm-1): 3326 (m, NH2), 3144 (m, triazole C-H), 2984, 2938 (m, sp3-
CH), 1750 (s, C=O ester), 1637, 1596 (s, adenine C=C, C=N). 1H-NMR ((CD3)2SO, 600 
MHz): 8.28 (s, 1H, Ar-H, H-8), 8.14 (s, 1H, Ar-H, H-2), 8.08 (s, 1H, Ar-H, H-24), 7.34-7.38 
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(m, 5H, Ar-H, H-30, H-31 and H-32), 7.33-7.34 (br, 2H, N-H), 6.14 (d, 1H, CH, J 2.65 Hz, H-
11), 5.46 (s, 2H, CH2, H-25), 5.39 (dd, 1H, CH, J 6.20 Hz and 2.60 Hz, H-12), 5.20 (s, 2H, 
CH2, H-28), 4.95 (dd, 1H, CH, J 6.10 Hz and 2.90 Hz, H-13), 4.54 (s, 2H, CH2, H-19), 4.30-
4.31 (m, 1H, CH, H-14), 3.63-3.65 (m, 1H, CH2, H-15), 3.55-3.57 (m, 1H, CH2, H-15), 1.53 (s, 
3H, CH3, H-17), 1.31 (s, 3H, CH3, H-17’). 13C-NMR ((CD3)2SO, 150 MHz): 167 (C=O, C-26), 
156 (Ar-C, C-6), 152.8 (Ar-C, C-2), 149 (Ar-C, C-4), 143.6 (Ar-C, C-20), 139.6 (Ar-C, C-8), 
135.6 (Ar-C, C-29), 128 (Ar-C, C-30, C-31, C-32), 125.5 (Ar-C, C-24), 119 (Ar-C, C-5), 113.5 
(C, C-16), 89.3 (CH, C-11), 84.5 (CH, C-14), 83.4 (CH, C-12), 81.6 (CH, C-13), 69.7 (CH2, C-
15), 66.8 (CH2, C-28), 63.6 (CH2, C-19), 50.3 (CH2, C-25), 27.0 (CH3, C-17), 25.2 (CH3, C-
17’). MS (ESI) m/z (%): 538 (70), 537 (100). HRMS C25H29N8O6: calc. 537.2210, found 
537.2203, error: 1.30 ppm. 
 
Benzyl 2-(4-((((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-
yl)methoxy)methyl)-1H-1,2,3-triazol-1-yl)acetate, 14 
 
To a solution of benzyl 2-(4-((((3aR,4R,6R,6aR)-6-(6-amino-9H-purin-9-yl)-2,2-
dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methoxy)methyl)-1H-1,2,3-triazol-1-yl)acetate, 
82 (910 mg, 1.70 mmol) in t-BuOH (30 mL) and water (30 mL), was added TFA (17 mL). The 
reaction mixture was stirred at r.t for 14 h. The reaction mixture was then concentrated in vacuo 
and purification by flash column chromatography (3 to 8% MeOH in CH2Cl2) afforded the 
product as a colourless oil, forming foam upon drying in vacuo (686 mg, 82%). Rf: 0 (6% 
MeOH in CH2Cl2). IR (νmax, cm-1): 3110-3204 (br, NH2, triazole C-H), 2980, 2906 (m, sp3-CH), 
1749 (s, C=O ester), 1643, 1574 (m, adenine C=C, C=N and Ph(C=C)). 1H-NMR ((CD3)2SO, 
600 MHz): 8.31 (s, 1H, Ar-H, H-8), 8.14 (s, 1H, Ar-H, H-2), 8.13 (s, 1H, Ar-H, H-24), 7.38-
7.39 (m, 5H, Ar-H, H-30, H-31 and H-32), 5.90 (d, 1H, CH, J 5.50 Hz, H-11), 5.51 (d, 1H, O-
H, J 6.30 Hz, H-16), 5.47 (s, 2H, CH2, H-25), 5.30 (d, 1H, O-H, J 4.90 Hz, H-17), 5.20 (s, 2H, 
CH2, H-28), 4.60 (s, 2H, CH2, H-19), 4.57-4.60 (m, 1H, CH, H-12), 4.13-4.15 (m, 1H, CH, H-
13), 4.02-4.05 (m, 1H, CH, H-14), 3.71-3.74 (m, 1H, CH2, H-15), 3.63-3.66 (m, 1H, CH2, H-
15). 13C-NMR ((CD3)2SO, 150 MHz): 167.8 (C=O, C-26), 156 (Ar-C, C-6), 152.8 (Ar-C, C-2), 
149.5 (Ar-C, C-4), 143.7 (Ar-C, C-20), 139.4 (Ar-C, C-8), 135.5 (Ar-C, C-29), 128 (Ar-C, C-
30, C-31, C-32), 125.4 (Ar-C, C-24), 119 (Ar-C, C-5), 87.2 (CH, C-11), 83.1 (CH, C-14), 73.3 
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(CH, C-12), 70.6 (CH, C-13), 70.1 (CH2, C-15), 66.8 (CH2, C-28), 63.7 (CH2, C-19), 50.3 
(CH2, C-25). MS (ESI) m/z (%): 498 (25), 497 (100). HRMS C22H25N8O6: calc. 497.1897, 
found 497.1911, error: 2.80 ppm. 
 
(R)-3-hydroxy-2,2-dimethyl-4-oxo-4-((3-oxo-3-(propylamino)propyl)amino)butyl 2-(4-
((((3aR,4R,6R,6aR)-6-(6-amino-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-
d][1,3]dioxol-4-yl)methoxy)methyl)-1H-1,2,3-triazol-1-yl)acetate, 17 
 
9-((3aR,4R,6R,6aR)-2,2-dimethyl-6-((prop-2-yn-1-yloxy)methyl)tetrahydrofuro[3,4-
d][1,3]dioxol-4-yl)-9H-purin-6-amine, 71 (53 mg, 0.15 mmol), CuSO4.5H2O (24 μL of 0.05 M 
stock solution, 1.20 µmol, 0.8 mol%), sodium ascorbate (0.24 mL of 0.05 M stock solution, 12 
µmol, 8 mol%), and (R)-3-hydroxy-2,2-dimethyl-4-oxo-4-((3-oxo-3-
(propylamino)propyl)amino)butyl 2-azidoacetate, 64 (64 mg, 0.15 mmol, 1.00 eq) were 
dissolved in t-BuOH (1.5 mL) and water (1.5 mL). After stirring at r.t for 15 h, LCMS indicated 
60% completion of the reaction. The reaction mixture was then concentrated in vacuo and 
purification by flash column chromatography (3 to 8% MeOH in CH2Cl2) afforded the product 
as a colourless oil (58 mg, 56%). Rf: 0.10 (10% MeOH in CH2Cl2). IR (νmax, cm-1): 3360, 3326 
(br, m, triazole C-H and NH2), 2942 (w, sp3-CH), 1754 (s, C=O ester), 1703, 1687 (s, 
C=ONH), 1619, 1572 (m, Ph(C=C) and adenine, C=C, C=N). 1H-NMR (CD3OD, 600 MHz): 
8.25 (s, 1H, Ar-H, H-8), 8.18 (s, 1H, Ar-H, H-2), 7.90 (s, 1H, Ar-H, H-24), 6.18 (d, 1H, CH, J 
2.57 Hz, H-11), 5.36 (dd, 1H, CH, J 6.05 Hz and 2.50 Hz, H-12), 5.34 (s, 2H, CH2, H-25), 5.02 
(dd, 1H, CH, J 6.00 Hz and 2.22 Hz, H-13), 4.59 (s, 2H, CH2, H-19), 4.47-4.48 (m, 1H, CH, H-
14), 4.03 and 4.12 (d, 2H, CH2, J 10.71 Hz, H-28), 3.78 (s, 1H, CH, H-31), 3.72-3.74 (m, 1H, 
CH2, H-15), 3.66-3.68 (m, 1H, CH2, H-15), 3.41-3.51 (m, 2H, CH2, H-34), 3.08-3.13 (m, 2H, 
CH2, H-38), 2.41 (t, 2H, CH2, J 6.77 Hz, H-35), 1.59 (s, 3H, CH3, H-17), 1.47-1.53 (m, 2H, 
CH2, H-39), 1.38 (s, 3H, CH3, H-17’), 0.95 (s, 3H, CH3, H-30), 0.91 (s, 3H, CH3, H-30), and 
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0.89 (t, 3H, CH3, J 7.00 Hz, H-40). 13C-NMR (CD3OD, 150 MHz): 175.2 (C=O, C-32), 173.6 
(C=O, C-36), 168 (C=O, C-26), 157.1 (Ar-C, C-6), 153.6 (Ar-C, C-2), 150.5 (Ar-C, C-4), 
145.4 (Ar-C, C-20), 141.4 (Ar-C, C-8), 126.6 (Ar-C, C-24), 120.3 (Ar-C, C-5), 115 (C, C-16), 
92.5 (CH, C-11), 87.3 (CH, C-14), 85.9 (CH, C-12), 83.4 (CH, C-13), 75.7 (CH, C-31), 72.7 
(CH2, C-28), 71.5 (CH2, C-15), 64.9 (CH2, C-19), 51.8 (CH2, C-25), 42.2 (CH2, C-38), 39.3 (C, 
C-29), 36.4 (CH2, C-34), 36.36 (CH2, C-35), 27.5 (CH3, C-17), 25.4 (CH3, C-17’), 23.6 (CH2, 
C-39), 21.7 (CH3, C-30), 25.5 (CH3, C-30), 11.7 (CH3, C-40). MS (ESI) m/z (%): 711 (20), 691 
(10), 690 (40), 689 (100). HRMS C30H45N10O9: calc. 689.3371, found 689.3378, error: 1.01 
ppm. 
 
(R)-3-hydroxy-2,2-dimethyl-4-oxo-4-((3-oxo-3-(propylamino)propyl)amino)butyl 2-(4-
((((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-
yl)methoxy)methyl)-1H-1,2,3-triazol-1-yl)acetate, 16 
 
(2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((prop-2-yn-1-yloxy)methyl)tetrahydrofuran-3,4-
diol, 72 (26 mg, 86 μmol), CuSO4.5H2O (15 μL of 0.05 M stock solution, 0.75 µmol, 0.8 
mol%), sodium ascorbate (0.15 mL of 0.05 M stock solution, 7.5 µmol, 8 mol%) and (R)-3-
hydroxy-2,2-dimethyl-4-oxo-4-((3-oxo-3-(propylamino)propyl)amino)butyl 2-azidoacetate, 64 
(29 mg, 85 μmol, 0.99 eq) were dissolved in t-BuOH (0.8 mL) and water (0.8 mL) in Argon 
condition (O2-free). THPTA ligand (1.0 mg, 2.30 μmol) was added. After stirring at r.t for 2 h, 
the reaction mixture was then concentrated in vacuo and purification by preparative HPLC, 
Gradient 3, product peak at 11.6 min, afforded the product as a colourless oil (49 mg, 90%). IR 
(νmax, cm-1): 3305 (m, NH2), 3108 (m, triazole C-H), 2965 (m, sp3-CH), 1748 (s, C=O ester), 
1643 (m, adenine C=C, C=N and C=ONH), 1535 (m, CONH). 1H-NMR (D2O, 600 MHz): 
8.49 (s, 1H, Ar-H, H-8), 8.44 (s, 1H, Ar-H, H-2), 8.14 (s, 1H, Ar-H, H-24), 6.18 (d, 1H, CH, J 
4.68 Hz, H-11), 5.47 (s, 2H, CH2, H-25), 4.81-4.97 (m, 1H, CH, H-12), 4.76 (dd, 2H, CH2, J 
12.23 Hz and 2.91 Hz, H-19), 4.50 (t, 1H, CH, J 4.92 Hz, H-13), 4.37-4.39 (m, 1H, CH, H-14), 
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4.03 and 4.12 (d, 2H, CH2, J 10.49 Hz, H-28), 3.94 (dd, 1H, CH2, J 11.14 Hz and 2.62 Hz, H-
15), 3.88 (dd, 1H, CH2, J 11.14 Hz and 4.26 Hz, H-15), 3.83 (s, 1H, CH, H-31), 3.45-3.53 (m, 
2H, CH2, H-34), 3.12 (dt, 2H, CH2, J 6.81 Hz and 2.06 Hz, H-38), 2.49 (t, 2H, CH2, J 6.40 Hz, 
H-35), 1.46-1.52 (m, 2H, CH2, H-39), 0.95 (s, 3H, CH3, H-30), 0.91 (s, 3H, CH3, H-30), and 
0.87 (t, 3H, CH3, J 7.00 Hz, H-40). 13C-NMR (D2O, 150 MHz): 175.0 (C=O, C-32), 174.3 
(C=O, C-36), 168.9 (C=O, C-26), 150.7 (Ar-C, C-6), 149 (Ar-C, C-4), 145.4 (Ar-C, C-2), 
144.7 (Ar-C, C-20), 143.2 (Ar-C, C-8), 127.1 (Ar-C, C-24), 119 (Ar-C, C-5), 89.2 (CH, C-11), 
84.6 (CH, C-14), 75.3 (CH, C-12), 75.0 (CH, C-31), 72.2 (CH2, C-28), 71.1 (CH, C-13), 69.8 
(CH2, C-15), 63.9 (CH2, C-19), 51.6 (CH2, C-25), 41.9 (CH2, C-38), 36.1 (CH2, C-35), 38.2 (C, 
C-29), 35.9 (CH2, C-34), 22.4 (CH2, C-39), 22.3 (CH3, C-30),  20.7 (CH3, C-30), 11.3 (CH3, C-
40). MS (ESI) m/z (%): 671 (20), 650 (30), 649 (100). HRMS C27H41N10O9: calc. 649.3058, 
found 649.3055, error: 0.46 ppm. 
 
2-(4-((((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-
yl)methoxy)methyl)-1H-1,2,3-triazol-1-yl)-N-(2-(3-phenylureido)ethyl)acetamide, 15 
 
(2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((prop-2-yn-1-yloxy)methyl)tetrahydrofuran-3,4-
diol, 72 (56.5 mg, 0.19 mmol), CuSO4.5H2O (30 μL of 0.05 M stock solution, 1.5 µmol, 0.8 
mol%), sodium ascorbate (0.30 mL of 0.05 M stock solution, 15 µmol, 8 mol%) and 2-azido-N-
(2-(3-phenylureido)ethyl)acetamide, 86 (55.5 mg, 0.20 mmol, 1.05 eq) were dissolved in t-
BuOH (1.71 mL) and water (1.71 mL) in Argon condition (O2-free). THPTA ligand (1.0 mg, 
2.30 μmol) was added. After stirring at r.t for 12 h, the reaction mixture was then concentrated 
in vacuo and purification by preparative HPLC Gradient 1, product peak at 3.6 min, afforded 
the product as a colourless oil, forming foam upon drying in vacuo (43 mg, 40%). IR (νmax, cm-
1): 3279 (m, NH2), 3097 (m, triazole C-H), 2965 (m, sp3-CH), 1659 (m, adenine C=N and 
CONH), 1596 (m, adenine C=C, and CONH). 1H-NMR (D2O, 600 MHz): 8.37 (s, 1H, Ar-H, 
H-8), 8.33 (s, 1H, Ar-H, H-2), 8.01 (s, 1H, Ar-H, H-24), 7.27-7.20 (m, 2H, Ar-H, H-35), 7.16-
7.17 (m, 2H, Ar-H, H-34), 7.06-7.09 (m, 1H, Ar-H, H-36), 6.11 (d, 1H, CH, J 5.06 Hz, H-11), 
5.28 (dd, 2H, CH2, J 16.50 Hz and 1.80 Hz, H-25), 4.77 (d, 1H, CH, J 5.80 Hz, H-12), 4.65 (dd, 
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2H, CH2, J 14.40 Hz and 1.50 Hz, and J 14.40 Hz and 2.30 Hz, H-19), 4.46 (t, 1H, CH, J 5.0 
Hz, H-13), 4.34-4.35 (m, 1H, CH, H-14), 3.86 (dd, 2H, CH2, J 11.30 Hz and 4.40 Hz, and J 
11.30 Hz and 2.70 Hz, H-15), 3.41-3.43 (m, 2H, CH2, H-28), 3.34-3.35 (m, 2H, CH2, H-29). 
13C-NMR (D2O, 150 MHz): 168 (C=O, C-26), 158 (C=O, C-31), 151 (Ar-C, C-6), 146.5 (Ar-C, 
C-2 and C-20), 142.6 (Ar-C, C-8), 138.5 (Ar-C, C-33), 129.9 (Ar-C, C-35 and C-36), 124.6 
(Ar-C, C-24), 121.7 (Ar-C, C-34), 121 (Ar-C, C-5), 88.9 (CH, C-11), 84.5 (CH, C-14), 74.8 
(CH, C-12), 71.0 (CH, C-13), 69.8 (CH2, C-15), 63.9 (CH2, C-19), 52.9 (CH2, C-25), 40.3 
(CH2, C-28), 39.7 (CH2, C-29). MS (ESI) m/z (%): 606 (10), 569 (30), 568 (100). HRMS 
C24H30N11O6: calc. 568.2394, found 568.2381, error: 2.30 ppm. 
 
(R)-3-hydroxy-4-((3-((2-mercaptoethyl)amino)-3-oxopropyl)amino)-2,2-dimethyl-4-
oxobutyl 2-(4-((((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-
2-yl)methoxy)methyl)-1H-1,2,3-triazol-1-yl)acetate, 18 
 
* Two Step 
Step 1 
(2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((prop-2-yn-1-yloxy)methyl)tetrahydrofuran-3,4-
diol, 72 (6.30 mg, 21 μmol), CuSO4.5H2O (4 μL of 0.05 M stock solution, 0.2 µmol, 0.8 mol%), 
sodium ascorbate (45 μL of 0.05 M stock solution, 2.2 µmol, 8 mol%) and (3R,22R)-3,22,24-
trihydroxy-2,2,23,23-tetramethyl-4,8,17,21-tetraoxo-12,13-dithia-5,9,16,20-tetraazatetracosyl 
2-azidoacetate, 87 (13.2 mg, 21 μmol, 1.00 eq) were dissolved in t-BuOH (120 μL) and water 
(240 μL) in Argon condition (O2-free). THPTA ligand (0.30 mg, 0.69 μmol) was added. After 
stirring at r.t for 12 h, LCMS indicated 50% completion of the reaction. The reaction mixture 
was then concentrated in vacuo and purification by preparative HPLC Gradient 9, product peak 
at 5 min, afforded the crude product as a light brown oil (≈18 mg, 93%). NMR showed that the 
ratio of starting material : product = 1:1.35 - 1:1.5.  
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Step 2 
To the crude material from Step 1 in acetonitrile (1.20 mL) and water (1.80 mL), was added 
TCEP (26.5 mg, 92 μmol, 4.50 eq). The reaction mixture was stirred at r.t for 2 h before freeze-
drying to remove the solvent. Purification by preparative HPLC Gradient 4, product peak at 
10.6 min, afforded the product as a colourless oil, forming foam upon drying in vacuo (13.4 mg, 
95%). 
 
1H-NMR (D2O, 600 MHz): 8.46 (s, 1H, Ar-H, H-8), 8.40 (s, 1H, Ar-H, H-2), 8.13 (s, 1H, Ar-H, 
H-24), 6.17 (d, 1H, CH, J 4.70 Hz, H-11), 5.47 (s, 2H, CH2, H-25), 4.79 (1H, CH, H-12, hidden 
under solvent peak), 4.75-4.76 (m, 2H, CH2, H-19), 4.50 (t, 1H, CH, J 4.82 Hz, H-13), 4.37-
4.39 (m, 1H, CH, H-14), 4.11 and 4.03 (d, 2H, CH2, J 10.76 Hz, H-28), 3.94 (dd, 1H, CH2, J 
11.28 Hz and 2.77 Hz, H-15), 3.87 (dd, 1H, CH2, J 11.28 Hz and 4.31 Hz, H-15), 3.83 (s, 1H, 
CH, H-31), 3.46-3.53 (m, 2H, CH2, H-34), 3.36 (dt, 2H, CH2, J 6.66 Hz and 2.15 Hz, H-38), 
2.64 (t, 2H, CH2, J 6.56 Hz, H-35), 2.51 (t, 2H, CH2, J 6.46 Hz, H-39), 0.95 (s, 3H, CH3, H-
30), 0.91 (s, 3H, CH3, H-30). 13C-NMR (D2O, 150 MHz): 175.0 (C=O, C-32), 174.6 (C=O, C-
36), 168.8 (C=O, C-26), 152 (Ar-C, C-6), 149.2 (Ar-C, C-4), 146.9 (Ar-C, C-2), 144.7 (Ar-C, 
C-20), 142.7 (Ar-C, C-8), 127.1 (Ar-C, C-24), 119.3 (Ar-C, C-5), 89.0 (CH, C-11), 84.6 (CH, 
C-14), 75.3 (CH, C-12), 74.9 (CH, C-31), 72.2 (CH2, C-28), 71.1 (CH, C-13), 69.8 (CH2, C-
15), 63.9 (CH2, C-19), 51.7 (CH2, C-25), 42.9 (CH2, C-38), 38.2 (C, C-29), 36.1 (CH2, C-34), 
35.9 (CH2, C-39), 23.8 (CH2, C-35), 20.8 (CH3, C-30), 20.3 (CH3, C-30). HRMS 
C26H38N10O9S: calc. 667.2617, found 667.2617, error: 0 ppm. 
 
Benzyl 2-(4-((((5aR,6R,8R,8aR)-8-(6-amino-9H-purin-9-yl)-2,2,4,4-
tetraisopropyltetrahydrofuro[3,4-f][1,3,5,2,4]trioxadisilepin-6-yl)methoxy)methyl)-1H-
1,2,3-triazol-1-yl)acetate, 89 
 
Benzyl 2-(4-((((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-
yl)methoxy)methyl)-1H-1,2,3-triazol-1-yl)acetate, 14 (353 mg, 0.71 mmol) was dissolved in 
pyridine (33 mL) and TIPDSCl2 (0.28 mL, 0.85 mmol, 1.20 eq) was added. The reaction 
mixture was stirred at r.t for 18 h before the solvent was removed in vacuo. Purification by flash 
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column chromatography (0 to 2.5% MeOH in CH2Cl2) afforded the product as a colourless oil, 
forming foam upon drying in vacuo (513 mg, 98%). Rf: 0.75 (6% MeOH in CH2Cl2). IR (νmax, 
cm-1): 3152 (m, triazole C-H), 2945, 2866 (m, sp3-CH), 1751 (s, C=O ester), 1573-1681 (m, 
adenine C=C, C=N). 1H-NMR (CD3OD, 600 MHz): 8.33 (s, 1H, Ar-H, H-8), 8.17 (s, 1H, Ar-
H, H-2), 8.01 (s, 1H, Ar-H, H-24), 7.27-7.33 (m, 5H, Ar-H, H-30, H-31 and H-32), 6.08 (d, 1H, 
CH, J 5.13 Hz, H-11), 5.38 (s, 2H, CH2, H-25), 5.21 (s, 2H, CH2, H-28), 5.01 (dd, 1H, CH, J 
5.13 Hz and 5.01 Hz (roofing effect), H-12), 4.71 (dd, 2H, CH2, J 12.15 Hz and 3.38 Hz, H-19), 
4.69 (dd, 1H, CH, J 4.63 Hz and 4.38 Hz (roofing effect, H-13), 4.25-4.27 (m, 1H, CH, H-14), 
3.85 (dd, 1H, CH2, J 10.90 Hz and 3.26 Hz, H-15), 3.76 (dd, 1H, CH2, J 10.90 Hz and 3.63 Hz, 
H-15), 0.95-1.10 (m, 28H, 4 x CH and 8 x CH3, H-16 and H-17). 13C-NMR (CD3OD, 150 
MHz): 168.1 (C=O, C-26), 157.2 (Ar-C, C-6), 153.9 (Ar-C, C-2), 150.8 (Ar-C, C-4), 145.7 
(Ar-C, C-20), 140.9 (Ar-C, C-8), 136.6 (Ar-C, C-29), 129.3-129.6 (Ar-C, C-30, C-31, C-32), 
126.6 (Ar-C, C-24), 120.3 (Ar-C, C-5), 89.9 (CH, C-11), 85.8 (CH, C-14), 78.1 (CH, C-12), 
74.4 (CH, C-13), 70.8 (CH2, C-15), 68.8 (CH2, C-28), 65.2 (CH2, C-19), 51.7 (CH2, C-25), 
17.6 (CH3, C-17), 14.3 (CH, C-16). MS (ESI) m/z (%): 741 (15), 740 (35), 739 (100). HRMS 
C34H51N8O7Si2: calc. 739.3419, found 739.3430, error: 1.50 ppm. 
 
Methyl 2-(4-((((5aR,6R,8R,8aR)-8-(6-amino-9H-purin-9-yl)-2,2,4,4-
tetraisopropyltetrahydrofuro[3,4-f][1,3,5,2,4]trioxadisilepin-6-yl)methoxy)methyl)-1H-
1,2,3-triazol-1-yl)acetate, 90 
 
 
 
 
 
 
 
 
To a solution of benzyl 2-(4-((((5aR,6R,8R,8aR)-8-(6-amino-9H-purin-9-yl)-2,2,4,4-
tetraisopropyltetrahydrofuro[3,4-f][1,3,5,2,4]trioxadisilepin-6-yl)methoxy)methyl)-1H-1,2,3-
triazol-1-yl)acetate, 89 (172 mg, 0.23 mmol) in MeOH (9 mL) and CH2Cl2 (9 mL), was added 
Pd/C 10% (17.7 mg, 16.6 μmol). The reaction mixture was stirred at r.t for 24 h under H2 
condition. The mixture was then filtered and the filtrated was concentrated in vacuo to afford 
the product as a white solid (150 mg, 97%). IR (νmax, cm-1): 3283 (w, NH2), 3147 (m, triazole C-
H), 2946, 2865 (m, sp3-CH), 1747 (s, C=O ester), 1600-1679 (m, adenine C=C, C=N). 1H-
NMR ((CD3)2SO, 600 MHz): 8.36 (s, 1H, Ar-H, H-8), 8.13 (s, 1H, Ar-H, H-2), 8.07 (s, 1H, Ar-
H, H-24), 7.34 (br, 2H, N-H), 5.98 (d, 1H, CH, J 5.47 Hz, H-11), 5.40 (s, 2H, CH2, H-25), 5.10 
(t, 1H, CH, J 5.20 Hz, H-12), 4.61-4.64 (m, 3H, CH and CH2, H-13 and H-19), 4.13-4.14 (m, 
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1H, CH, H-14), 3.77 (dd, 1H, CH2, J 10.86 Hz and 3.96 Hz, H-15), 3.67-3.70 (m, 4H, CH2 
(1H) and CH3, H-15 and H-28), 1.00-1.10 (m, 28H, 4 x CH and 8 x CH3, H-16 and H-17). 13C-
NMR ((CD3)2SO, 150 MHz): 168.7 (C=O, C-26), 157.3 (Ar-C, C-6), 154.0 (Ar-C, C-2), 150.7 
(Ar-C, C-4), 145.7 (Ar-C, C-20), 141.0 (Ar-C, C-8), 126.6 (Ar-C, C-24), 120.2 (Ar-C, C-5), 
89.7 (CH, C-11), 85.8 (CH, C-14), 78.0 (CH, C-12), 74.3 (CH, C-13), 70.7 (CH2, C-15), 65.1 
(CH2, C-19), 53.3 (CH3, C-28), 51.6 (CH2, C-25), 17.4-17.9 (CH3, C-17), 14.4 (CH, C-16). MS 
(ESI) m/z (%): 685 (20), 665 (13), 664 (40), 663 (100) (15), 740 (35), 739 (100). HRMS 
C28H47N8O7Si2: calc. 664.3185, found 664.3180, error: 0.75 ppm. 
 
Methyl 2-(4-((((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-
yl)methoxy)methyl)-1H-1,2,3-triazol-1-yl)acetate, 91 
 
To a solution of methyl 2-(4-((((5aR,6R,8R,8aR)-8-(6-amino-9H-purin-9-yl)-2,2,4,4-
tetraisopropyltetrahydrofuro[3,4-f][1,3,5,2,4]trioxadisilepin-6-yl)methoxy)methyl)-1H-1,2,3-
triazol-1-yl)acetate, 90 (48 mg, 72 μmol) in MeOH (2 mL), was added NH4F (23 mg, 0.62 
mmol, 8.60 eq). The reaction mixture was stirred at r.t for 2 h then concentrated in vacuo. 
Purification by flash column chromatography (3 to 10% MeOH in CH2Cl2) afforded the product 
as a colourless oil (26 mg, 86%). Rf: 0.12 (10% MeOH in CH2Cl2). 1H-NMR (CD3OD, 600 
MHz): 8.31 (s, 1H, Ar-H, H-8), 8.18 (s, 1H, Ar-H, H-2), 8.02 (s, 1H, Ar-H, H-24), 7.34 (br, 
2H, N-H), 6.06 (d, 1H, CH, J 4.80 Hz, H-11), 5.35 (s, 2H, CH2, H-25), 4.69-4.73 (m, 2H, CH2, 
H-19), 4.59 (t, 1H, CH, J 4.80 Hz, H-12), 4.34 (t, 1H, CH, J 4.7 Hz, H-13), 4.20-4.22 (m, 1H, 
CH, H-14), 3.86 (dd, 1H, CH2, J 10.80 Hz and 3.60 Hz, H-15), 3.78 (dd, 1H, CH2, J 10.80 Hz 
and 3.20 Hz, H-15), 3.77 (s, 3H, CH3, H-28). 13C-NMR (CD3OD, 150 MHz): 168.8 (C=O, C-
26), 157.0 (Ar-C, C-6), 153.9 (Ar-C, C-2), 150.3 (Ar-C, C-4), 145.8 (Ar-C, C-20), 140.9 (Ar-
C, C-8), 126.6 (Ar-C, C-24), 120.3 (Ar-C, C-5), 89.7 (CH, C-11), 85.3 (CH, C-14), 76.2 (CH, 
C-12), 72.1 (CH, C-13), 71.0 (CH2, C-15), 65.1 (CH2, C-19), 53.3 (CH3, C-28), 51.6 (CH2, C-
25). MS (ESI) m/z (%): 741 (15), 740 (35), 739 (100). HRMS C16H21N8O6: calc. 421.1584, 
found 421.1588, error: 0.95 ppm. 
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Failed synthetic attempts 
But-3-ynoic acid, 74 
(Table 4.1) 
Table 4.1 
 
Conditions Results 
NaIO4, K2Cr2O7, HNO3, water, r.t 150 polymerised 
 
To water (35 mL) at 0oC, were added NaIO4 (11.80 g, 55.00 mol, 2.20 eq), K2Cr2O4 (0.08g, 
0.25 mol, 1 eq) and HNO3 (0.08 mL, 1.25 mmol). But-3-yn-1-ol, 73 (1.81g, 25.0 mol) was 
added slowly to the reaction mixture whilst stirring. The reaction was exorthermic. The reaction 
mixture was stirred at 10oC for 30 min. The aqueous reaction mixture was extracted with Et2O 
(3 x 100 mL). The combined extract was dried (MgSO4). The solvent was removed in vacuo to 
give a brown paste.  
 
(R)-3-hydroxy-2,2-dimethyl-4-oxo-4-((3-oxo-3-(propylamino)propyl)amino)butyl 1-(2-
((tert-butoxycarbonyl)amino)ethyl)-1H-1,2,3-triazole-4-carboxylate, 79 
(Figure 4.5) 
To a solution of 1-(2-((tert-butoxycarbonyl)amino)ethyl)-1H-1,2,3-triazole-4-carboxylic acid, 
78 (0.26 g, 1.00 mmol) in DMF at 0oC, were added PyAOP (1.03 g, 1.98 mmol, 1.98 eq) and 
HOAt (0.14g, 1.00 mmol, 1.00 eq). To this mixture, a solution of 20 (0.26g, 0.99 mmol, 0.99 
eq) and DIPEA (0.30 mL, 0.22 mmol, 0.22 eq) in DMF (8 mL) was added. The total reaction 
mixture was heated at 60oC whilst stirring for 15 h. The solvent was removed in vacuo and the 
crude was redissolved in EtOAc. TLC (10% MeOH in EtOAc) did not detect any new product 
formation. Purification by flash column chromatography (0 to 2% MeOH in EtOAc) did not 
give any of the product. 
 
 
 
 
 
73 74 
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1-(2-((tert-Butoxycarbonyl)amino)ethyl)-1H-1,2,3-triazole-4-carboxylic acid, 78  
(Table 4.2) 
Table 4.2 
[Reactant] M Solvent ratio (A:B) Catalyst loading (mol%) Time 
stirring 
at r.t (h) 
Yield 
% 
 
 
t-BuOH water CuSO4.5H2O sodium 
ascorbat
e 
0.05 0.05 1 2 22 90 18 h 41 
0.12 0.13 1 2 5.6 24 48 h 75 
 
Entry 1  
To a solution of propiolic acid (39.5 mg, 0.55 mmol, 1.00 eq) in t-BuOH (1.86 mL), were added 
CuSO4.5H2O (3.00 mg, 0.01 mmol, 22.0 mol%) and sodium ascorbate (12.5 mg, 0.06 mmol, 90 
mol%) in water (3.71 mL). The reaction mixture was stirred vigorously and tert-butyl (2-
azidoethyl)carbamate, 77 (103 mg, 0.55 mmol) in t-BuOH (1.85 mL) and water (3.71 mL) were 
added to it. The reaction mixture was then stirred at r.t for 18 h before t-BuOH was removed in 
vacuo. As t-BuOH was removed, a white precipitate appeared. The precipitate was filtered and 
washed with cold water three times and dried in vacuo to give the product as white flakes (57 
mg, 41%). 
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(R)-3-hydroxy-2,2-dimethyl-4-oxo-4-((3-oxo-3-(propylamino)propyl)amino)butyl 2-(4-
((((3aR,4R,6R,6aR)-6-(6-amino-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-
d][1,3]dioxol-4-yl)methoxy)methyl)-1H-1,2,3-triazol-1-yl)acetate, 17 
(Table 4.3) 
Table 4.3 
Entry [Reactant] M 
 
64               71 
Solvent ratio 
(A:B) 
Catalyst loading (mol%) Time 
stirring at 
r.t (h) 
Yield 
% 
 t-
BuOH 
water CuSO4.5H2O sodium 
ascorbate 
1 0.1 0.06 1 1 4.8 20 48 h ✗ 
2 0.02 0.02 1 2 6.5 23.5 48 h ✗ 
 
Entry 1  
9-((3aR,4R,6R,6aR)-2,2-dimethyl-6-((prop-2-yn-1-yloxy)methyl)tetrahydrofuro[3,4-
d][1,3]dioxol-4-yl)-9H-purin-6-amine, 71 (115 mg, 0.33 mmol), CuSO4.5H2O (4.00 mg, 16.0 
µmol, 4.8 mol%), sodium ascorbate (13.4 mg, 68.0 µmol, 20 mol%), and (R)-3-hydroxy-2,2-
dimethyl-4-oxo-4-((3-oxo-3-(propylamino)propyl)amino)butyl 2-azidoacetate, 64 (190 mg, 
0.55 mmol, 1.67 eq) were dissolved in t-BuOH (3.1 mL) and water (3.1 mL). The reaction 
mixture was stirred at r.t for 48 h. LCMS did not detect any product formation. 
 
Entry 2  
9-((3aR,4R,6R,6aR)-2,2-dimethyl-6-((prop-2-yn-1-yloxy)methyl)tetrahydrofuro[3,4-
d][1,3]dioxol-4-yl)-9H-purin-6-amine, 71 (46.2 mg, 125 µmol), CuSO4.5H2O (2.00 mg, 8.00 
µmol, 6.5 mol%), sodium ascorbate (9.70 mg, 45.0 µmol, 23.5 mol%), and (R)-3-hydroxy-2,2-
dimethyl-4-oxo-4-((3-oxo-3-(propylamino)propyl)amino)butyl 2-azidoacetate, 64 (48.0 mg, 
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126 µmol, 1.01 eq) were dissolved in t-BuOH (2.3 mL) and water (4.6 mL). The reaction 
mixture was stirred at r.t for 48 h. LCMS did not detect any product formation. 
 
2-(4-((((3aR,4R,6R,6aR)-6-(6-amino-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-
d][1,3]dioxol-4-yl)methoxy)methyl)-1H-1,2,3-triazol-1-yl)acetic acid, 80 
(Table 4.4) 
Table 4.4 
 
Entry  [Reactant] M Solvent ratio 
(A:B) 
Catalyst loading†(mol%) Time (h),  
T (oC) 
Yield 
% 
 63 
 
71 
 
t-BuOH water CuSO4.5H2O  sodium 
ascorbate 
1 0.06 0.05 1 1 1.8 9 48 h, r.t ✗ 
2 0.07 0.07 1 1 0.9 9 48 h, r.t ✗ 
3 0.06 0.05 1 1 0.9 18 48 h, r.t ✗ 
4 0.02 0.02 1 1 1.5 7.5 1 h, 
microw 
100oC  
✗ 
†Catalysts’ stock solution in water: [CuSO4.5H2O] = [sodium ascorbate] = 0.1 M for the first 3 entries 
and of 0.05 M for the last entry. 
 
Entry 1 
9-((3aR,4R,6R,6aR)-2,2-dimethyl-6-((prop-2-yn-1-yloxy)methyl)tetrahydrofuro[3,4-
d][1,3]dioxol-4-yl)-9H-purin-6-amine, 71 (51.0 mg, 0.11 mmol), along with CuSO4.5H2O (0.02 
mL of 0.1 M stock solution, 2.00 µmol, 1.8 mol%), sodium ascorbate (0.1 mL of 0.1 M stock 
solution, 0.01 mmol, 9 mol%), and 2-azidoacetic acid, 63 (13.0 mg, 0.12 mmol, 1.09 eq) were 
dissolved in t-BuOH (1.0 mL) and water (1.0 mL). The reaction mixture was stirred at r.t for 48 
h, and monitored by LCMS over 48 h. No product was detected. 
63 71 80 
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Entry 2  
9-((3aR,4R,6R,6aR)-2,2-dimethyl-6-((prop-2-yn-1-yloxy)methyl)tetrahydrofuro[3,4-
d][1,3]dioxol-4-yl)-9H-purin-6-amine, 71 (53.0 mg, 0.17 mmol), along with CuSO4.5H2O (0.01 
mL of 0.1 M stock solution in water, 1.00 µmol, 0.9 mol%), sodium ascorbate (0.1 mL of 0.1 M 
stock solution in water, 0.01 mmol, 9 mol%), and 2-azidoacetic acid, 63 (15.6 mg, 0.16 mmol, 
0.94 eq) were dissolved in t-BuOH (1.1 mL) and water (1.1 mL). The reaction mixture was 
stirred at r.t for 48 h, and monitored by LCMS over 48 h. No product was detected. 
 
Entry 3  
9-((3aR,4R,6R,6aR)-2,2-dimethyl-6-((prop-2-yn-1-yloxy)methyl)tetrahydrofuro[3,4-
d][1,3]dioxol-4-yl)-9H-purin-6-amine, 71 (51.2 mg, 0.11 mmol), along with CuSO4.5H2O (0.01 
mL of 0.1 M stock solution in water, 1.00 µmol, 0.9 mol%), sodium ascorbate (0.2 mL of 0.1 M 
stock solution in water, 0.02 mmol, 18 mol%), and 2-azidoacetic acid, 63 (14.5 mg, 0.14 mmol, 
1.27 eq) were dissolved in t-BuOH (1.1 mL) and water (1.1 mL). The reaction mixture was 
stirred at r.t for 48 h, and monitored by LCMS over 48 h. No product was detected. 
 
Entry 4  
9-((3aR,4R,6R,6aR)-2,2-dimethyl-6-((prop-2-yn-1-yloxy)methyl)tetrahydrofuro[3,4-
d][1,3]dioxol-4-yl)-9H-purin-6-amine, 71 (23.8 mg, 69.0 µmol), along with CuSO4.5H2O (0.02 
mL of 0.05 M stock solution in water, 1.00 µmol, 1.5 mol%), sodium ascorbate (0.1 mL of 0.05 
M stock solution in water, 5.00 µmol, 7.5 mol%), and 2-azidoacetic acid, 63 (7.00 mg, 69.0 
µmol, 1.00 eq) were dissolved in t-BuOH (1.8 mL) and water (1.7 mL). The reaction mixture 
was stirred and heated under microwave at 100oC for 1 h, and monitored by LCMS. No product 
was detected. Starting materials were degraded. 
 
Benzyl 2-(4-((((3aR,4R,6R,6aR)-6-(6-amino-9H-purin-9-yl)-2,2-
dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methoxy)methyl)-1H-1,2,3-triazol-1-
yl)acetate, 82 
(Table 4.5 and Table 4.6) 
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Table 4.5 
 
 
Entry 
 
[Reactant] M Solvent ratio 
(A:B) 
Catalyst loading † (mol%) Time (h),  
T (oC) 
Yield % 
81 71 t-BuOH water CuSO4.5H2O  sodium 
ascorbate 
1 0.02 0.02 1 1 0.75 7.5 312 h, r.t 59 
2 0.02 0.02 1 1 0.75 15 20 min, 100oC 
microw 
Trace of 
product 
in LCMS 
3 0.02 0.02 1 1 0.75 15 1.3 h, 100oC 
microw 
Trace of 
product 
in LCMS 
4 0.02 0.02 1 1 0.75 15 1.3 h, 100oC, 
then 1 h, 
150oC microw 
Degrade
d 
✗ 
5 7 x 10-3 
then 
0.02 
0.02 1 1 0.8 7.3 264 h, r.t ‡ 25 
6 0.02 0.02 1 1 0.2 1.85 192 h, r.t 56 
†Catalysts’ stock solution in water: [CuSO4.5H2O] = [sodium ascorbate] = 0.05 M. ‡ 24 h, r.t at 7 x 10-3 
M of 81 then 240 h at 0.02 M of 81 
 
Entry 1 
9-((3aR,4R,6R,6aR)-2,2-dimethyl-6-((prop-2-yn-1-yloxy)methyl)tetrahydrofuro[3,4-
d][1,3]dioxol-4-yl)-9H-purin-6-amine, 71 (23.8 mg, 69.0 µmol), CuSO4.5H2O (0.01 mL of 0.05 
M stock solution, 0.50 µmol, 0.75 mol%), sodium ascorbate (0.1 mL of 0.05 M stock solution, 
5.00 µmol, 7.5 mol%), and benzyl 2-azidoacetate, 81 (14.8 mg, 77.0 µmol, 1.10 eq) were 
dissolved in t-BuOH (1.8 mL) and water (1.8 mL). The reaction mixture was stirred at r.t for 
312 h, and monitored by LCMS over the course. LCMS detected the formation of the product. 
81 71 82 
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The reaction mixture was then concentrated in vacuo and purification by flash column 
chromatography (2 to 3.3% MeOH in CH2Cl2) afforded the product as a colourless oil, forming 
foam upon drying in vacuo (22 mg, 59%). 
 
Entry 2  
9-((3aR,4R,6R,6aR)-2,2-dimethyl-6-((prop-2-yn-1-yloxy)methyl)tetrahydrofuro[3,4-
d][1,3]dioxol-4-yl)-9H-purin-6-amine, 71 (23.8 mg, 69.0 µmol), CuSO4.5H2O (0.01 mL of 0.05 
M stock solution, 0.50 µmol, 0.75 mol%), sodium ascorbate (0.2 mL of 0.05 M stock solution, 
10.0 µmol, 15 mol%), and benzyl 2-azidoacetate, 81 (14.8 mg, 77.0 µmol, 1.10 eq) were 
dissolved in t-BuOH (1.8 mL) and water (1.8 mL). The reaction mixture was stirred and heated 
under microwave at 100oC for 20 min. LCMS only detected a trace of the product.  
 
Entry 3  
9-((3aR,4R,6R,6aR)-2,2-dimethyl-6-((prop-2-yn-1-yloxy)methyl)tetrahydrofuro[3,4-
d][1,3]dioxol-4-yl)-9H-purin-6-amine, 71 (23.8 mg, 69.0 µmol), CuSO4.5H2O (0.01 mL of 0.05 
M stock solution, 0.50 µmol, 0.75 mol%), sodium ascorbate (0.2 mL of 0.05 M stock solution, 
10.0 µmol, 15 mol%), and benzyl 2-azidoacetate, 81 (14.8 mg, 77.0 µmol, 1.10 eq) were 
dissolved in t-BuOH (1.8 mL) and water (1.8 mL). The reaction mixture was stirred and heated 
under microwave at 100oC for 80 min and monitored by LCMS in 20 min intervals. LCMS only 
detected a trace of the product which did not improve over the course of time.  
 
Entry 4  
9-((3aR,4R,6R,6aR)-2,2-dimethyl-6-((prop-2-yn-1-yloxy)methyl)tetrahydrofuro[3,4-
d][1,3]dioxol-4-yl)-9H-purin-6-amine, 71 (23.8 mg, 69.0 µmol), CuSO4.5H2O (0.01 mL of 0.05 
M stock solution, 0.50 µmol, 0.75 mol%), sodium ascorbate (0.2 mL of 0.05 M stock solution, 
10.0 µmol, 15 mol%), and benzyl 2-azidoacetate, 81 (14.8 mg, 77.0 µmol, 1.10 eq) were 
dissolved in t-BuOH (1.8 mL) and water (1.8 mL). The reaction mixture was stirred and heated 
under microwave at 100oC for 80 min and at 150oC for 1 h monitored by LCMS in 20 min 
intervals. LCMS only detected a trace of the product when the temperature was 100oC, which 
did not improve over the course of time. After heating under microwave at 150oC for 1 h, 
starting materials were degraded. 
 
Entry 5 
9-((3aR,4R,6R,6aR)-2,2-dimethyl-6-((prop-2-yn-1-yloxy)methyl)tetrahydrofuro[3,4-
d][1,3]dioxol-4-yl)-9H-purin-6-amine, 71 (152 mg, 0.44 mmol), CuSO4.5H2O (0.07 mL of 0.05 
M stock solution, 3.50 µmol, 0.8 mol%), sodium ascorbate (0.64 mL of 0.05 M stock solution, 
32.0 µmol, 7.3 mol%), and benzyl 2-azidoacetate, 81 (30.0 mg, 0.16 µmol, 0.36 eq) were 
dissolved in t-BuOH (11 mL) and water (11 mL). The reaction mixture was stirred at r.t for 24 
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h. LCMS detected the formation of the product. Benzyl 2-azidoacetate, 81 (54.0 mg, 0.28 µmol, 
0.64 eq) was added further to the stirring reaction mixture. The reaction mixture was then 
stirred at r.t for a further 240 h. LCMS indicated approximately 45% completion of the reaction. 
After that, it was concentrated in vacuo and purification by flash column chromatography (2 to 
4% MeOH in CH2Cl2) afforded the product as a colourless oil, forming foam upon drying in 
vacuo (60 mg, 25%). 
 
Entry 6  
9-((3aR,4R,6R,6aR)-2,2-dimethyl-6-((prop-2-yn-1-yloxy)methyl)tetrahydrofuro[3,4-
d][1,3]dioxol-4-yl)-9H-purin-6-amine, 71 (416 mg, 1.20 mmol), CuSO4.5H2O (0.19 mL of 0.05 
M stock solution, 9.50 µmol, 0.2 mol%), sodium ascorbate (1.75 mL of 0.05 M stock solution, 
87.5 µmol, 1.85 mol%), and benzyl 2-azidoacetate, 81 (229 mg, 1.20 mmol, 1.00 eq) were 
dissolved in t-BuOH (30 mL) and water (30 mL). The reaction mixture was stirred at r.t for 192 
h. LCMS indicated approximately 61% completion of the reaction. After that, it was 
concentrated in vacuo and purification by flash column chromatography (2 to 4% MeOH in 
CH2Cl2) afforded the product as a colourless oil, forming foam upon drying in vacuo (220 mg, 
56%). 
 
Table 4.6 
Entry 
 
[Reactant] M Solvent ratio 
(A:B) 
Catalyst loading † (mol%) Time 
(h),  
r.t 
Completion 
% 
81 71 t-BuOH water CuSO4.5H2O  sodium 
ascorbate 
1 0.06 0.06 1 1 0.8 7.5 26 h 90 
2 0.15 0.15 1 1 0.8 7.5 26 h 80 
3 0.06 0.06 1 1 0.8 7.5 24 h 96 
†Catalysts’ stock solution: [CuSO4.5H2O] = [sodium ascorbate] = 0.05 M. 
 
Entry 1 
9-((3aR,4R,6R,6aR)-2,2-dimethyl-6-((prop-2-yn-1-yloxy)methyl)tetrahydrofuro[3,4-
d][1,3]dioxol-4-yl)-9H-purin-6-amine, 71 (100 mg, 0.29 mmol), CuSO4.5H2O (45 µL of 0.05 M 
stock solution, 2.25 µmol, 0.8 mol%), sodium ascorbate (0.42 mL of 0.05 M stock solution, 
21.0 µmol, 7.5 mol%), and benzyl 2-azidoacetate, 81 (55.9 mg, 0.29 mmol, 1.00 eq) were 
dissolved in t-BuOH (2.4 mL) and water (2.4 mL). After stirring at r.t for 26 h, LCMS indicated 
90% completion of the reaction. 
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Entry 2  
9-((3aR,4R,6R,6aR)-2,2-dimethyl-6-((prop-2-yn-1-yloxy)methyl)tetrahydrofuro[3,4-
d][1,3]dioxol-4-yl)-9H-purin-6-amine, 71 (101 mg, 0.29 mmol), CuSO4.5H2O (45 µL of 0.05 M 
stock solution, 2.25 µmol, 0.8 mol%), sodium ascorbate (0.42 mL of 0.05 M stock solution, 
21.0 µmol, 7.5 mol%), and benzyl 2-azidoacetate, 81 (57.0 mg, 0.30 mmol, 1.03 eq) were 
dissolved in t-BuOH (1.0 mL) and water (1.0 mL). After stirring at r.t for 26 h, LCMS indicated 
80% completion of the reaction. 
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7. Appendix 
Appendix 2.1. PDBs used in structural alignment of protein kinases 
 
PDB (AURKA) PDB (AURKB) PDB (PKA) 
 
1MQ4   1OL5   1OL7   2BMC 
2C6E   2DWB   2J4Z   2NP8 
2WTV   2WTW   2X6D   2X6E   
2X81   2XRU   3E5A   3EFW 
3H0Y   3H0Z   3H0Z   3H10 
3HA6   3K5U   3LAU   3M11   
3MYG   3NRM   3O50   3O51   
3R21   3UO4   3UOJ   3UOL   
3UP2   3UP7   3VAP   3W18   
3W2C   4B0G   4BN1   4BYJ   
4DEE   4DHF   4J8M   4JBO   
4JBP   4JBQ   4PRJ   4UYN   
4UZD   4UZH 
 
 
 
 
 
 
 
 
2BFX 2BFY 4AF3 
4B8L 4B8M 4C2V 
4C2W 
 
1APM 1ATP 1BKX 1BX6 1CDK 
1CME 1CTP 1FMO 1J3H 1JBP 
1JLU 1L3R 1Q24 1Q61 1Q62 
1Q8T 1Q8U 1Q8W 1RDQ 1RE8 
1REJ 1REK 1SMH 1STC 1SVE 
1SVG 1SVH 1SZM 1XH4 1XH5 
1XH6 1XH7 1XH8 1XH9 1XHA 
1YDR 1YDS 1YDT 2C1A 2C1B 
2ERZ 2F7E 2F7X 2GFC 2GNF 
2GNG 2GNH 2GNI 2GNJ 2GNL 
2GU8 2JDS 2JDT 2JDV 2OH0 
2OJF 2QCS 2QUR 2QVS 2UVX 
2UVY 2UVZ 2UW0 2UW3 2UW4 
2UW5 2UW6 2UW7 2UW8 2UZT 
2UZU 2UZV 2UZW 2VNW 2VNY 
2VO0 2VO3 2VO6 2VO7 3AG9 
3AGL 3AGM 3AMA 3AMB 3BWJ 
3DND 3DNC 3E8C 3E8E 3FHI 
3FJQ 3IDB 3KKV 3L9L 3L9M 
3L9N 3NNJ 3NX8 3OOG 3OVV 
3OW3 3OWP 3OXT 3P0M 3POD 
3PVB 3QAL 3QAM 3TNP 3VQH 
3ZO1 3ZO2 3ZO3 3ZO4 4AE6 
4AE9 4AXA 4C33 4C34 4C35 
4C36 4C37 4C38 4DFX 4DFZ 
4DG0 4DG2 4DG3 4DH1 4DH3 
4DH5 4DH7 4DH8 4HPT 4HPU 
4IAC 4IAD 4IAF 4IAI 4IAK 
4IAY 4IAZ 4IB0 4IB1 4IB3 
4IE9 4IJ9 4O21 4O22 4WIH 
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Appendix 2.2. Comparison of the B-factors of the hinge region and activation loop of 1OL7 and 
4BN1 
 
1OL7 
ATOM   NUMBER    RESIDUE      B-FACTOR      ELEMENT  
ATOM   1217  N   TRP A 277     40.57           N   
ATOM   1218  CA  TRP A 277     36.62           C   
ATOM   1219  C   TRP A 277     35.74           C   
ATOM   1220  O   TRP A 277     35.61           O   
ATOM   1221  CB  TRP A 277     42.09           C   
ATOM   1222  CG  TRP A 277     50.97           C   
ATOM   1223  CD1 TRP A 277     54.30           C   
ATOM   1224  CD2 TRP A 277     58.62           C   
ATOM   1225  NE1 TRP A 277     59.86           N   
ATOM   1226  CE2 TRP A 277     58.91           C   
ATOM   1227  CE3 TRP A 277     59.93           C   
ATOM   1228  CZ2 TRP A 277     61.19           C   
ATOM   1229  CZ3 TRP A 277     61.29           C   
ATOM   1230  CH2 TRP A 277     63.73           C   
ATOM   1231  N   SER A 278     44.94           N   
ATOM   1232  CA  SER A 278     46.77           C   
ATOM   1233  C   SER A 278     50.47           C   
ATOM   1234  O   SER A 278     54.17           O   
ATOM   1235  CB  SER A 278     42.80           C   
ATOM   1236  OG  SER A 278     54.88           O   
ATOM   1237  N   VAL A 279     51.50           N   
ATOM   1238  CA  VAL A 279     57.94           C   
ATOM   1239  C   VAL A 279     59.15           C   
ATOM   1240  O   VAL A 279     67.05           O   
ATOM   1241  CB  VAL A 279     44.98           C   
ATOM   1242  CG1 VAL A 279     43.31           C   
ATOM   1243  CG2 VAL A 279     57.04           C   
ATOM   1244  N   HIS A 280     63.81           N   
ATOM   1245  CA  HIS A 280     67.43           C   
ATOM   1246  C   HIS A 280     70.50           C   
ATOM   1247  O   HIS A 280     82.51           O   
ATOM   1248  CB  HIS A 280     66.79           C   
ATOM   1249  CG  HIS A 280     72.05           C   
ATOM   1250  ND1 HIS A 280     73.34           N   
ATOM   1251  CD2 HIS A 280     75.11           C   
ATOM   1252  CE1 HIS A 280     80.03           C   
ATOM   1253  NE2 HIS A 280     83.14           N   
ATOM   1254  N   ALA A 281     68.02           N   
ATOM   1255  CA  ALA A 281     68.33           C   
ATOM   1256  C   ALA A 281     68.64           C   
ATOM   1257  O   ALA A 281     67.99           O   
ATOM   1258  CB  ALA A 281     60.98           C   
ATOM   1259  N   PRO A 282     70.43           N   
ATOM   1260  CA  PRO A 282     67.06           C   
ATOM   1261  C   PRO A 282     69.62           C   
ATOM   1262  O   PRO A 282     80.00           O   
ATOM   1263  CB  PRO A 282     67.65           C   
ATOM   1264  CG  PRO A 282     63.34           C   
ATOM   1265  CD  PRO A 282     64.78           C   
ATOM   1266  N   SER A 283     65.02           N   
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ATOM   1267  CA  SER A 283     59.53           C   
ATOM   1268  C   SER A 283     55.99           C   
ATOM   1269  O   SER A 283     69.93           O   
ATOM   1270  CB  SER A 283     55.46           C   
ATOM   1271  OG  SER A 283     55.84           O   
ATOM   1272  N   SER A 284     60.56           N   
ATOM   1273  CA  SER A 284     63.49           C   
ATOM   1274  C   SER A 284     63.54           C   
ATOM   1275  O   SER A 284     57.98           O   
ATOM   1276  CB  SER A 284     63.76           C   
ATOM   1277  OG  SER A 284     77.24           O   
ATOM   1278  N   ARG A 285     64.16           N   
ATOM   1279  CA  ARG A 285     67.66           C   
ATOM   1280  C   ARG A 285     68.61           C   
ATOM   1281  O   ARG A 285     72.84           O   
ATOM   1282  CB  ARG A 285     62.91           C   
ATOM   1283  N   ARG A 286     71.24           N   
ATOM   1284  CA  ARG A 286     75.06           C   
ATOM   1285  C   ARG A 286     79.18           C   
ATOM   1286  O   ARG A 286     80.60           O   
ATOM   1287  CB  ARG A 286     73.44           C   
ATOM   1288  CG  ARG A 286     71.75           C   
ATOM   1289  CD  ARG A 286     72.37           C   
ATOM   1290  NE  ARG A 286     72.92           N   
ATOM   1291  CZ  ARG A 286     77.01           C   
ATOM   1292  NH1 ARG A 286     80.80           N   
ATOM   1293  NH2 ARG A 286     73.00           N   
HETATM 1294  N   TPO A 287     82.59           N   
HETATM 1295  CA  TPO A 287     81.36           C   
HETATM 1296  CB  TPO A 287     85.77           C   
HETATM 1297  CG2 TPO A 287     78.62           C   
HETATM 1298  OG1 TPO A 287     96.25           O   
HETATM 1299  P   TPO A 287     94.10           P   
HETATM 1300  O1P TPO A 287     105.80          O   
HETATM 1301  O2P TPO A 287     103.14          O   
HETATM 1302  O3P TPO A 287     103.19          O   
HETATM 1303  C   TPO A 287     84.40           C   
HETATM 1304  O   TPO A 287     82.15           O   
HETATM 1305  N   TPO A 288     86.52           N   
HETATM 1306  CA  TPO A 288     85.55           C   
HETATM 1307  CB  TPO A 288     87.59           C   
HETATM 1308  CG2 TPO A 288     82.26           C   
HETATM 1309  OG1 TPO A 288     93.55           O   
HETATM 1310  P   TPO A 288     87.77           P   
HETATM 1311  O1P TPO A 288     91.79           O   
HETATM 1312  O2P TPO A 288     93.35           O   
HETATM 1313  O3P TPO A 288     95.16           O   
HETATM 1314  C   TPO A 288     89.28           C   
HETATM 1315  O   TPO A 288     86.14           O   
ATOM   1316  N   LEU A 289     87.01           N   
ATOM   1317  CA  LEU A 289     88.25           C   
ATOM   1318  C   LEU A 289     87.34           C   
ATOM   1319  O   LEU A 289     90.27           O   
ATOM   1320  CB  LEU A 289     78.91           C   
ATOM   1321  N   CYS A 290     89.51           N   
ATOM   1322  CA  CYS A 290     89.73           C   
ATOM   1323  C   CYS A 290     90.22           C   
ATOM   1324  O   CYS A 290     91.11           O   
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ATOM   1325  CB  CYS A 290     80.05           C   
ATOM   1326  N   GLY A 291     90.88           N   
ATOM   1327  CA  GLY A 291     84.36           C   
ATOM   1328  C   GLY A 291     80.67           C   
ATOM   1329  O   GLY A 291     72.19           O   
ATOM   1330  N   THR A 292     72.87           N   
ATOM   1331  CA  THR A 292     68.66           C   
ATOM   1332  C   THR A 292     69.67           C   
ATOM   1333  O   THR A 292     81.32           O   
ATOM   1334  CB  THR A 292     64.26           C   
ATOM   1335  OG1 THR A 292     62.83           O   
ATOM   1336  CG2 THR A 292     66.76           C   
ATOM   1337  N   LEU A 293     65.76           N   
ATOM   1338  CA  LEU A 293     57.85           C   
ATOM   1339  C   LEU A 293     54.37           C   
ATOM   1340  O   LEU A 293     59.11           O   
ATOM   1341  CB  LEU A 293     58.26           C   
ATOM   1342  CG  LEU A 293     59.75           C   
ATOM   1343  CD1 LEU A 293     56.85           C   
ATOM   1344  CD2 LEU A 293     55.33           C   
ATOM   1345  N   ASP A 294     45.72           N   
ATOM   1346  CA  ASP A 294     46.04           C   
ATOM   1347  C   ASP A 294     42.63           C   
ATOM   1348  O   ASP A 294     40.46           O   
ATOM   1349  CB  ASP A 294     47.18           C   
ATOM   1350  CG  ASP A 294     53.87           C   
ATOM   1351  OD1 ASP A 294     53.07           O   
ATOM   1352  OD2 ASP A 294     44.18           O   
 
 
4BN1 
ATOM   NUMBER    RESIDUE      B-FACTOR      ELEMENT  
ATOM   1222  N   TRP A 277      50.36           N   
ATOM   1223  CA  TRP A 277      55.42           C   
ATOM   1224  C   TRP A 277      51.58           C   
ATOM   1225  O   TRP A 277      51.76           O   
ATOM   1226  CB  TRP A 277      50.87           C   
ATOM   1227  CG  TRP A 277      58.49           C   
ATOM   1228  CD1 TRP A 277      63.00           C   
ATOM   1229  CD2 TRP A 277      67.07           C   
ATOM   1230  NE1 TRP A 277      63.47           N   
ATOM   1231  CE2 TRP A 277      73.15           C   
ATOM   1232  CE3 TRP A 277      65.12           C   
ATOM   1233  CZ2 TRP A 277      77.08           C   
ATOM   1234  CZ3 TRP A 277      70.17           C   
ATOM   1235  CH2 TRP A 277      70.70           C   
ATOM   1236  N   SER A 278      49.59           N   
ATOM   1237  CA  SER A 278      55.05           C   
ATOM   1238  C   SER A 278      56.32           C   
ATOM   1239  O   SER A 278      54.31           O   
ATOM   1240  CB  SER A 278      47.01           C   
ATOM   1241  OG  SER A 278      67.87           O   
ATOM   1242  N   VAL A 279      50.55           N   
ATOM   1243  CA  VAL A 279      56.77           C   
ATOM   1244  C   VAL A 279      62.31           C   
ATOM   1245  O   VAL A 279      54.29           O   
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ATOM   1246  CB  VAL A 279      56.82           C   
ATOM   1247  CG1 VAL A 279      50.42           C   
ATOM   1248  CG2 VAL A 279      52.79           C   
ATOM   1249  N   HIS A 280      65.48           N   
ATOM   1250  CA  HIS A 280      67.21           C   
ATOM   1251  C   HIS A 280      59.30           C   
ATOM   1252  O   HIS A 280      67.63           O   
ATOM   1253  CB  HIS A 280      69.35           C   
ATOM   1254  CG  HIS A 280      74.61           C   
ATOM   1255  ND1 HIS A 280      68.93           N   
ATOM   1256  CD2 HIS A 280      74.09           C   
ATOM   1257  CE1 HIS A 280      71.38           C   
ATOM   1258  NE2 HIS A 280      74.23           N   
ATOM   1259  N   ALA A 281      57.47           N   
ATOM   1260  CA  ALA A 281      66.72           C   
ATOM   1261  C   ALA A 281      73.42           C   
ATOM   1262  O   ALA A 281      71.50           O   
ATOM   1263  CB  ALA A 281      64.66           C   
ATOM   1264  N   PRO A 282      71.56           N   
ATOM   1265  CA  PRO A 282      65.81           C   
ATOM   1266  C   PRO A 282      68.41           C   
ATOM   1267  O   PRO A 282      60.30           O   
ATOM   1268  CB  PRO A 282      69.11           C   
ATOM   1269  CG  PRO A 282      74.40           C   
ATOM   1270  CD  PRO A 282      62.45           C   
ATOM   1271  N   SER A 283      71.62           N   
ATOM   1272  CA  SER A 283      62.93           C   
ATOM   1273  C   SER A 283      59.42           C   
ATOM   1274  O   SER A 283      59.19           O   
ATOM   1275  CB  SER A 283      57.85           C   
ATOM   1276  OG  SER A 283      70.25           O   
ATOM   1277  N   SER A 284      69.23           N   
ATOM   1278  CA  SER A 284      75.78           C   
ATOM   1279  C   SER A 284      85.22           C   
ATOM   1280  O   SER A 284      90.86           O   
ATOM   1281  CB  SER A 284      77.25           C   
ATOM   1282  OG  SER A 284      82.32           O   
ATOM   1283  N   ARG A 285      94.04           N   
ATOM   1284  CA  ARG A 285      93.40           C   
ATOM   1285  C   ARG A 285      100.10          C   
ATOM   1286  O   ARG A 285      114.72          O   
ATOM   1287  CB  ARG A 285      89.67           C   
ATOM   1288  N   ARG A 286      93.25           N   
ATOM   1289  CA  ARG A 286      93.98           C   
ATOM   1290  C   ARG A 286      102.38          C   
ATOM   1291  O   ARG A 286      102.50          O   
ATOM   1292  CB  ARG A 286      77.66           C   
HETATM 1293  N   TPO A 287      106.03          N   
HETATM 1294  CA  TPO A 287      94.54           C   
HETATM 1295  CB  TPO A 287      92.06           C   
HETATM 1296  CG2 TPO A 287      95.97           C   
HETATM 1297  OG1 TPO A 287      83.93           O   
HETATM 1298  P   TPO A 287      77.52           P   
HETATM 1299  O1P TPO A 287      71.15           O   
HETATM 1300  O2P TPO A 287      73.40           O   
HETATM 1301  O3P TPO A 287      98.95           O   
HETATM 1302  C   TPO A 287      101.03          C   
HETATM 1303  O   TPO A 287      112.16          O   
192 
 
HETATM 1304  N   TPO A 288      100.37          N   
HETATM 1305  CA  TPO A 288      109.47          C   
HETATM 1306  CB  TPO A 288      120.35          C   
HETATM 1307  CG2 TPO A 288      121.25          C   
HETATM 1308  OG1 TPO A 288      133.23          O   
HETATM 1309  P   TPO A 288      153.57          P   
HETATM 1310  O1P TPO A 288      117.84          O   
HETATM 1311  O2P TPO A 288      133.44          O   
HETATM 1312  O3P TPO A 288      133.59          O   
HETATM 1313  C   TPO A 288      110.43          C   
HETATM 1314  O   TPO A 288      112.01          O   
ATOM   1315  N   LEU A 289      105.94          N   
ATOM   1316  CA  LEU A 289      106.99          C   
ATOM   1317  C   LEU A 289      109.44          C   
ATOM   1318  O   LEU A 289      103.15          O   
ATOM   1319  CB  LEU A 289      109.87          C   
ATOM   1320  CG  LEU A 289      108.24          C   
ATOM   1321  CD1 LEU A 289      92.63           C   
ATOM   1322  CD2 LEU A 289      90.67           C   
ATOM   1323  N   CYS A 290      108.82          N   
ATOM   1324  CA  CYS A 290      108.73          C   
ATOM   1325  C   CYS A 290      104.71          C   
ATOM   1326  O   CYS A 290      102.72          O   
ATOM   1327  CB  CYS A 290      92.96           C   
ATOM   1328  SG  CYS A 290      135.29          S   
ATOM   1329  N   GLY A 291      89.23           N   
ATOM   1330  CA  GLY A 291      87.52           C   
ATOM   1331  C   GLY A 291      75.64           C   
ATOM   1332  O   GLY A 291      51.20           O   
ATOM   1333  N   THR A 292      72.14           N   
ATOM   1334  CA  THR A 292      61.07           C   
ATOM   1335  C   THR A 292      52.72           C   
ATOM   1336  O   THR A 292      60.68           O   
ATOM   1337  CB  THR A 292      70.16           C   
ATOM   1338  OG1 THR A 292      61.93           O   
ATOM   1339  CG2 THR A 292      54.62           C   
ATOM   1340  N   LEU A 293      52.64           N   
ATOM   1341  CA  LEU A 293      42.61           C   
ATOM   1342  C   LEU A 293      44.20           C   
ATOM   1343  O   LEU A 293      42.90           O   
ATOM   1344  CB  LEU A 293      41.82           C   
ATOM   1345  CG  LEU A 293      54.18           C   
ATOM   1346  CD1 LEU A 293      48.52           C   
ATOM   1347  CD2 LEU A 293      46.12           C   
ATOM   1348  N   ASP A 294      43.69           N   
ATOM   1349  CA  ASP A 294      35.96           C   
ATOM   1350  C   ASP A 294      43.43           C   
ATOM   1351  O   ASP A 294      44.92           O   
ATOM   1352  CB  ASP A 294      40.14           C   
ATOM   1353  CG  ASP A 294      49.06           C   
ATOM   1354  OD1 ASP A 294      47.38           O   
ATOM   1355  OD2 ASP A 294      55.69           O   
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Appendix 2.3. Validation of CHEMPLP as the docking function  
CHEMPLP was able to reproduce the conformations of the ligands AK8, YPH and ZZL as in the original 
crystal structures: 3EFW, 4JBP and 2WTV respectively. 
 
Appendix 2.3. a) Re-evaluation of 3EFW. Ligand: AK8 re-docking result. AK8 crystallised 
structure (C atoms in grey), AK8 solution generated by CHEMPLP (C atoms in green). H-
bonds (dashed lines). 
 
Appendix 2.3. b) Re-evaluation of 4JBP. Ligand: YPH re-docking result. YPH crystallised 
structure (C atoms in grey), YPH solution generated by CHEMPLP (C atoms in green). H-
bonds (dashed lines). 
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Appendix 2.3. c) Re-evaluation of 2WTV. Ligand: ZZL re-docking result. ZZL crystallised 
structure (C atoms in grey), ZZL solution generated by CHEMPLP (C atoms in green). H-bonds 
(dashed lines). 
 
Appendix 4.1. Retrosynthesis of compound 19 
 
 
92 93 19 
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Figure 7.1. Retrosynthesis of 19 
 
Compound 19 may be synthesised from azide 92 and alkyne 93. The synthesis of azide 92 is 
similar to that of 2-azido-N-(2-(3-phenylureido)ethyl)acetamide, 86. It was suggested that 
synthesis of alkyne 93 might be completed from N-functionalised dibromomaleimide. 177 Since 
the N-functionalised dithiophenolmaleimides proved more challenging and required subtle 
tuning of the reactions, the dibromomaleimide variants were chosen. 177 
As -OR nucleophile may add twice to the same place or to an already substituted end, reaction 
that involves but-3-yn-1-ol as the nucleophile can be performed carefully in mild conditions 
(mild base) and after the reaction involving adenine as the nucleophile. 178 Adenine may be 
replaced by other amine moieties present in kinase inhibitors. 
 
Figure 7.2. Proposed synthesis of 93. (i) ClCO2Me, NMM; (ii) tert-butyl 4-aminobutanoate; 
(iii) (protected-NH2)-adenine, base; (iv) But-3-yn-1-ol, base. 
 
 
 
 
 
 
  
93 
94 
96 
95 
R = CH2CH2CH2COOt-Bu 
96 98 99 100 
93 
97 
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